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Understanding and Exploiting Viral Protein US28 During Human Cytomegalovirus Latency 
Elizabeth Grace Elder 
Human cytomegalovirus (HCMV) is a ubiquitous herpesvirus which infects 50-100% of humans 
worldwide. HCMV causes a lifelong subclinical infection in immunocompetent individuals, but is a serious 
cause of mortality and morbidity in the immunocompromised and in neonates. Like other herpesviruses, 
HCMV establishes latency in specific cell types following primary infection, and reactivates periodically 
during the lifetime of the host. One important site of HCMV latency is early myeloid lineage cells, 
including hematopoietic progenitor cells and monocytes, in which the critical viral lytic promoter, the 
major immediate early promoter (MIEP), is repressed. This is mediated by a combination of host and 
viral factors, including the viral G-protein coupled receptor US28.   
Here, I explore mechanisms by which US28 optimises host cells for latent carriage.  Using an unbiased 
proteomic screen, I have assessed changes in total host proteins induced by US28 and find that 
interferon-inducible genes are downregulated by US28. I validate that MHC Class II and two PYHIN 
proteins, MNDA and IFI16, are downregulated during experimental latency in primary human CD14+ 
monocytes.  By overexpressing IFI16, I show that IFI16 can activate the viral major immediate early 
promoter and immediate early gene expression during latency via NF-κB, a function which explains why 
downregulation of IFI16 during latency is advantageous for the virus. I also show that MNDA is a 
potential restriction factor for HCMV latency. Since PYHIN proteins are sensors of double stranded DNA, I 
also investigate whether US28 interferes with the sensing of dsDNA. 
I also examine the antiviral potential of two US28-targeting reagents during HCMV latency. Lowering 
latent viral loads in solid organ or hematopoietic stem cell transplant donors and recipients is likely to 
lead to lower incidence of HCMV-disease in transplant patients. The first reagent, a US28-specific 
nanobody, inhibits US28 function and partially reverses latency. This leads to lytic gene expression, and 
subsequent recognition and killing of latently infected cells by naturally existing T cells from seropositive 
individuals. The second, a US28-specific immunotoxin, has previously been shown to directly kill latently 
infected cells.  I show that new derivatives of this immunotoxin are more efficacious and can kill latently 
infected cells after a short incubation, paving the way for their use in ex vivo normothermic perfusion of 
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1.1.  Natural history of human cytomegalovirus 
1.1.1. Herpesviruses 
The herpesvirales are an order of large, double-stranded DNA viruses which infect vertebrate and 
invertebrate species (https://talk.ictvonline.org/taxonomy/) [1]. The herpesviridae family, which infect 
reptiles, birds, and mammals, are subdivided into three subfamilies: alpha-, beta-, and gamma-
herpesviruses. There are nine herpesviruses known to infect humans (Table 1-1). The most recent of 
these to be discovered was the gamma herpesvirus HHV-8, Kaposi sarcoma associated herpesvirus 
(KSHV), in 1994 [2], while the betaherpesvirus human cytomegalovirus (HCMV, HHV-5) was isolated in 
the 1950s [3]. 
During primary infection, herpesviruses typically replicate (lytic infection) in a wide array of tissues and 
cell types [4]. Herpesviruses also establish a latent infection in specific cell types within the host (Table 
1-1). During latent infection, the viral genome is maintained in the absence of the production of new 
infectious virions. However, under certain conditions, the virus can reactivate from latency to produce 
new infectious viral particles. In the next section I will explain how latency and reactivation underpins 




Table 1-1 Human herpesviruses 
Subfamily Virus Formal 
name 
Cellular site(s) of latency 
Alphaherpesvirinae Herpes simplex virus type 1 
(HSV-1) 
HHV-1 Sensory neurons (trigeminal 
ganglia) [5] 
Herpes simplex virus type 2 
(HSV-2) 
HHV-2 Sensory neurons (trigeminal 
ganglia) [5] 
Varicella-Zoster virus (VZV) HHV-3 Neurons  (predominantly 
dorsal root ganglia) [6] 
Betaherpesvirinae Human cytomegalovirus (HCMV) HHV-5 Hematopoietic progenitors 
and early myeloid lineage cells 
[7] 




Likely hematopoetic lineage 
[8,9] 
Human herpesvirus-6B (HHV-6B); 
Roseolovirus 
HHV-6B Likely myeloid lineage [8,9] 
Human herpesvirus-7 (HHV-7); 
Roseolovirus 
HHV-7 Unknown, likely hematopoietic 
lineage [8] 
Gammaherpesvirinae Epstein-Barr virus 
(EBV) 
HHV-4 B lymphocytes [10] 
Kaposi sarcoma associated 
herpesvirus (KSHV) 
HHV-8 B lymphocytes [11] 
 
1.1.2. HCMV infection in healthy individuals 
HCMV is a ubiquitous pathogen which infects 45-99% of individuals worldwide [12]. HCMV 
seroprevalence is correlated with socioeconomic status and, in the UK, approximately 50% of adults 
contain anti-CMV IgG in their serum [12,13]. Primary infection of healthy children and adults with HCMV 
is often asymptomatic but can result in mild flu-like symptoms [14] and HCMV shedding is routinely 
detectable in bodily fluids including saliva, urine, breast milk, semen, and vaginal fluid [15–17]. Broad 
and robust immune responses are generated during primary infection with HCMV, incorporating both 
cellular and humoral immunity [18]. In particular, strong T cell responses against a variety of viral 
epitopes are made which  enable control of virus replication and, after resolution of infection, extremely 
high frequencies of CMV-specific T cells are routinely detected in HCMV-seropositive individuals [18].  
Despite this effective control of lytic replication, healthy individuals never clear HCMV, and individuals 
can also be re-infected with additional strains of HCMV during their lifetime [19]. In healthy virus 
carriers, circulating HCMV-specific effector T cells predominantly recognise viral epitopes  that are 
expressed during lytic infection, but not during latent infection [20]. This general inability of effector T 
16 
 
cells in HCMV seropositive carriers to recognise latently infected cells helps the virus to remain 
undetected by the immune system during latency, which is routinely established in CD34+ hematopoietic 
progenitor cells and early myeloid lineage cells such as CD14+ monocytes [20]. 
Reactivation of HCMV from latency, discussed in much greater detail later, occurs sporadically 
throughout the lifetime of healthy individuals as myeloid progenitor cells which carry latent genomes 
differentiate into mature dendritic cells and macrophages [21,22]. Reactivation events in healthy carriers 
are also well controlled by existing immune responses and, therefore, asymptomatic but likely result in 
reseeding of the latent viral reservoir [20]. This model of latency and continual reactivation supports the 
view that HCMV can cause a lifelong subclinical infection in healthy individuals and helps explain the 
maintenance of high levels of HCMV-specific T cells in normal healthy carriers.  
1.1.3. Congenital HCMV infection 
Transfer of HCMV from mother to foetus during pregnancy is a leading cause of HCMV-associated 
disease. Congenital HCMV (cCMV) infection occurs in an estimated 0.8% of live births in the UK [23]. 
While many cCMV infections are asymptomatic at birth, approximately 15% will go on to develop long 
term developmental problems, including sensorineural hearing loss, vestibular dysfunction, and mental 
retardation [23]. Indeed, cCMV is the leading non-genetic cause of hearing loss. 
Transfer of HCMV from mother to foetus can occur in three ways: (1) primary infection of a seronegative 
mother; (2) secondary infection of a seropositive mother; and (3) reactivation of an existing HCMV 
infection in a seropositive mother [23,24]. In an individual mother, the risk of transmission to the foetus 
and clinical disease is highest if she undergoes primary HCMV infection [24,25]. However, since the 
majority of world populations have high HCMV seropositivity, the majority of cCMV cases are attributed 
to non-primary infection [26]. 
1.1.4. HCMV in the transplant setting 
Both allogeneic hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) patients are 
at serious risk of HCMV-associated disease. Both types of transplant procedures require 
immunosuppression to avoid organ rejection or graft-versus-host disease. Coupled with inflammation 
associated with surgery, and allogeneic reactions, transplant patients often develop viremia and 
disseminated HCMV infection, which can, in some cases, be fatal [14,27–30]. The risk of symptomatic 
CMV disease depends on the type of transplant, and the serostatus of the donor (D) and recipient (R) 
[27].  Seropositive HSCT patients are at highest risk of disease if the donor is seronegative (D-R+) and 
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intermediate risk if both recipient and donor are seropositive (D+R+); seronegative recipients are at low 
risk from a seropositive donor (D+R-), and, clearly, the lowest risk if both recipient and donor are 
seronegative. In SOT patients, seropositive recipients are at low risk if the donor is seronegative (D-R+), 
and intermediate if the donor is seropositive (D+R+). Seronegative recipients are at high risk from a 
seropositive donor (D+R-).  
Managing HCMV in the transplant setting varies from centre to centre; antiviral drugs (See §1.1.6) are 
used in prophylactic regimens in some cases and only after detecting HCMV DNA in the blood in others 
[28,30]. Unfortunately, these antivirals are not well-tolerated in all patients, often causing marrow 
suppression and renal impairment, and the development of resistance mutations is commonplace 
[28,30]. Ensuring successful engraftment via immunosuppression, whilst preventing HCMV disease by 
allowing immune function, is a delicate balancing act for transplant physicians. 
1.1.5. Other HCMV pathologies 
HCMV is linked with other pathologies in both healthy and immunocompromised hosts. Human 
immunodeficiency virus (HIV)-acquired immunodeficiency syndrome (AIDS) patients are at risk of HCMV 
disease, most commonly CMV retinitis [31], while intensive care patients, such as those with sepsis, 
frequently experience disease linked to HCMV reactivation [32]. Meanwhile, older HCMV seropositive 
individuals have higher all-cause mortality, atherosclerosis and arterial hypertension in the absence of 
symptomatic infection [33–35]. Finally, HCMV has been linked with various cancers, most notably breast 
cancer and glioblastoma [36–40]. This link remains controversial, since HCMV does not readily transform 
cells, and whole genomes are not detected in cancers, but results showing improvement in patient 
survival upon treatment with HCMV antivirals mean that the link merits further investigation [39,41].  
1.1.6. HCMV treatment and prevention 
There is no licensed HCMV vaccine, though several candidates are under development [14,24,42–44]; an 
incomplete understanding of the correlates of protection against HCMV in a given clinical setting (e.g. 
pregnancy, SOT) likely limits progress towards an effective vaccine. Efforts towards preventing cCMV by 
educating pregnant women about risks and hygiene measures are under investigation [45,46]. 
Ganciclovir (GCV), and its orally-available derivative valganciclovir, are the first-line treatments for HCMV 
disease, and are also used as prophylaxis in SOT patients [44].  GCV, a guanosine analogue, is 
phosphorylated by the viral kinase UL97 to become a monophosphorylated species, and then 
subsequently phosphorylated by cellular kinases to become a nucleotide analogue and competitive 
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inhibitor for viral DNA polymerase catalytic subunit UL54 [47]. While largely efficacious in the transplant 
setting, resistance to GCV does occur via mutations in UL97 and UL54 [44], and it can cause neutropenia 
and thrombocytopenia leading to susceptibility to bacterial and fungal infections [30,44]. GCV can also 
inhibit myeloid reconstitution following HSCT [44]. GCV can reduce some cCMV-associated pathologies, 
but it is by no means fully efficacious, and works best for infants diagnosed within the first 30 days after 
birth [20].  Second-line therapies include cidofovir, acyclovir, and foscarnet also all target the viral DNA 
polymerase subunit UL54. These are also are susceptible to resistance mutations and also associated 
with toxicity [44]. Letermovir has recently been approved for prophylactic treatment of HSCT patients, 
and targets the viral terminase complex, inhibiting capsid assembly [44,48,49]; unfortunately, antiviral 
resistance can also develop for this compound during the course of treatment [49]. No licensed therapy 
targets latently infected cells, and thus current antiviral regimens will always leave latent reservoirs 
intact [44]. 
1.1.7. Species specificity of cytomegaloviruses 
There are many mammalian cytomegaloviruses described, including, but not limited to, murine, rat, 
guinea pig, bovine, equine, canine, swine, rhesus macaque, and chimpanzee [50]. Each cytomegalovirus 
is specific to its host; that is, murine cytomegalovirus (MCMV) does not productively infect human cells 
or, indeed, human beings, and HCMV does not productively infect mouse cells or mice [51]. This 
important feature means what when using a model organism, the cytomegalovirus used is that which 
naturally infects that organism.  
Many animal cytomegaloviruses are used to dissect aspects of CMV biology; particularly in vivo 
phenomena, which cannot be studied in humans for ethical reasons. These models, which include 
murine, rat, guinea pig, and rhesus macaque, are described extensively elsewhere [50,52–57]. Like all 
animal models for human diseases, there are advantages and disadvantages to each. In general, many 
HCMV genes have clear homologues in animal CMVs, but there has been extensive gene duplication and 
diversion, as well as gains and losses of function for individual genes during the course of evolution.  
MCMV is perhaps the most commonly used animal model for cytomegalovirus infection, and has been 
incredibly useful to CMV researchers. Two differences, highly pertinent to this project, exist: the major 
immediate early promoter (see §1.2.3 and 1.3.4) has a different arrangement of transcription factor 
binding sites, and hence may be regulated differently, and the cellular site of MCMV latency remains 
controversial [58–61]. For these reasons, studies of MCMV latency and reactivation must be interpreted 
with some caution by those interested in HCMV latency and reactivation.  
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1.2. Lytic infection of human cytomegalovirus 
1.2.1. HCMV virions and genome structure 
Lytic viral infections follow a basic pattern: virus particles enter cells, viral genes are expressed, the viral 
genome is replicated, new viral particles are assembled, and these particles egress from cells. HCMV is 
an enveloped virus of approximately 200 nm in diameter [62,63]. The tegument layer, containing many 
soluble proteins, lies in the space between the envelope and the capsid. The capsid, which has 
icosahedral symmetry, contains one copy of the HCMV genome in a linear form [63]. 
The HCMV genome is a non-segmented double stranded DNA (dsDNA) molecule of approximately 230 
kb, making it the largest genome of any human viral pathogen [63]. While it is linear within virions, it 
circularises within cells and is rapidly chromatinised in host nuclei [64,65]. The genome is organised into 
a short and a long arm, each flanked by inverted repeat sequences [63]. The portion of the genome on 
which a given HCMV gene resides determines the name of the gene, and so, for example, genes in the 
unique long arm are denoted UL(XX), or US(XX) for those resident in the unique short region where XX 
designates the number of the open reading frame (ORF) within that region.  There are over 200 ORFs 
encoded by HCMV, located on both the positive and negative DNA strands, with many genes overlapping 
[63]. As well as viral proteins, the genome encodes for multiple microRNAs and long non-coding RNAs; 
the functions of many HCMV genes have yet to be fully elucidated [66–68].  
1.2.2. Tropism, entry, and tegument proteins 
HCMV productively infects a wide range of cell types, including fibroblasts, epithelial cells, endothelial 
cells, smooth muscle cells, astrocytes, dendritic cells, and macrophages [69]. HCMV can enter cells via 
several different mechanisms, including direct fusion with the outer membrane, endocytosis, and 
pinocytosis [69–74], depending on the specific cell type involved. HCMV particles interact with heparan 
sulfate proteoglycans, but the co-receptors for HCMV entry are subjects of ongoing study, and likely vary 
by cell type and entry mechanism; co-receptors identified include integrins, PDGFRα, and neuropilin2 
[70,73].  
One very important determinism of cell tropism is the glycoprotein composition of the virion envelope. 
The glycoproteins can form a trimeric complex (gH/gL/gO) or a pentameric complex 
(gH/gL/UL128/UL130/UL131). Virions with pentameric complexes can enter endothelial cells and 
fibroblasts, whereas virions containing only trimeric complexes can only enter fibroblasts [73]. This is 
important since serial passage of laboratory viruses in fibroblasts leads to deletion of a genomic region 
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called ULb’, which contains the UL128/UL130/UL131 components of the pentamer, leading to a loss of 
tropism for endothelial cells [75,76].  
At least some of the incoming proteins and RNAs associated with HCMV particles are known to be 
functional before their de novo transcription during infection [77]. Lots of these are the tegument 
proteins, which have roles including immune evasion, capsid trafficking to the nucleus, and activation of 
viral gene expression [77–79]. In particular, incoming tegument protein pp71 (encoded by UL82) induces 
the degradation of components of promyelocytic leukemia (PML) bodies which repress viral gene 
transcription in the nuclei of permissive cells [77] – this is discussed in greater depth in §1.3.4. 
1.2.3. Lytic gene expression: a regulated cascade 
Herpesvirus gene transcription is temporally regulated. Classically, there are three major kinetic classes 
of viral genes: immediate early, early, and late,[80], but additional, intermediate classes of genes have 
been described, such as ‘leaky-late’ [81,82]. Nevertheless, temporal regulation is critical to the biology of 
HCMV replication. 
Immediate early (IE) genes are the first to be transcribed. They transactivate early gene transcription, 
modulate cell cycle, and counteract a variety of host defence responses [83,84]. The Major Immediate 
Early (MIE) gene products IE1 and IE2 (also known as IE72 and IE86) are expressed from the Major 
Immediate Early Promoter/Enhancer region (henceforth referred to as the MIEP).  This region, shown in 
Figure 1-1, consists of core, enhancer, unique, and modulator sequences upstream of the transcription 
start site [83,85,86], as well as regulatory sequences in the first intron that can also act as a promoter for 
alternative IE transcripts [87–89]. Since HCMV DNA is rapidly chromatinised upon entry into the nucleus, 
the MIEP is subject to regulation by chromatin structure [85,86,90–92]. 
Once the MIEP is activated, and IE gene products are expressed, early gene expression is transactivated. 
As a generalisation, early gene products encode the viral DNA replication machinery, a step necessary for 
late gene expression. Late genes encode for structural components of the virion, such as the envelope 
glycoproteins and tegument proteins.  
HCMV genes of all kinetic classes, as well as tegument proteins, have immune evasion functions. This 
spans the disruption of sensing mechanisms, the antagonism of interferon responses and innate 
immunity, cell death pathways, antigen presentation, cytokine and chemokine responses, and T-, B-, and 
NK-cell immunity [93–97]. Despite this, healthy individuals control HCMV replication and carry HCMV 
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asymptomatically for the duration of their lifetimes; it is viral latency that underpins persistence. In this 
next section, I will explain where and how latent viral infections are established and maintained in hosts. 
 
 
Figure 1-1 Organisation of the Major Immediate Early locus, based on [83,86]. The MIEP consists of modulator, 
unique, enhancer, and core regions which are bound by the indicated activatory or repressive transcription factors. 
NF1, nuclear factor 1; CREB/ATF, cAMP response element binding protein/activatory transcription factor; NF-κB, 
nuclear factor-kappa B; AP1, activator protein 1; C/EBP, CCAAT-enhancer-binding protein; SP1, Sp1 Transcription 
Factor; SRF, serum response factor; PPARγ, peroxisome proliferator activated receptor gamma; MRF, modulator 
recognition factor 1, HUGO name ARID5A; ERF, Ets-repressor factor; YY1, ying yang 1; MDBP, methylated DNA 
binding proteins; Gfi-1, growth factor independent 1 transcriptional repressor.  The approximate positions of the 
TATA-box and cis-repression sequence (crs) is indicated; the crs is bound by IE2 protein at late times of infection to 
repress transcription of MIE gene products. The canonical transcription start site (TSS) is indicated at +1bp. Exons 
(yellow) and introns (green) are numbered. The intronic promoters iP1 and iP2 also contribute to full-length IE1 and 
IE2 proteins; the position of the initiator AUG codon is indicated. IE1 is comprised of coding regions from exons 2, 
3, and 4; IE2 is comprised of coding regions from exons 2, 3, and 5; these, and other MIE proteins, are generated by 





1.3. HCMV latency and reactivation 
1.3.1. Natural sites of HCMV latency and reactivation 
By definition, latent carriage of HCMV requires the maintenance of the viral genome in the absence of 
the production of infectious virus particles; however, under certain conditions, virus is able to reactivate 
and produce new virus particles [98]. This ability to reactivate sets latency apart from so-called ‘abortive 
infection’, and cellular differentiation is intimately linked with both latency and reactivation [98]. 
One important natural site of HCMV latency is in cells of the early myeloid lineage. CD34+ hematopoietic 
progenitors (HPCs) and their derivatives, including granulocyte-macrophage progenitors and CD14+ 
monocytes, are latently infected in seropositive individuals [99–102]. Reactivation of HCMV has been 
observed directly ex vivo in differentiated myeloid cells [21,22] and in vitro upon differentiation of CD34+ 
progenitor cells and CD14+ monocytes into mature dendritic cells or macrophages [103,104]. While 
differentiation-independent virus reactivation has been recently reported in an immortal myeloid cell 
line [105], the mechanism of reactivation from latency has only been extensively described during 
myeloid cell differentiation (described in the next three sections).  
Some groups have suggested that endothelial cells might also be sites of HCMV latency [27,106]. 
However, to date, no group has been able to take these cell types from a seropositive donor, show that 
they are latently infected, and then show that they can reactivate virus; however, this does not preclude 
that these cell types may contribute to long-term persistence of HCMV. 
1.3.2. HCMV latency and reactivation experimental models 
The most relevant experimental models of HCMV latency and reactivation are infections of primary early 
myeloid lineage cells from healthy donors. CD34+ HPCs are typically resident in the bone marrow and, 
because they are stem cells, these are thought to represent the long term site of latency in humans 
[107]. For ex vivo work, HPCs can be derived directly from bone marrow, after cytokine-mediated 
mobilisation from bone marrow into blood, as well as from umbilical cord blood. These can be cultured 
in a simple, serum- and cytokine- free medium, or can be expanded using cytokines/serum, and can also 
be co-cultured with supporting stromal cells. Reactivation is induced using further cytokines that induce 
differentiation [108–110]. Thus, while CD34+ HPCs are a highly relevant model for HCMV latency and 
reactivation, there are several challenges associated with their use: they are difficult to obtain in large 
numbers, they are a heterogeneous population within any single experiment, and additional 
experimental sources of heterogeneity mean that repeating observations is not always straightforward.  
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Similarly, granulocyte-macrophage progenitor cells are also an experimental model of latency and 
reactivation [101], with the source material being fetal liver from aborted foetuses. The source material 
is therefore limited and subject to heterogeneity. CD14+ monocytes can be obtained via venepuncture 
and thus are a much more readily available cell type compared with CD34+ HPCs [111,112]. Some groups 
work with monocytes in a serum- and cytokine-free media, and the work presented here uses this 
system, which aims to avoid differentiation. Others culture monocytes in serum and/or cytokines to 
more closely mimic circulating monocytes in vivo [113,114] 
In addition to practical and ethical considerations, a major disadvantage of primary cell models is that 
they cannot readily be genetically modified. Therefore, several cell lines have been used for the study of 
HCMV latency and reactivation. A great deal of early work was performed in human embryonal NTera2 
carcinoma cells [115,116], while Kasumi-3 cells are a CD34+ myeloblastic cell line [117], and THP-1 cells 
are a myelomonocytic leukemia cell line [118,119]. Each supports a form of latency and reactivation, but 
none recapitulates all aspects of latency and reactivation known to occur in primary cells [120], with a 
major difficulty being the dilution of viral genome as cells divide during the course of latent infection. 
Recently, an inducible pluripotent stem cell (iPSC) line has been identified which supports latency and 
reactivation [121], and can combine the ability to track latency through all stages of myeloid 
differentiation with an ability to genetically modify cells. Finally, a humanised NOD-scid IL2Rγc null 
(huNSG) mouse model of HCMV latency and reactivation might allow interrogation of viral processes 
that are only observable in vivo [122], but results from this mouse model need to be interpreted 
carefully since the mouse cells of non-hematopoietic origin do not get productively infected. 
1.3.3. Viral gene expression during latency and reactivation 
Viral latency was once believed to be equivalent to viral quiescence, involving little or no viral 
transcription or modulation of host cell gene expression and function. However, HCMV latency is now 
well established to mediate multiple changes in host processes such as antigen presentation, cytokine 
production, apoptosis, differentiation, and motility [112,113,123–128], and these can be related to the 
expression of viral gene products during latency. 
Viral gene expression during experimental and natural latency is a subject of ongoing study. Prior to 
recent advances in transcriptomics, only a handful of viral transcripts were known to be expressed 
during latency, including the protein coding genes UL138, UL144, US28, UL111a, and LUNA, as well as 
some long non-coding RNAs and micro RNAs [20,129,130]. These analyses were based on microarrays or 
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targeted RT-PCR studies [124,131–133], but unbiased methods, including single-cell RNAseq, has 
identified that latency-associated gene expression is more broad and complex than previously conceived, 
though the absolute levels of transcripts are much lower during HCMV latency than during lytic infection 
[134–136]. However, besides the lack of production of infectious virions, a key hallmark of latency is still 
accepted to be the suppression of immediate early (IE) gene expression in latently infected cells, both ex 
vivo and in in vitro models [101–103,131,137,138].  
Conversely, the initiating step in reactivation is transcription of IE1/IE72 and IE2/IE86 transcripts to begin 
the lytic transcription programme [7,103,104]. As described in §1.2.3, these transcripts can originate 
from the canonical transcription start site (Figure 1-1), and the intronic promoters iP1 and iP2. One 
group has recently suggested that iP1 and iP2 are the major sources of IE1 and IE2 during reactivation, 
and proposed a ‘promoter-switching’ paradigm [89]. They drew these conclusions after measuring levels 
of the three promoter-derived transcripts during the phorbol ester-induced differentiation of THP-1 cells 
as well as knocking out iP1 and iP2 and seeing reduced reactivation in CD34+ HPCs. However, 
unpublished work from our own laboratory, and that of collaborators (C. O’Connor, personal 
communication) has failed to recapitulate the strong bias towards iP1 and iP2 driven transcripts during 
reactivation in both primary monocytes and THP-1 or Kasumi-3 cells. However, in these unpublished 
studies, while the canonical transcripts predominate, iP2 was more prevalent when using reactivation 
stimuli that promote macrophage differentiation, rather than dendritic cell differentiation. Mutagenesis 
in the intronic region as carried out in the studies defining iP1 and iP2, must, I believe, be interpreted 
with caution, since regulatory elements in that region may act upstream as well as downstream; for 
example, a CTCF site (a well-established chromatin insulator) is present in the first intron of the major IE 
region [88]. 
Following recent insights into the apparent broad range of viral transcription during HCMV latency, it is 
now incumbent upon groups to identify latency-associated functions for transcripts detected in latently 
infected cells, for example by knocking out these genes in the context of a latent infection. Such 
approaches have identified important roles for latency-associated expression of UL111a, which is 
involved in immune evasion [123,139], LUNA, which disperses  promyelocytic leukemia (PML) bodies and 
is essential for reactivation [109,140], and the microRNA miR-UL112-1, which represses IE1 translation 




1.3.4. Control of viral gene expression during latency and reactivation 
HCMV latency and reactivation is intimately linked with myeloid differentiation (§1.3.1) and, consistent 
with this, some latency-associated viral gene promoters contain elements that are differentially 
regulated during myeloid differentiation. For example, the promoters of LUNA and UL144 (in some viral 
isolates) contain GATA2 responsive elements, and GATA2 is expressed in myeloid cells allowing 
expression of these genes during latency [129,130,142].  
Perhaps the most important determinant of latency and reactivation is control of IE gene expression. As 
described in §1.2.3, IE gene expression is regulated by chromatin structure at the MIEP. Analyses of 
chromatin structure at the major immediate early promoter reveals that latency correlates  with a 
repressive chromatin structure around the MIEP, including the presence of the heterochromatin marker 
HP1 [103,104,143], as well as the histone modifications histone-H3-lysine-27-trimethylation (H3K27me3) 
and histone-H3-lysine-9-trimethylation (H3K9me3) [136,144] (see also Figure 1-2). Histone deacetylase 
(HDAC) activity is also important for maintaining a repressed chromatin state as treatment of latently 
infected monocytes with HDAC inhibitors leads to transient activation of IE gene expression [145].  
The differentiation of CD34+ progenitor cells, which can carry latent HCMV in vivo, into mature dendritic 
cells results in the removal of repressive H3K27me3 and H3K9me3 marks and associated HP1 from the 
MIEP [103,104,136,144]. Additionally, phosphorylation of histone H3-serine-10 (H3S10P) at the MIEP has 
been shown to precede the removal of repressive marks during the differentiation of experimentally 
infected monocytes into immature dendritic cells [146]. Acetylation of histone H4 has also been 
demonstrated during reactivation from latency in maturing dendritic cells [103,104]. As such, an open 
chromatin structure around the MIEP permits the initiation of IE transcription which is necessary for 
reactivation. 
Clearly, a repressive chromatin structure around the MIEP must be established during latency in myeloid 
progenitors and then modified during reactivation to permit efficient IE gene expression in differentiated 
dendritic cells and macrophages (Figure 1-2). We know that this process relies upon both cellular and 
viral factors; these can function by direct binding to the MIEP or by indirect mechanisms and have either 
activatory or repressive functions. A long-standing hypothesis states that it is the balance of these 
activatory or repressive factors that then controls whether or not the MIEP drives IE gene transcription, 
and that cellular differentiation must alter this balance [147–149].  
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Some host cell transcription factors bind directly to the overlapping 18, 19, and 21 bp repeats within the 
MIEP as well as other motifs in more upstream sequences (direct acting factors)[86]. This includes the 
repressive factors YY1 and ERF, and the activatory factors NF-κB and CREB. In undifferentiated, non-
permissive cells, the repressive factors YY1 [116] and ERF [150,151] bind to the 21 bp repeats. ERF is 
thought to recruit HDAC1 to the MIEP, thus providing a link between transcription factors binding to 
specific DNA sequence motifs and epigenetic modification. Interestingly, absolute levels of YY1  
decreased during differentiation of the non-permissive NT2 cell line [116]. 
KAP1 was more recently identified as a chromatin organiser that can mediate repression during latency  
in CD34+ HPCs [144]. While not strictly a DNA-binding protein, KAP1 was found to constitutively associate 
with HCMV DNA in CD34+ progenitor cells, and KAP1 deposition across the viral genome correlated with 
the presence of the KAP1 effector SETDB1, as well as HP1 and H3K9me3 marks at the MIEP. When KAP1 
was depleted, these marks were lost and the virus entered lytic replication in the absence of cellular 
differentiation. Furthermore, KAP1 activity was shown to be repressed during lytic infection by mTOR-
mediated phosphorylation, thus providing a potential mechanism for exiting latency. 
Other host factors which do not, themselves, bind to viral DNA are thought to control the presence or 
activation of other direct-acting factors. As discussed, mTOR-mediated phosphorylation of KAP1 
abrogates the repressive activity of KAP1, implying that mTOR is important for regulating latency. Other 
host kinases are also important. Linking reactivation with cellular differentiation, interleukin-6 (IL-6)/ 
lipopolysaccharide (LPS)-stimulated activation of ERK-MAPK pathways was shown to be crucial for 
inducing MIEP activity in maturing dendritic cells [146,152]. In this study, CREB was phosphorylated by 
the downstream kinase MSK, which is required for its activation at the MIEP. The absence of this MSK 
signalling cascade during latency in myeloid progenitors may therefore prevent CREB activity and help 
MIEP suppression.  
The role of viral factors during latency is becoming more appreciated [129]. These include viral factors 
that may enter myeloid cells as components of the virion. For example, the viral long non-coding RNA 
4.9, has been reported to bind the MIEP and recruit the repressor complex PRC2 to the MIEP [136]. The 
viral transactivator pp71,which activates the MIEP, is excluded from the nucleus of  undifferentiated 
myeloid cells and, since pp71 has been shown to be important for antagonising the suppressive functions 
of PML bodies on the MIEP during lytic infection, exclusion of pp71 may help an initial PML-mediated 
repression of the MIEP upon infection [153]. However, other reports in different systems note that 
knockdown of PML components had no effect on the establishment of latency [154,155] and, 
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furthermore, a recent study found that the viral factor LUNA actually disperses PML bodies during latent 
infection in CD34+ cells [109]. 
Transcribed viral genes also contribute to latency and reactivation. For example, the latency-associated 
gene product UL138 manipulates cellular signalling pathways from the ER, probably in concert and in 
opposition with other members of the ULb’ region [156]. UL138 has been reported to repress MIEP 
activity, in part by blocking histone lysine-demethylase activity during latency [157]  and also likely via 
manipulation of EGFR signalling [157,158]. Meanwhile, other viral factors promote reactivation from 
latency, including LUNA and UL7 [109,128,140]. 
The virally-encoded G-protein coupled receptor US28 is expressed during lytic and latent infections, as 
well as coming in with the virion [159] and has recently gained prominence as an essential protein for 
latency. In §1.4, I will describe how US28 is able to alter cell signalling in a differentiation dependent 




Figure 1-2 Regulation of HCMV latency and reactivation during myeloid differentiation, taken from 
[160]. HCMV infects CD34+ progenitor cells and establishes latency (top left). The HCMV genome is 
maintained in the nucleus as an episome (blue circle) and is chromatinised. The MIEP (represented 
bottom left) is prevented from driving IE gene expression by a repressive chromatin state. Histones 
(purple) are trimethylated at H3K9 and H3K27. The repressive factor HP1 associates with the MIEP, as do 
ERF and YY1, and KAP1 acts to suppress the MIEP from distal binding sites. Latency-associated viral 
factors (listed) contribute to MIEP suppression, and the activatory factor pp71 is excluded from the 
nucleus.  During differentiation-induced reactivation in mature dendritic cells or macrophages (top 
right), transcription of IE genes is activated leading to full lytic replication and release of infectious 
virions. As a result of differentiation, the chromatin structure around the MIEP is more open (bottom 
right), and activatory histone marks including histone acetylation (Ac) and H3-serine-10-phosphorylation 
(S10P) are present. Activated CREB and NF-κB become associated with the MIEP, as do histone acetyl 
transferases (HATs). Several viral factors are reported to be important for reactivation in myeloid cells, 




1.4. Viral protein US28 is essential for HCMV latency 
1.4.1. US28 structure, expression, and function during lytic infection 
HCMV encodes four G protein coupled receptors (GPCRs), namely US27, US28, UL33, and UL78 
[161,162]. One of these, US28, is a seven transmembrane domain protein coupled to host trimeric G 
proteins via an aspartate-arginine-tyrosine (DRY) amino acid motif [163] (Figure 1-3) . US28 is a 
chemokine receptor homologue, binding CC and CX3C chemokines via a variety of binding mechanisms 
involving the N terminus; residue Y16 in particular is known to be important for binding CCL5 and CX3CL1 
[164]. However, ligand binding is not required for all signalling activity of US28 and US28 can signal 
constitutively [163,165–168]. The C terminal region also has multiple serine residues that can be 
phosphorylated and is an important regulatory region that binds beta-arrestins [166,169]. 
Expressed in both lytic and latent HCMV infections [67,159,163,170–173], US28 protein (pUS28) is 
incorporated into infectious virions [159] and, during lytic infection, pUS28 is localised to endocytic 
vesicles and is constitutively recycled to/from the cell surface [174]. Pharmacological studies indicate 
that at least some proportion of US28 is localised to the cell surface during latent infection [172]. 
During lytic infection, the functions of US28 depend on the specific cell type infected [163,166] (Table 
1-2). Part of this ‘functional selectivity’ of US28 owes to the ability of US28 to interact with host G 
proteins which vary in a context and cell type-dependent manner [163,166], and which also interact with 
a swathe of different CC and CX3C chemokines [165], but, as described above, not all US28-functions are 
dependent on ligands. US28 can, in a cell-type dependent manner, induce calcium influx, cell adhesion, 
angiogenic signalling, and cell migration and, during lytic infection, activate pathways including MAPK, 
NF-κB, and STAT3 (references in Table 1-2).  US28 is also likely to function as a chemokine sink during 
lytic infection, to aid in immune evasion [175].  Furthermore, US28 is a positive regulator of transcription 
from the MIEP in cells permissive for lytic infection, a process dependent on p38 MAP kinase activation 
and NF-κB activation [176]. Despite these functions, US28 is not essential for lytic infection in vitro 
[159,177], but does enhance cell-to-cell spread in epithelial cells [178]. Possible in vivo functions of US28 
are not informed by e.g. MCMV, in part because MCMV encodes only one GPCR, M33, which could 
therefore be homologous to any of the four HCMV GPCRs. However, US28 may be important for 





Figure 1-3 Serpentine diagram of US28, highlighting functional domains, motifs, and amino acids. Plot was 




Table 1-2 Selected functions of US28, adapted from [163]. US28 activates the pathways, unless otherwise stated. 
Signalling pathway/ 
cellular function 




Arterial smooth muscle cells 
CCL5, CXCL3 [169,184] 





DRY motif [126,186] 
Cellular migration Smooth muscle cells 
Macrophages 
CC chemokines (positive 
regulator) 
CX3CL1 (negative regulator) 
[187,188] 
MAPK Embryonic kidney 
Differentiated myeloid cells 
 
DRY motif (positive regulator) [176,189] 
Endothelial cells 
Neural progenitor cells 
 
CCL5 (positive regulator) [190] 
Undifferentiated myeloid 
cells 




Glioblastoma cell line 
Epithelial cells 





DRY motif (negative 
regulator) 
[189] 
STAT3 Endothelial cells CCL5 [190] 




VEGF secretion Glioblastoma cell line 
Fibroblasts 
Ligand independent [40,181,192] 
 
 
1.4.2. US28 is essential for HCMV latency 
Three research groups, including my own laboratory, have independently found that US28 gene deletion 
viruses (ΔUS28) fail to establish latency in early myeloid lineage cells [159,173,189]. Cord blood-derived 
and bone marrow-derived CD34+ progenitor cells [159,173,193], Kasumi-3 cells [159,193], CD14+ 
monocytes [189], and THP-1 cells [189,193] all show this phenotype and, in each setting, the lack of US28 
leads to the failure to repress the MIEP, thus driving IE expression and the full lytic replication cycle with 
the eventual release of infectious viral particles. Removing US28 from the virus uncouples 
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permissiveness for lytic infection from cellular differentiation, since monocytes infected with ΔUS28 
HCMV abnormally undergo lytic infection, though they do not show differentiation-specific cell surface 
markers [189].  US28 is expressed and translated de novo as well as entering the cell with the virion [159] 
and both incoming US28 and de novo expressed US28 are important for the establishment and ongoing 
maintenance of latency in myeloid progenitor cells [193].  
Use of characterised mutants of US28 has elucidated some US28-mediated functions that are important 
for latency. As described in §1.4.1, the Y16F mutant removes some ligand binding activity [164] and the 
R129A mutant abrogates coupling of G-proteins to the DRY box motif of US28 [181,184,194] . Expression 
of wild-type US28 (US28-WT) in trans rescues latency-establishment in THP-1 cells with the ΔUS28 virus 
[189]. Similarly, expression of US28-Y16F in trans could also complement the US28 deletion virus 
suggesting that certain modes of ligand binding may not be necessary for the latency-associated function 
of US28 [189]. However, deletion of the entire ligand binding domain of US28 in the virus  causes lytic 
infection in myeloid cells [193], which is perhaps explained by work demonstrating the multiple modes 
by which US28 can bind a wide array of ligands [165]. It is clear, however, that infection with virus 
carrying US28-R129A or infection of THP-1 cells expressing US28-R129A with ΔUS28 virus fails to lead to 
latency establishment, providing clear evidence that US28-signalling via G proteins is essential for latency 
[189,193]. The way that US28 signalling manipulates the host environment to support latency is 
therefore of great interest and under intense study, and will be described in the next section. 
However, one group has produced findings that seemingly contradict these studies [195]. They 
constructed a virus with two stop codons close to the 5’ end of the US28 ORF, as well viruses with the 
US28-R129A and US28-Y16F mutations, and a destabilising domain attached to US28 (ddFKBP) which 
causes protein degradation unless in the presence of a molecule called Shield-1. However, neither the 
growth characteristics of these viruses nor US28 protein expression were validated by the authors. They 
infected fetal liver-derived CD34+ progenitor cells to examine the maintenance of HCMV latency and 
subsequent reactivation by transfer to fibroblasts or genome copy number. The authors concluded that 
the US28-stop virus can establish latency but fail to reactivate in long-term culture (over 14 d.p.i.), but 
did not show earlier time points; previous analyses have demonstrated that infection of myeloid cells 
with ΔUS28 viruses leads to lytic gene expression and infectious virus production within 7 days [159,189], 
providing one potential explanation for the discrepancy. Quite strangely, in that same study, the US28-
stop virus reactivated following stimulus, however, the lack of error bars throughout the study does not 
allow one to be certain about the precision of their analysis. Furthermore, the authors found that the 
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US28-Y16F virus failed to establish latency, with high levels of immediate virus production.  It is unclear 
how this observation could fit with any model of US28 function during latency and reactivation, and the 
lack of controls for protein production, virus growth kinetics, or time course of how latent infection 
progresses does not lead one to feel confident in their results. As an explanation for the discrepancy 
between their study and previously published studies [159,173,189], the authors suggest that (i) there 
are differences between the cells used and (ii) that while their study uses stop mutants, the previous 
work used whole ORF deletions, and “US28 is encoded on a polycistronic transcript that also includes 
US27 and US29 which could affect the expression of US27 and US29”.  While US28 is certainly encoded 
on a polycistronic transcript encoding US27, as well as a monocistronic transcript [66,67], I could find no 
evidence that US29 is encoded by such a transcript, and the authors do not provide a citation. 
Furthermore, unpublished data from the O’Connor laboratory suggests that US28 ORF deletions do not 
affect US27/US29 expression and that, in their system, a US28-stop virus also fails to establish latency (C. 
O’Connor, personal communication, manuscript in preparation). On the basis of the strength of the 
evidence provided by the four different laboratories, it seems most likely that US28 is essential for the 
both establishment and maintenance of latency. 
1.4.3. US28 manipulation of cell signalling during latency  
One argument in favour of an essential role of US28 in latency establishment and maintenance is the 
body of mechanistic data linking US28 signalling in myeloid cells with the suppression of lytic gene 
expression.  
Analyses of the activation states of cellular kinases during latent infection, or in myeloid cells 
overexpressing US28 in isolation have revealed several signalling pathways that are important for latency 
(summarised in Figure 1-4). Infection of CD34+ progenitor cells with WT virus, but not ΔUS28 HCMV, 
drives activation of the STAT3-iNOS pathway, and the resultant nitric oxide production was shown to 
suppress the MIEP [173]. Furthermore, these authors showed that presence of US28 in the context of 
latent infection may reprogramme infected cells to become immunosuppressive monocytes akin to 
myeloid-derived suppressor cells, rather than conventional monocytes or, indeed, parts of other myeloid 
or lymphoid lineages. 
Additionally, US28 has been found to attenuate several cellular signalling pathways, such as ERK, MSK, 
NF-κB, and STAT5 [189] when expressed in isolation in undifferentiated myeloid cells. It is interesting to 
note that ERK signalling is crucial for CREB phosphorylation at the MIEP and subsequent deposition of 
the activatory mark H3S10P on the MIEP upon differentiation-induced reactivation [146]. Consistent 
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with this, and the ability of US28 to attenuate ERK signalling, infection of monocytes with ΔUS28 HCMV 
(which no longer suppresses the MIEP) is also associated with activated CREB and phosphorylated H3S10 
on the MIEP. Furthermore, pharmacological inhibition of ERK in combination with NF-κB could prevent 
lytic replication of ΔUS28 HCMV in monocytes and, conversely, treatment of monocytes with small 
molecule inhibitors of US28 also results in a lytic infection rather than latency [189]. 
Attenuation of these cellular signalling pathways by US28 is reversed when US28-expressing cells are 
differentiated into macrophage-like cells using phorbol esters such as phorbol 12-myristate 13-acetate 
(PMA) [189]. The implication, then, is that US28 helps to maintain latency via the attenuation of MIEP-
activatory cascades but does not block signalling from these pathways during reactivation, and may even 
support their function during cellular differentiation. Indeed, in reporter systems, US28 represses the 
MIEP in undifferentiated THP-1 monocytes, but activates the MIEP in PMA-differentiated THP-1 derived 
macrophages [189]. 
Recent work has also shown that US28 decreases c-fos levels during latency. Binding to the AP-1 site 
within the MIEP by fos/jun dimers activates the MIEP and so, in decreasing c-fos, US28 enacts MIEP 
suppression via an additional mechanism. As such, treatment of myeloid cells with a c-fos inhibitor 
reduced lytic gene expression when infecting with ΔUS28 HCMV [193]. 
The functions of US28 during latency extend beyond MIEP suppression. US28 has been linked to 
hematopoietic reprogramming during latency, to ensure latently infected CD34+ HPCs differentiate into 
myeloid lineage cells [173,195]. Given the wide array of signalling pathways modulated by US28, there 
are likely further functions of US28 that are important for the establishment and maintenance of HCMV 
latency. In Chapter 3, I will present the results of a proteomic screen that aims to address the additional 





Figure 1-4 US28 controls several signalling pathways to suppress the MIEP in early myeloid lineage cells, taken 
from [160]. US28 is present at the cell surface, and probably other membranes, of latently infected cells. Here, it 
attenuates several signalling pathways and transcription factors, including NF-κB, c-fos, and ERK1/2. NF-κB can no 
longer enter the nucleus (dashed line), nor bind and activate the MIEP. c-fos typically forms a dimer with c-jun to 
form the AP1 complex; US28 causes loss of c-fos, the AP1 complex does not form and thus cannot activate the 
MIEP. Attenuation of ERK1/2 causes loss of ERK1/2 phosphorylation (P) and subsequent activation of MSK and, 
therefore, MSK does not phosphorylate and activate CREB. Inactive CREB cannot activate the MIEP. US28 is also 
reported to activate the STAT3-iNOS signalling axis, leading to nitric oxide (NO) production. NO suppresses the 
MIEP in myeloid cells by unknown mechanisms. By these, and probably other pathways, US28 helps establish and 




1.5. Pattern recognition and nucleic acid sensing during HCMV infection 
1.5.1. Lytic infection 
HCMV is a large double stranded DNA virus that replicates its genome in the nucleus. However, viral 
nucleic acids are substrates for pattern recognition receptors (PRR) in the cytosol as well as in the 
nucleus [196]. PRR induction leads to activation of both IRF3 and NF-κB transcription factors, leading to 
Type I interferon induction and production of pro-inflammatory cytokines. Early activation of PRRs, via 
HCMV envelope glycoproteins and HCMV DNA, is likely pro-viral and depends on Toll-like receptors (TLR) 
2 and TLR9, cGAS, STING, and IFI16 [196–198]. Cytosolic HCMV DNA likely results from early uncoating of 
viral capsids [199], while intact viral capsids deliver HCMV DNA to the nucleus. In certain contexts, cGAS 
and IFI16 can be either nuclear or cytosolic proteins [199–205], explaining how both are reported to 
contribute to innate sensing of HCMV DNA [78,94,209,196–199,203,206–208]. 
During lytic infection, HCMV interferes with pattern recognition receptor signalling, and the downstream 
effects of interferon, suggesting that some portions of this innate immune signalling must be evaded, 
modulated, or co-opted to ensure efficient viral replication. There are numerous viral factors known to 
play a role in this evasion [78,79,94,198,203,208,210,211]; a summary of these is presented in Figure 1-5.  
As well as innate sensing, HCMV must overcome intrinsic immunity that suppresses HCMV gene 
transcription. This centres around the heterochromatinization of incoming HCMV DNA and association 
with PML nuclear bodies, and is evaded by tegument proteins and immediate early genes during lytic 
infection [65,86,90,153,155,212–215]. Interestingly, PML nuclear bodies have more recently been 
proposed as signalling platforms that contribute to induction of innate immunity, making evasion of 
these structures beneficial to the virus on multiple levels [216,217] After the onset of viral transcription, 
viral dsRNA is a substrate for innate sensing and effectors such as RIG-I and PKR; this is also evaded by 
HCMV gene products [196,218–221].  Overall, HCMV lytic infection is associated with the generation of 
large quantities of pathogen-associated molecular patterns (PAMPs) that are, or can be, sensed by 
components of host intrinsic and innate immunity. These are actively evaded or manipulated by HCMV 





Figure 1-5 HCMV evasion of pattern recognition receptors and interferon induction, adapted from [198]. HCMV 
glycoproteins can be detected by TLR2, leading to activation of IRF3 and NF-κB pathways and Type I interferon 
induction. Premature uncoating of viral capsids leads to HCMV DNA availability in the cytosol; this may be sensed 
by cGAS leading to STING activation, which also activates IRF3 and NF-κB pathways, leading to Type I interferon 
induction. HCMV DNA in the nucleus is a substrate for IFI16-mediated sensing, leading to interferon induction via 
cGAS and/or STING. Viral antagonists of these processes are shown in blue. Other DNA sensors, such as DNA-
PK/DAI/LRRFIP1/AIM2 have been proposed, but no viral antagonist identified. 
1.5.2. Latent infection 
In contrast to lytic infection, latency is associated with far less viral gene transcription, and little-to-no 
genome replication. It is therefore questionable whether viral PAMPs are detectable during HCMV latent 
infection [198]. No study, to date, has analysed whether viral DNA/RNA is sensed during entry of virus 
into cellular sites of HCMV latency, or whether it is sensed during the ongoing maintenance of latency. 
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PML bodies are dispersed during HCMV latency by the latency-associate gene product LUNA [109], which 
one could argue is one example of suppression of intrinsic immunity during latency. However, many of 
the evasins described in Figure 1-5 are not expressed during latency, and, importantly, the tegument 
protein pp65, which disrupts IFI16 functions [203,208,215,222], does not reach the nucleus of CD34+ 
HPCs [223]. Furthermore, while many studies have analysed DNA sensing in differentiated THP-1 cells, 
which are permissive for HCMV lytic infection [197,199,206,209,224], none have looked at 
undifferentiated THP-1 cells (a model for HCMV latency). Therefore, what intrinsic anti-viral functions 
are active in undifferentiated myeloid cells, and what, if any, viral nucleic acid sensing occurs during 




1.6. The PYHIN proteins are DNA sensors and transcriptional regulators 
1.6.1. The PYHIN family of proteins: a brief overview 
Located in the 1q23 locus of the human genome, the PYHIN family of proteins have relatively recently 
come to light as innate immune sensors or mediators of host defences. PYHIN proteins, unique to 
eutherian and marsupial mammals [225], contain a Pyrin domain (a member of the death domain 
superfamily) which can oligomerise, and at least one of three HIN-200 domain subtypes, which can bind 
DNA. The five members of the human PYHIN family are annotated in Figure 1-6. These are myeloid cell 
nuclear differentiation antigen (MNDA), interferon-inducible protein X (IFIX; formally denoted as 
PYHIN1), pyrin domain-only protein 3 (POP3), gamma interferon-inducible protein 16 (IFI16), and absent 
in melanoma 2 (AIM2). There is large diversity of the PYHIN family between species both in sequence 
and number of families, which makes the use of animal models to study the function of these proteins 
challenging [225]. For example, mice have at least 13 PYHIN proteins, and only gene Aim2 has true 
orthology with its human counterpart, AIM2 [225]. POP3 lacks a HIN-200 domain and likely regulates 
inflammasome structures of the other PYHIN proteins [226]; this function, and other PYHIN protein 
functions will be described in more detail in the next sections.  
 
Figure 1-6 Domain architecture of the PYHIN proteins. Pyrin domains (PYD) are annotated based on a review by 
Connolly and Bowie [227], and nuclear localisation sequences (NLS) and HIN domains are labelled based on UniProt 
annotations. The PYHIN proteins are shown in order corresponding to the arrangement of the genes along 




AIM2 was first reported as an interferon-inducible gene with a role in cancer biology [228,229]. Later, it 
was found to respond to cytosolic DNA in mice and human cells [230–233]. AIM2 can respond to 
microbial DNA as well as cytosolic host DNA, and these responses are comprehensively reviewed 
elsewhere [234] 
AIM2 was found to play such a role in 2009[7–10] in the cytosol of mice and human cells. AIM2, and its 
responses to bacterial, viral, and other pathogenic DNA is comprehensively reviewed elsewhere 
[234,235]. The key function of AIM2 is the activation of inflammasome responses in response to cytosolic 
DNA. AIM2 is believed to exist in an auto-inhibitory state whereby the HIN domain blocks sites in the 
Pyrin domain required for signalling. Upon binding DNA in the cytosol in a sequence independent 
manner via the HIN domain, the Pyrin domain can now mediate an interaction with ASC (apoptosis-
associated speck-like protein containing a CARD). ASC now binds caspase-1, which cleaves the pro-
inflammatory cytokines IL-1β and IL-18, and Gasdermin D, which initiates pyroptosis. AIM2 (Aim2 in 
mice) has been shown to be activated by murine cytomegalovirus (MCMV), and Aim2 deficient mice had 
higher viral titres at 36 hours post infection [236]. Furthermore,  AIM2 is activated by HCMV infection, 
which may be antagonised by pp65; the subsequent production of IL-1β is antagonised by IE2 protein 
[237–239]. AIM2 also has antiviral effects against human papillomavirus (HPV) [240] and hepatitis B virus 
(HBV) [241], and HSV-1 encodes an antagonist of AIM2 [242].  
1.6.3. IFIX 
IFIX, or PYHIN1, has recently been identified by one group as a nuclear antiviral factor and sensor for 
HSV-1 [243]. In their study, Diner et al. defined an interactome for all four of the HIN domain-containing 
PYHIN proteins in HEK293 cells. They noted that IFIX was able to interact with PML body components. As 
described in §1.5.1, PML bodies are critical components of intrinsic immunity, inducing chromatinization 
and repression of viral gene expression. Knockdown of IFIX increased HSV-1 titres in infected fibroblasts, 
suggesting that IFIX is a restriction factor for HSV-1. IFIX could bind DNA in a sequence independent 
manner, responded to transfected DNA by inducing the expression of interferon-beta (IFNβ), and 
chromatin immunoprecipitation (ChIP) analyses found HSV-1 DNA is associated with IFIX. A follow-up 
study found that IFIX is antagonised by an early HSV-1 gene product, a hallmark of an antiviral factor, and 





IFI16 was first identified as a transcript constitutively expressed in T- and B- lymphocytes but interferon-
γ-inducible in myeloid U937 and HL60 cells [245]. Quite a number of roles have been described for IFI16, 
for example in cellular senescence [246,247], the DNA damage response [224,248,249], pro-
inflammatory pathways [250–253], and in innate defence against viruses (reviewed in [227,254,255]). 
IFI16 has both transcriptional and signalling functions that contribute to the restrictive role of IFI16 for 
numerous viral pathogens; I will describe the most pertinent of these below.  
IFI16 was first identified as a sensor of transfected DNA in the cytosol where, via an interaction with 
STING, it induces IFNβ [256]. Since then, IFI16 has been shown to respond to transfected DNA insults to 
induce Type I interferon responses or silence transcription from transfected plasmids [206,257,258]. 
IFI16 has also been identified as a restriction factor for the DNA viruses HSV-1 [201,204,215,259–262], 
HSV-2 [263], HCMV [208,215,264], KSHV [204,265–268], EBV [265], and HPV [269]. IFI16 can also 
respond to or restrict transcription of DNA intermediates during HIV [270–272], Human T-lymphotropic 
virus type 1 (HTLV-1) [273], HBV infections [274] and, perhaps counter intuitively, IFI16 is also a reported 
restriction factor for the RNA viruses Zika virus, Chikungunya virus, and Sendai virus [258,275]. 
As alluded to earlier, IFI16 is reported to contribute to innate sensing of herpesviral DNA in both the 
cytosol [199,206,270] and the nucleus [215,261,265,269,276]. This likely involves cooperative 
aggregation of IFI16, via Pyrin domains [215,277], to generate either an AIM2-like inflammasome 
[265,267,276] or a structure capable of activating cGAS or STING [201,209,261] and subsequent 
induction of IL-1β or Type I interferon, respectively. How IFI16 can discriminate between self- and non-
self DNA in the nucleus has been of great interest; in one model, IFI16 binds DNA via its HIN domains in a 
sequence-independent but length-dependent manner, and the minimum length is longer than the 
distance between nucleosomes and transcription bubbles [256,277–279]. The clustering of IFI16 occurs 
as IFI16 tracks along DNA duplexes in a 1D manner and contacts other scanning IFI16 molecules [279]; 
nuclear IFI16 puncta are observable during the first 15 minutes of HSV-1 infection [259,280]. However, 
other structures are proposed to be substrates for IFI16 recognition [281,282] and, at low multiplicity of 
infection (MOI), IFI16 can only lead to innate signalling once HSV-1 viral transcription and replication is 
initiated, suggesting that more complex DNA structures are sensed by IFI16 [262].   
IFI16 also restricts viral infections by modulating viral transcription. In the vast majority of cases, IFI16 
represses lytic gene transcription, and this can be via interaction with PML body components 
[259,283,284], the sequestration of Sp1 transcription factor [264,271], and promoting repressive histone 
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marks [268,274,283]. In fact, transcriptional repression by IFI16 makes the presence of IFI16 essential for 
the maintenance of EBV latency [285], and IFI16 must be degraded for efficient KSHV reactivation from 
latency [267]. It is worth noting that there is only weak evidence that IFI16 directly binds to DNA to exert 
transcription repression. 
The transcriptional role of IFI16 during HCMV infection is slightly more complex.  During HCMV infection 
of fibroblasts, IFI16 is co-opted by the viral tegument protein UL83 (pp65) [79,208]. This binding serves 
multiple roles: firstly, the IFI16/UL83 complex may bind and does activate the MIEP during the first 6 
hours of infection [79,264]. The binding of UL83 blocks oligomerisation of IFI16 Pyrin domains, thus 
preventing innate immune signalling and cytokine induction [215] but, likely, also prevents the 
repression of HCMV early gene expression (UL54, UL44) [208,264,286]. Thus, at low multiplicities of 
infection, IFI16 is both required for efficient HCMV lytic infection (for IE gene expression) but is then 
restrictive to HCMV replication. Since the MIEP must be transcriptionally repressed for efficient latency 
establishment, it might be predicted that the regulation of IFI16 expression by HCMV is important for 
latency. 
1.6.5. MNDA 
MNDA was the first human PYHIN protein to be identified; it is interferon-α-inducible, and its expression 
is specific to cells of the myeloid lineage [287–290]. No antiviral functions associated with MNDA are 
published, though in at least two settings viral gene products have been found able to interact with 
MNDA. Firstly, the KSHV Latency-associated nuclear antigen (LANA) was identified as an MNDA 
interactor by a yeast-2-hybrid screen and by immunoprecipitation when both genes are transfected into 
293T cells [291]. Secondly, again in an overexpression analysis in 293T cells, UL83 can bind and disrupt 
aggregation of the Pyrin domain of MNDA [215]. Of note, unpublished data presented at a conference 
from the Bowie lab has suggested that MNDA can contribute to Type I interferon induction (Andrew 
Bowie, personal communication), which is consistent with the ability of MNDA to bind DNA [292] .  
MNDA is relatively uncharacterised compared to AIM2 or IFI16. MNDA bears hallmarks of an important 
transcriptional regulator for myeloid differentiation [293–297]; for example, ectopic expression of MNDA 
in conjunction with three other transcription factors induced reprogramming of fibroblasts that drove 
changes in morphology, and increases in phagocytosis, chemotaxis, and cytokine production consistent 
with monocyte-like behaviour [294].  In support of transcriptional activity, MNDA can stimulate the 
binding of the transcription factor YY1 to its target DNA sequences [298], which is intriguing since YY1 is 
a known repressor of the MIEP [116]. 
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Reduced levels of MNDA transcripts have been associated with myelodysplastic syndrome [299–301], a 
syndrome thought to involve aberrant myeloid cell apoptosis [302]. As such, two reports have sought to 
define the behaviour of MNDA during apoptosis. In the myeloid cell line HL-60, MNDA is exported to the 
cytoplasm upon stimulation with hydrogen peroxide, a crude stimulus designed to induce apoptosis, 
[303] thus showing that MNDA has dynamic behaviour in response to cell stresses. In the same study, 
the authors found that exogeneous MNDA expression in K652 cells increased protection for TRAIL-
induced apoptosis [303]. The second study monitored the behaviour of MNDA in ex vivo neutrophils 
from healthy patients and septic patients, a condition that involves the failure of neutrophils to undergo 
apoptosis [304]. Ex vivo neutrophils from healthy patients underwent apoptosis within 24 hours, and this 
was characterised by cytoplasmic redistribution of MNDA and cleavage of MNDA to distinct ~27 and ~35 
kDa products. Levels of MNDA cleavage correlated with Annexin-V positivity, a well-established early 
marker of apoptosis. In neutrophils from septic patients, these events did not occur. Knockdown of 
MNDA in HL-60 cells protected these cell lines from UV light-induced apoptosis, as characterised by 
Annexin-V positivity, mitochondrial membrane potential, and caspase-3 activity. Interestingly, MNDA 
interacted with Mcl-1 (a critical myeloid pro-survival protein) in the cytoplasm and promoted the 
degradation of Mcl-1 in response to apoptotic stimuli. This interaction is extremely pertinent to HCMV 
latency, since Mcl-1 is known to be upregulated as a result of the binding/internalisation of virus into 
monocytes and to promote the survival of latently infected CD34+ cells and monocytes [112,114,305]. 
The upregulation/stabilisation of Mcl-1 has thus far been shown to be dependent on ERK and PI3K 
signalling, and critical to allow long-term survival of what are typically short-lived circulating monocytes.   
It is, therefore, an interesting question as to how MNDA might be regulated by, and regulate responses 




1.7. Nanobodies as immunotherapeutic agents 
1.7.1. Camelid antibody domains as therapeutic agents 
Typical IgG molecules from mammals, including humans and mice, are dimers of dimers containing a 
heavy and a light chain. In turn, the heavy chain contains 3 constant domains and one variable domain, 
while the light chain contains one constant domain and one variable domain (Figure 1-7). Together, the 
variable domains of the heavy and light chains compose the complementarity determining region, i.e. 
the antigen binding portion of the antibody [306]. 
 
Figure 1-7 A comparison of the domain architectures of human IgG (A), camelid heavy-chain only 
immunoglobulin (B), VHH domains/nanobodies (C), and a bivalent nanobody (D). (A) Human IgG contains heavy 
(green) and light (blue) chains that contain constant domains (CH and CL) and variable domains (VH and VL). 
Together, CH2 and CH3 form the Fc portion of the molecule, and 2x (CH1, CL, VH, and VL) form the Fab fragment. (B) 
Camelid heavy-chain only immunoglobulin molecules are dimers of constant (CH2 and CH3) and variable (VHH) 
polypeptides. (C) VHH domain antibodies are known as nanobodies, can contain only a VHH domain. (D) 
Nanobodies may be multimerised by chemical or genetic mechanisms. This bivalent nanobody represents the 
bivalent US28 nanobody VUN100b, discussed later; the C terminus of one nanobody is connected to the N terminus 
of the next by an encoded polypeptide linker. 
In contrast, camelid species (camels, llamas, alpacas) naturally produce heavy chain-only antibodies as 
part of their array of immunoglobulin molecules [307]. The variable domain of these heavy chains (VHH) 
therefore confers the antigen specificity of the molecule (Figure 1-7). Camelids can be immunised in 
manners similar to the immunisation of mice and rabbits in order to generate antibodies to an antigen of 
interest, and the resulting VHH domain coding sequences can be cloned from immunised animals and 
used to generate libraries from which high-affinity VHH genes can be isolated [307,308]. These single-
domain antibodies, henceforth termed nanobodies (Nbs), are much smaller than monoclonal antibodies 
45 
 
(15 kDa when unmodified), have higher solubility in water, are expressed from only one coding 
sequence, and can more easily access active sites or ligand binding regions of target proteins [307]. 
Nanobodies have potential applications as experimental, imaging, diagnostic, and therapeutic tools 
[309–311]. There is one currently licensed nanobody for therapeutic use, Caplacizumab, for the 
treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Patients with aTTP suffer from 
inappropriate and life-threatening blood clotting due to an abundance of unprocessed von Willebrand 
factor (VWF) strings [312,313]. This is typically due to an autoimmune antibody response to the enzyme 
which cleaves VWF. Caplacizumab is a bivalent humanized anti-VWF nanobody that prevents VWF 
binding to platelets and reduces the length of acute TTP episodes [314]. 
Other nanobodies have been investigated for the treatment of acute viral infections, including 
respiratory syncytial virus (RSV) and rotavirus [307,315], though a Phase IIb clinical trial of the RSV 
nanobody therapeutic was stopped in 2018 due to a lack of efficacy ( 
https://clinicaltrials.gov/ct2/show/NCT03418571). In addition, nanobodies targeting human G protein 
coupled receptors have been investigated for therapeutic potential [316–318] , as well as nanobodies 
targeting HCMV US28 [182,308], which I will discuss in the next section. 
1.7.2. Anti-US28 nanobodies modulate US28 activity 
HCMV nucleic acids and US28 protein can be detected in tumour samples from glioblastoma patients 
[36,190]. US28 is thought to be oncomodulatory in glioblastoma, and constitutive signalling from US28 
was recently shown to accelerate glioblastoma growth in an experimental setting [40,181,182]. On this 
basis, Martine Smit’s group (Vreije Universitet, Amsterdam) developed an anti-US28 nanobody (US28-
Nb) [182]. The monovalent nanobody could displace the ligands CCL5 and CX3CL1 from binding US28 in 
competition assays, with a Kd (US28 binding) of approximately 340 nM. Binding was enhanced 
approximately 100-fold by the linking of two US28-Nb molecules together to form a bivalent nanobody. 
Interestingly, this bivalent format was then also able to block US28 constitutive signalling as measured by 
US28’s known ability to activate NF-κB in reporter assays in some cell models, while the monovalent 
format was not able to do this. The bivalent US28-Nb could then block the acceleration of glioblastoma 
spheroid growth in an experimental setting [182].  
The group then developed a higher-affinity monovalent US28-targetting nanobody termed VUN100 
[308]. VUN100 was developed with the aim of conjugating a photosensitiser to the nanobody such that it 
could be used in photodynamic therapy for the treatment of glioblastoma. Briefly, the nanobody-
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photosensitiser conjugate binds US28 on the surface of glioblastoma cells, and when illuminated by the 
correct wavelength of light, the photosensitiser is activated and produces reactive oxygen species 
leading the death of the bound cell [308]. 
Subsequently, the group developed a bivalent form of VUN100, termed VUN100b, which I will describe 
in more detail in Results. In a collaboration between our two laboratories, and in particular Timo de 
Groof and myself, we investigated the effect of these nanobodies on HCMV latency, since US28 is 
expressed on the cell surface of latently infected cells [172]. In Chapter 7, I will describe how anti-US28 
nanobodies induce IE gene expression during latency and how this leads to recognition and killing by 
cytotoxic T cells. Therefore, I will provide some background to this potentially therapeutic concept, often 
termed ‘shock and kill’, in the next section. 
1.7.3. Shock and kill for reducing latent viral loads 
Latent reservoirs of viral pathogens are significant barriers to eradication of these viruses from their 
hosts [20,319,320]. During latency, human herpesviruses and retroviruses maintain their viral genomes 
in the absence of infectious virus particle production, often with little-to-no viral gene expression [321].  
As such, latent infections are refractory to treatment with typical antivirals that target replication of the 
virus [320]. Furthermore, the relatively low levels of viral gene expression during latency reduces the 
levels of viral antigens that would otherwise be readily detectable by host immune cells e.g. cytotoxic T 
lymphocytes (CTLs) [20]. 
The shock and kill strategy aims to reverse latency and drive lytic viral gene expression (shock) leading to 
recognition and elimination by naturally present immune responses (kill), and has been extensively 
explored by HIV-1 biologists and clinicians [319,320]. HIV-1 latency, like herpesvirus latency, is 
dependent on repressive chromatin structures around its key viral promoter [86,321–323]. Approaches 
to target the epigenetic machinery, such as with inhibitors of histone deacetylases (HDACi) and histone 
methyl transferases have been trialled [319,320]. Some have shown promising results in cell line models, 
and have induced detectable HIV-1 replication in patients, but none has led to a reduction in the latent 
viral reservoir [319,320]. This is presumed to be a result of an inability to target deep tissue latent virus 
reservoirs, failure to induce killing, because of drug interference with CTL function, and subversion of 
apoptotic pathways by the reactivated virus [319,324,325].  
More recently, herpesvirologists have begun to explore latency reversal and shock and kill 
[20,320,326,327]. Work from my own laboratory has shown that HDACi induce transient activation of 
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lytic IE gene expression in latently infected monocytes, resulting in CTL-mediated killing of infected cells 
[145]. Ongoing work by colleagues aims to use additional epigenetic machinery-targeting small 
molecules to improve shock and kill, and preliminary data suggests that seropositive individuals who are 
already taking these drugs for other conditions have lower latent viral loads. As described in §1.1.2, up to 
5% of a seropositive individual’s CD8+ T cells are capable of recognising lytic IE antigen [74], which might 
aid in the efficiency of the ‘kill’ part of shock and kill. 
However, host-targeting antivirals have off-target effects, and it may be preferable to use a specific 
virus-targeting molecule to induce shock and kill. In §1.4.2, I presented the evidence for US28 being 
essential for HCMV latency due to the ability of US28 to suppress the MIEP. In Chapter 7, I will show how 
US28-targeting nanobodies inhibit US28 function in myeloid cells and induce IE gene expression, leading 




1.8. US28-targeting immunotoxins for killing of HCMV-infected cells 
1.8.1. Immunotoxins as anti-cancer and anti-microbial agents 
Ligand-toxin fusion proteins, or immunotoxins, have shown promise for targeting cancer and infectious 
diseases [328,329]. The principle of an immunotoxin is that a toxin is conjugated to a molecule that binds 
and is internalised by a receptor on target cells. The toxin is then cleaved within cells and, if enough 
immunotoxin has been internalised, the target cell is killed. The ligand can be based upon the native 
ligand for a given receptor, or be a receptor-targeting antibody. Cancerous cells and pathogen-infected 
cells frequently have upregulation of cell-surface receptors, or the presence of unique receptors, making 
these diseases targets for immunotoxin-based treatments. Some have been licensed as therapies, such 
as trastuzumab emtansine (T-DM1), a conjugate which targets HER2-positive breast cancers [330,331]. 
Some examples of immunotoxins in development or clinical use are given in Table 1-3.  
Table 1-3 Immunotoxins: examples and modes of action 
Disease Ligand Toxin 
HER2-positive breast 
cancer [331] 
Anti-HER2 monoclonal antibody 
(trastuzumab) 
DM1/Mertansine, inhibitor of 
microtubule formation 
Hairy cell leukemia [332] Anti-CD22 monoclonal antibody Pseudomonas aeruginosa Exotoxin A, 
translation inhibitor 
Latent HIV-1 [333] Anti-CD30 monoclonal antibody  Monomethyl auristatin E, inhibitor of 
microtubule formation 
Acute myeloid leukemia 
[332] 
Granulocyte-macrophage 
colony stimulating factor (GM-
CSF) 
Diphtheria toxin 
HCMV [334] CX3CL1 (fractalkine), bound by 
HCMV US28 
Pseudomonas aeruginosa Exotoxin A, 
translation inhibitor 
 
1.8.2. F49A-FTP, a US28-targeting immunotoxin 
US28 binds the chemokine CX3CL1/fractalkine with higher affinity than the host native receptor, CX3CR1 
[334,335].  US28 is also expressed during both lytic and latent infection (§1.4) and, therefore, represents 
a target in patients with active CMV disease and those who harbour latent virus. Spiess and colleagues 
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[334] designed an immunotoxin to take advantage of these properties. The immunotoxin ligand 
consisted of the soluble domain of CX3CL1 (after removal of its mucin stalk domain) containing an F49A 
mutation, decided upon following rational mutagenesis. The toxin was the cytotoxic domain of 
Pseudomonas aeruginosa Exotoxin A, which is cleaved from CX3CL1 by the host protease furin following 
internalisation. The immunotoxin, termed F49A-FTP, had a 182-fold greater affinity for US28 than for 
CX3CR1. It also killed lytically infected cells and showed antiviral activity in an infected humanised 
mouse, with greater potency than the established CMV antiviral ganciclovir.  
In a collaboration with members of my own laboratory, F49A-FTP was then shown able to specifically kill 
latently infected cells and block reactivation at a concentration of 5x10-8 M following a 72 hour 
incubation [172]. This was true for experimentally latent monocytes, CD34+ cells, and naturally latent 
monocytes from seropositive donors. The results suggested that F49A-FTP could be used to target the 
latent viral reservoir. Perhaps not unexpectedly, resistance mutants did arise  during serial passage of 
virus in lytic infection [334,336] and, in all but one case, this involved a premature stop codon resulting 
in a truncated pUS28. This truncated pUS28, though expressed, was present at lower levels at the cell 
surface and was less able to bind and initiate responses to chemokines; it was therefore postulated that 
this viral mutant might lack in vivo fitness. 
Other than antiviral resistance, there are additional potential problems with an F49A-FTP strategy for 
treatment of HCMV. Immunotoxins tend to be immunogenic because they contain ‘foreign’ antigens 
[337]. Anti-drug antibodies are induced and neutralise any efficacy during long term treatment of a 
patient. However, the possibility of treating an HCMV positive graft ex vivo prior to transplantation could 
negate such problems. One such system which would lend itself to such an approach is the ex vivo 
normothermic perfusion system for solid organs [338,339]. Ex vivo normothermic perfusion (EVNP) is a 
novel technique that can recondition an organ and restore function in sub-optimal organs prior to 
transplantation. During this procedure, a solid organ can be perfused with buffers that could contain a 
drug, such as the F49A-FTP. Indeed, in collaboration with our laboratory, transplant physicians at the 
University Health Network (Toronto, Canada) are attempting to reduce the latent load in cadaveric lung 
prior to transplant. To optimise such an intervention, the immunotoxin needs to be able to kill infected 
cells following less than 6 hours of incubation (a typical maximum length of normothermic perfusion). 
Furthermore, since their original study, the designers of the immunotoxin had been experimenting with 
variations in the FTP construct [340], and a company (Synklino ApS) had been established to perform 
preclinical testing of newer FTP constructs.  In Chapter 8, I will address whether these new FTP 
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constructs can kill latently infected cells with greater efficacy and in a shorter window, to permit more 




2. Materials and Methods 
2.1. Cells 
All cells were maintained at 37 °C in a 5% CO2 atmosphere. THP-1 cells (ECACC 88081201) were cultured 
in RPMI-1640 media (Sigma) supplemented with 10% heat-inactivated fetal bovine serum (FBS; PAN 
Biotech), 100 U/mL penicillin and 100 µg/mL streptomycin (Sigma), and 0.05 mM 2-mercaptoethanol 
(Gibco). Kasumi-3 cells (ATCC® CRL-2725) were cultured in RPMI-1640 media (Sigma) supplemented with 
20% heat-inactivated fetal bovine serum (PAN Biotech), 100 U/mL penicillin and 100 µg/mL streptomycin 
(Sigma). During infections, THP-1 and Kasumi-3 cells were cultured in a low-serum (1%) version of this 
media for a minimum of 24 hours prior to inoculation, and maintained in this low-serum media 
throughout the infection. MIEP-eGFP reporter THP-1 cells [118] were a gift from M Van Loock, Johnson & 
Johnson. RPE-1 cells (ATCC® CRL-4000™) and Human foreskin fibroblasts (Hff1; ATCC® SCRC-1041™) were 
maintained in DMEM (Sigma) supplemented with 10% heat-inactivated FBS and 100 U/mL penicillin and 
100 µg/mL streptomycin. 293T cells (ECACC 12022001) were maintained in DMEM (Sigma) 
supplemented with 10% heat-inactivated FBS but without penicillin or streptomycin. Hff-TERT and Hff-
TERT US28-V5 cells were a gift from L. Nobre, University of Cambridge. These were also maintained in 
DMEM 10% FBS plus penicillin/streptomycin. Phorbol 12-myristate 13-acetate (PMA, Sigma) was used to 
induce myeloid cell differentiation at a concentration of 20 ng/mL in primary monocytes, and 100 ng/mL 
in THP-1 cells. 
Primary CD14+ monocytes were isolated from apheresis cones (NHS Blood & Transplant Service) or from 
peripheral blood taken from healthy volunteers as previously described [111]. Briefly, CD14+ monocytes 
were isolated from total peripheral blood mononuclear cells (PBMC) by magnetic-activated cell sorting 
(MACS) using CD14+ microbeads (Miltenyi Biotech). The monocytes were plated on tissue culture dishes 
(Corning) or slides (Ibidi), or kept in suspension in X-Vivo 15 media (Lonza) supplemented with 2 mM L-
glutamine. Mature dendritic cells were generated by treating CD14+ monocytes with granulocyte-
macrophage colony-stimulating factor (GM-CSF, Miltenyi, 1000U/mL) and interleukin-4 (IL-4, Miltenyi, 
1000U/mL) for 5 or 6 days before addition of lipopolysaccharide (LPS, Invivogen, 50 ng/mL) for 2 further 
days. CD4+ and CD8+ T cells were isolated by MACS from monocyte-depleted PBMC using CD4 and CD8 
microbeads (Miltenyi Biotec).  These primary cells were cultured in X-vivo 15 (Lonza) supplemented with 
2 mM L-glutamine (Gibco) at 37°C in 5% CO2. Phorbol myristate acetate (PMA, Sigma-Aldrich) was used 
as described in figure legends at 20 ng/mL. 
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Primary human CD34+ hematopoietic progenitor cells, isolated from adult bone marrow, were purchased 
from STEMCELL Technologies and cultured in X-Vivo 15 media (Lonza). 
2.2. Inhibitors 
The c-fos inhibitor T5524 was purchased from Cayman Chemical, solubilised in dimethyl sulfoxide 
(DMSO) and used at 10 μM. The Janus kinase inhibitor Ruxolitinib was purchased from Cell Guidance 
Systems, solubilised in DMSO and used at 5 μM. The IKKα inhibitor/NF-κB pathway inhibitor BAY11-7082 
was purchased from Santa Cruz, solubilised in DMSO, and used at a concentration of 5 μM. 
2.3. Generation of lentiviruses and retroviruses 
The lentiviral vectors encoding US28 from the VHL/E strain of HCMV have been described previously 
[189]; US28 is expressed in these vectors from the Spleen Focus-Forming Virus (SFFV) promoter. The 
lentiviral vectors pHRSIN UbEm and pHRsin SV40blast were a kind gift from D. van den Boomen, 
University of Cambridge, and were based upon a previously published lentiviral system [341,342]. Briefly, 
expression of the gene of interest is also driven by the SFFV promoter, and the selectable markers 
Emerald and blasticidin resistance are driven by the Ubiquitin promoter (UbEm) and the SV40 promoter 
(SV40blast), respectively. The sequence encoding US28 from the VHL/E strain of HCMV was cloned into 
pHRSIN UbEm using the EcoR1 and Spe1 sites. The sequence encoding IFI16 was cloned into pHRsin 
SV40blast using the BamHI and NotI sites. The coding sequence of MNDA was cloned from a TrueClone® 
cDNA clone (Origene) into pHRsin SV40blast using XhoI and NotI sites. Correct plasmid sequences were 
verified by Sanger Sequencing (Department of Biochemistry, University of Cambridge). Primer sequences 
are given in Table 2-1.  
The retroviral vector pBABE eGFP US28-3XFLAG was a gift from C. O’Connor (Cleveland Clinic, USA). The 
Q5 site directed mutagenesis kit (New England Biotech) was used to generate the US28-R129A mutant of 
this vector, which was verified by Sanger Sequencing (Department of Biochemistry, University of 
Cambridge). Expression of US28 in these vectors is driven by the HIV-1 long terminal repeat and partial 
gag. 
Generation of VSV-G pseudotyped lentiviral particles was conducted generally in line with the Broad 
Institute Protocols. Five hundred thousand 293T cells were transfected with 1250 ng of lentiviral 
expression vector, 625 ng of lentiviral packaging vector psPAX and 625 ng of envelope vector pMD.2G 
(both gifts from S. Karniely, Weizmann Institute, Israel) using transfection reagent FuGene6 (Promega) 
according to the manufacturer’s instructions. For generation of VSV-G pseudotyped retrovirus particles, 
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1250 ng of the murine leukemia virus retroviral packaging vector KB4 [343] (a gift from H. Groom, 
University of Cambridge) was transfected along with 625 ng pMD.2G and 1250 ng retroviral expression 
vector.  
2.4. Lentiviral and retroviral transduction 
Supernatants from transfected 293T cells were harvested at 36 and 60 hours post transfection, filtered 
through a 0.45 µm syringe filter, and used to transduce THP-1 cells in the presence of 2 μg/mL 
polybrene. When necessary, lentiviral titres were determined by in-house p24 enzyme-linked 
immunosorbent assay (ELISA) by Isobel Jarvis (Department of Medicine, University of Cambridge).  For 
transduction with puromycin-resistance vectors, puromycin (2 μg/mL, Sigma) was added to media and 
refreshed every 2-5 days until all control non-transduced THP-1 cells were dead. Similarly, where 
blasticidin-resistance vectors were used, blasticidin (10 μg/mL, Invivogen) was added to media. Emerald 
positive cells were isolated by fluorescence associated cell sorting (FACS) using a BD FACSAriaIII 
instrument. 
2.5. Preparation and transfection of DNA into THP-1 cells 
All DNA transfections used a mock-transfected control, which contained equivalent levels of the 
transfection reagent, Fugene6 (Promega). Poly dA:dT was purchased from Invivogen and transfected at a 
final concentration of 1 μg/mL. pUC19 (Addgene #50005) [344] was digested with BglI and purified by 
phenol/chloroform/isoamyl alcohol extraction [345]. THP-1 cells (2 x 105) were transfected with 1 or 2 μg 
of the digested plasmid using transfection reagent FuGene6 (Promega) for 24 hours prior to RNA 
extraction. The plasmid pmaxGFP was a component of the Amaxa Nucleofection Kit R (Lonza) and drives 
GFP expression from a modified 780bp HCMV MIEP. EF1alpha GFP was a gift from P. Upton (Department 
of Medicine, University of Cambridge). These, and pHRsin UbEm (described above), were transfected 
into THP-1 cells (750 ng / 2 x 105 cells) using transfection reagent FuGene6 (Promega) and GFP 
expression was analysed by flow cytometry using a BD Accuri Instrument 24 hours after transfection.  
2.6. Human cytomegaloviruses 
Infection of monocytes and THP-1 cells were carried out at a multiplicity of infection (MOI) of 3 as 
determined by titration on RPE-1 cells. When required, latently infected, mCherry positive THP-1 cells 
were sorted using a BD FACSAriaIII instrument. Hff1 and RPE-1 cells were infected at indicated MOIs as 
determined by titration on Hff1 and RPE-1 cells, respectively. 
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TB40/E BAC4 strains, recombinant viruses derived from bacterial artificial chromosomes (BAC), were 
propagated in RPE-1 cells by seeding 50% confluent T175 flasks with virus at an MOI of 0.1. Spread of 
virus was monitored for 2-6 weeks following inoculation by fluorescence microscopy, and infected 
monolayers were subcultured twice during this period. When cells were 95-100% infected (on the basis 
fluorescent tag detection), supernatants were harvested on three occasions spaced over 7 days and 
stored at -80°C. In the final harvest, the monolayer was scraped and also stored at -80°C. After thawing 
the virus-containing media, cell debris was pelleted by centrifugation at 1500 x g for 20 minutes at RT. 
Then, the clarified supernatant was concentrated by high speed centrifugation at 14500 x g for 2 hours 
at 18°C. Virus-containing pellets were then resuspended in X-vivo-15 media in aliquots at -80°C.  
TB40/EmCherry-US28-3XFLAG and TB40/EmCherry-US28Δ have been described previously [159].  
TB40/Egfp [346] and TB40/E BAC4 SV40 mCherry IE2-2A-GFP[121] were kind gifts from E.A. Murphy, 
SUNY Upstate Medical University. TB40/E BAC4 IE2-eYFP has been described previously [347,348]. 
TB40/E BAC4 GATA2mCherry has been described previously[349]. TB40/E with deleted NF-κB sites in the 
MIEP at positions −94, −157, −262 and −413, and the revertant virus, were a kind gift from Jeffery Meier 
and Ming Li (University of Iowa, United States), and have been described previously[146]. 
UV-inactivation of virus was performed by placing a 100 μL aliquot of virus in one well of a 24-well plate 
and placing this within 10cm of a UV germicidal (254 nm) lamp for 15 minutes, which routinely results in 
no detectable IE gene expression upon infection of Hff1 cells. 
2.7. Immunofluorescence staining and image analysis 
Cells were fixed with 2% paraformaldehyde for 15 minutes and permeablised with 0.1% Triton-X100 for 
10 minutes at RT. Blocking and antibody incubations were performed in phosphate buffered saline (PBS) 
with 1% bovine serum albumin and 5% normal goat serum. Primary antibodies used: anti-IFI16 (Santa 
Cruz sc-8023, 1:100), anti-FLAG (Sigma F1804, 1:1000), anti-MNDA (Cell Signaling Technology 3329, 
1:100), anti-IE (Argene 11-003, 1:1000 or directly conjugated to FITC, 1:100), anti-GFP (directly 
conjugated to FITC, Abcam ab6662, 1:200), anti-mCherry (Abcam ab167453, 1:500), anti-HLA DR 
(conjugated to Brilliant Violet 421, Biolegend Clone L423 or Abcam ab92511 1:100), anti-NF-κB (Abcam 
ab16502, 1:500). Secondary antibodies used: goat anti-mouse Alexa 488 (Thermo Fisher A11001, goat 
anti-mouse Alexa 594 (Thermo Fisher, A11005), chicken anti-rabbit Alexa 488 (Thermo Fisher A21441) 
goat anti-rat Alexa 488 (Abcam ab150157), donkey anti-rat Alexa 594 (Thermo Fisher, A21209). Cells 
were imaged with a widefield Nikon TE200 microscope and images were processed using ImageJ. For 
contingency analyses of IFI16 expression during experimental latency, cells were assigned as ‘IFI16 
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positive/negative’, and ‘infected/uninfected’ and then counted. These results were then analysed using 
Fisher’s Exact statistical test for significance. For analysis of signal intensity, nuclear stained images were 
used to create a mask from which intensity values of the corresponding IFI16/MNDA stained image were 
derived using the Analyze Particles feature of ImageJ. Cells were assigned as infected or uninfected 
based on signal from the GFP/mCherry stain. The average signal intensity of uninfected cells was used to 
normalise the signal intensity in order to compare different fields of view. 
For nanobody binding experiments, THP-1 cells were pelleted and resuspended in 4% paraformaldehyde 
(Sigma-Aldrich) and seeded in a 96 well U-bottom plate. Cells were fixed for 10 minutes at room 
temperature. After fixation, cells were permeabilized with 0.5% NP-40 (Sigma-Aldrich) for 30 minutes at 
room temperature. Nanobodies were incubated for 1 h at RT and detected using Mouse-anti-Myc 
antibody (1:1000, 9B11 clone, Cell Signaling Technology). US28 was visualized with the rabbit-anti-US28 
antibody (1:1000, Covance). Subsequently, cells were washed and incubated with Goat-anti-Rabbit Alexa 
Fluor 546 (1:1000 in 1% (v/v) FBS /PBS, Thermo Fisher Scientific) and Goat-anti-Mouse Alexa Fluor 488 
(1:1000 in 1% (v/v) FBS/PBS, Thermo Fisher Scientific). 
2.8. Western blotting 
Except for US28, virion, and ERK blots, cells were lysed directly in Laemmli Buffer and separated by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Following transfer to 
nitrocellulose, the membrane was blocked in 5% milk in tris buffered saline (TBS) with 0.1% Tween-20. 
Primary antibodies used: anti-IFI16 (Santa Cruz sc-8023, 1:500), anti-MNDA (Cell Signaling Technology 
3329, 1:250), anti-STAT1 (Cell Signaling Technology 14994, 1:1000), anti-phosphoSTAT1 Tyr701 (Cell 
Signaling Technology 9167, 1:1000, anti-beta actin (Abcam ab6276, 1:5000), (GAPDH, Abcam ab8245, 
1:5000). Secondary antibodies used: anti-mouse-horse radish peroxidase (HRP) conjugate, (Santa Cruz 
sc-2005 or Thermo Fisher 31430), anti-rabbit HRP (Santa Cruz sc-2004), anti-rat HRP (Cell Signaling 
Technology 7077). These membranes were developed using electrochemiluminescence (standard or 
prime) reagents from GE Healthcare. 
For US28 blots of THP-1 cells, cells were pelleted, washed once in ice cold PBS, then lysed in lysis buffer 
(25 mM Tris HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP40, 5% glycerol, plus protease inhibitors) for 
30 minutes, vortexing every 10 minutes. After the addition of non-reducing Laemmli buffer, samples 
were heated at 42°C for 10 minutes and then separated by SDS-PAGE. Polyvinylidene difluoride (PVDF) 
membranes were used for transfer, and blocked membranes were incubated with the rabbit anti-US28 
antibody [191] (a gift from M. Smit, Vrije University) at 1:1000 dilution. To quantify western blots, the 
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Analyze Gels feature of Image J was used to plot the band intensities. These membranes were developed 
using electrochemiluminescence (standard or prime) reagents from GE Healthcare. 
For US28-V5 blots of Hff-TERT cells and virions, Hff-TERT cells were pelleted, washed once in ice cold 
PBS, then lysed in radioimmunoprecipitation assay buffer (25 mM Tris pH 7.5, 150 mM NaCl, 0.5% 
sodium deoxycholate, 1% Triton X-100, and 1% NP-40 with protease inhibitor cocktail) on ice for 30 
minutes. Cell debris was removed by centrifugation at 13,000 x g.  HCMV virions were pelleted by high 
speed centrifugation at 14500 x g for 2 hours at 18°C. Virus-containing pellets were then resuspended in 
solubilisation buffer (10 mM Tris-Cl, pH 8.0, 400 mM NaCl, and 10 mM EDTA) on ice for 1 hour, vortexing 
every 15 minutes. After the addition of non-reducing Laemmli buffer, cell and virion samples were 
heated at 42°C for 10 minutes and then separated by SDS-PAGE. PVDF membranes were used for 
transfer, and blocked membranes were incubated with anti-V5 (Thermo Fisher R960-25, 1:1000), anti 
pp65 (Santa Cruz sc56976 1:1000), and anti-beta actin (Abcam ab6276, 1:5000). These membranes were 
developed using electrochemiluminescence (standard or prime) reagents from GE Healthcare. 
For analysis of ERK phosphorylation following nanobody treatment, mock transduced or US28-expressing 
THP-1 cells were seeded in a 6 wells plate and incubated with 100 nM nanobodies. After 48 h, cells were 
lysed in native lysis buffer (25 mM Tris HCL pH7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 5% Glycerol, 1 
mM NaF, 1 mM NaVO3, cOmpleteTM protease inhibitor cocktail) for 10 minutes on ice. Cell debris was 
removed by centrifugation at 13,000 x g. Lysates were then separated on a 10% SDS-PAGE gel under 
reducing conditions and transferred to 0.45 μm PVDF blotting membrane (GE healthcare). Total ERK1/2 
and phospho-ERK1/2 were detected using p44/42 MAPK antibody (1:1000 in 5% bovine serum albumin 
(BSA)/TBS-T, #9102, Cell Signaling Technology) and phospho-p44/42 MAPK (Thr202/Tyr204) (1:1000 in 
5% BSA/TBS-T, #9101, Cell Signaling Technology). Actin was detected using anti-actin antibody (1:2000 in 
5% BSA/TBS-T, Clone AC-74, Sigma-Aldrich). Antibodies were detected using Goat anti-Rabbit IgG-HRP 
conjugate (1:10000, #1706515, Bio-Rad) or Goat anti-Mouse IgG-HRP conjugate (1:10000, #1706516, 
Bio-Rad). Blots were developed using Western Lightning Plus-ECL (Perkin-Elmer, Waltham, MA, USA) and 
visualized with ChemidocTM (Bio-Rad). 
2.9. Flow cytometry  
Transduced THP-1 cells and MIEP-reporter THP-1 cells were analysed on a BD Accuri C6 Instrument. Live 
cells were gated using forward and side scatter. Paraformaldehyde-fixed cells were stained using anti-
HLA-DR Allophycocyanin (APC) conjugate (Biolegend, Clone L243, 1:50).  
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T cell/PBMC preparations were analysed for purity using anti-human CD3 antibody conjugated to 
fluorescein-isothiocyanate (FITC) (BD Biosciences), anti-human CD4 antibody conjugated to 
phycoerythrin (PE) and anti-human CD8 antibody conjugated to Peridinin-Chlorophyll protein/Cyanine 
5.5 (PerCP/Cy5.5) (both from BioLegend). Antibodies were incubated with samples for 30 minutes and 
fixed with 2% paraformaldehyde before analysis by flow cytometry on the BD Accuri C6 Instrument. 
Latently infected CD14+ monocytes were fixed with 1% paraformaldehyde and stained using anti-HLA-DR 
Pacific blue conjugate (Biolegend, Clone L243, 1:50) and anti-HLA-A,B,C, PE-Cyanine 7 (Cy7) conjugate 
(Biolegend, Clone W6/32, 1:50), before analysis on the Nxt Attune Instrument (Thermo Fisher). 
2.10. Cytokine detection by ELISA 
Commericial ELISA kits were used to detect interleukin 1-beta (IL-1β) (Thermo Fischer), interferon beta 
(IFNβ) (Elabscience), and interferon alpha (IFNα) (PBL Assay Sciences). These were used according to the 
manufacturer’s instructions and absorbance a 490 nm was read using an iMarkTM Microplate Absorbance 
Reader (BioRad).  
2.11. RNA and DNA extraction, reverse transcription, and quantitative PCR 
RNA was extracted and purified using Direct-Zol RNA MiniPrep kit (Zymo Research) according to the 
manufacturer’s instructions. A total of 5 ng of purified RNA was used in one-step RT-qPCR reactions, 
performed using QuantiTect SYBR® Green RT-PCR Kit reagents (Qiagen) on a StepOne Real-Time PCR 
instrument (Applied Biosystems). For two-step RT-qPCR analysis, reverse transcription was performed 
using the Qiagen QuantiTect Reverse Transcription kit, and then cDNA was used in qPCR analysis using 
New England Biotech LUNA SYBR Green qPCR reagents. TATA-box binding protein (TBP) or 
Glyceraldehyde phosphate dehydrogenase (GAPDH) were used as reference genes and relative gene 
expression was analysed using ΔCt or ΔΔCt values. Primer sequences are given in Table 2-1. 
To extract DNA from HCMV infected cells, cells were pelleted and washed in citrate wash buffer (40mM 
sodium citrate, 10mM KCl, 135mM NaCl pH 3.0) for one minute before washing in PBS. Cells were then 
resuspended at 5 x 106 /mL in Buffer A (100 mM KCl, 10 mM Tris-HCl pH 8.3, 2.5 mM MgCl2) followed by 
the addition of an equal volume of Buffer B (10 mM Tris-HCl pH 8.3, .5 mM MgCl2 , 1 % Tween-20, 1% 
NP-40, 0.4 mg/mL Proteinase K) and then incubated at 60°C for 1 hour followed by 95°C for 10 minutes. 
HCMV DNA abundance was then analysed using New England Biotech LUNA SYBR Green qPCR reagents 
using the GAPDH promoter region as a reference sequence, and the UL44 promoter region as the HCMV 
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genomic target. Relative HCMV DNA levels were then analysed using ΔCt or ΔΔCt values. Primer 
sequences are given in Table 2-1. 
Table 2-1 List of primers used in this project. Application (Appn) is denoted by 'Q' for (RT)-qPCR, 'C' for cloning, ‘M’ 
for site directed mutagenesis. Targets in the promoter region are denoted by ‘prom’.  All primer sequences are 5’-
3’. 
Target Appn Forward Reverse 
IE72/ 
IE1 
Q GTCCTGACAGAACTCGTCAAA TAAAGGCGCCAGTGAATTTTTCTTC 
UL44 Q TACAACAGCGTGTCGTGCTCCG GGCGTAAAAAACATGCGTATCAAC 
UL138 Q ACGACGAAGACGATGAACCC CCCGATGAGATCTTGGTCCG 
UL32 Q GGTTTCTGGCTCGTGGATGTCG CACACAACACCGTCGTCCGATTAC 
US11 Q TACTCCGAAACATCGGGCAG CGCGGGTAGTATGCCTGAAT 
GAPDH Q TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
US28 Q AATCGTTGCGGTGTCTCAGT TGGTACGGCAGCCAAAAGAT 
TBP Q CGGCTGTTTAACTTCGCTTC CACACGCCAAGAAACAGTGA 
IFNB Q AAACTCATGAGCAGTCTGCA AGGAGATCTTCAGTTTCGGAGG 
CXCL10 Q TTCAAGGAGTACCTCTCTCTAG CTGGATTCAGACATCTCTTCTC 
MNDA Q GGAAGAAGCATCCATTAAGG GTTTGTCTAGACAGGCAAC 
IFI16 Q CTGCACCCTCCACAAG GTTTGTCTAGACAGGCAAC 
HLA-
DRA 
Q TGTAAGGCACATGGAGGTGA TAGGGCTGGAAAATGCTGA 
BETA2.7 Q ATCACGATGGATCGTTGCGA CACTCTCCTGTCACGACACC 
AIM2 Q CAGGAGGAGAAGGAGAAAGTTG GTGCAGCACGTTGCTTTG 
IFIX Q GAGACTGGAACCAAAAGGC CGCGATTATTGGGTCTTC 
NFKBIA Q ACATCAGCACCCAAGGACACC CCGCACCTCCACTCCATCC 
UL44 
prom 
Q AACCTGAGCGTGTTTGTG CGTGCAAGTCTCGACTAAG 
GAPDH 
prom 









MNDA C GATCCTCGAGATGGTGAATGAATACAAG GATCCAATTGTCAATTAACATTCATTTGG 
US28-
R129A 





2.12. Proteomic analysis 
These procedures were performed prior to the beginning of this project but an abridged version of these 
methods is included to aid interpretation of the analyses presented later.  
Cells were harvested lysed in 2% SDS/50 mM Triethylamminium bicarbonate and 50 μg of each sample 
was digested with trypsin using a modified Filtered Aided Sample Preparation protocol. Samples were 
further purified by acid precipitation and two-phase partitioning, and dried under vacuum. Samples were 
then labelled with tandem mass tag reagents and pooled prior to high pH reverse-phase fractionation. 
High pH fractions were pooled orthogonally into 24 samples for analysis by Liquid chromatography–mass 
spectrometry on an Orbitrap Fusion, using synchronous precursor selection mode to isolate reporter ions. 
Data were analysed using the MASCOT search node within Proteome Discoverer.  
2.13. Gene ontology analysis 
The gene ontology (GO)-term enrichment database search feature of geneontology.org was used to 
compare a given subset of genes identified in the proteomic analysis with either all human genes or all 
proteins identified in the proteomic analysis. Biological process GO-terms were analysed for enrichment 
using the FDR correction within the enrichment analysis tool. 
2.14. Interferome analysis 
The gene IDs of the top 40-downregulated proteins identified in the proteomic analysis (§3.1), or those 
of the 40 proteins which showed zero fold change, or the whole list of identified proteins, were entered 
in the Interferome database search function and noted if they were positively inducible by either Type I 
or Type II interferon using a cut-off of 2-fold induction.  
2.15. Nanobody production 
Nanobody gene fragments were recloned in frame with a myc-His6 tag in the pET28a production vector. 
The bivalent format VUN100b was constructed by addition of a 30GS-linker in frame with the two 
VUN100 nanobody fragments. Nanobodies were produced as described previously [350]. Purity of the 
nanobodies was verified by SDS-PAGE. 
2.16. Nanobody binding ELISA 
Nanobody binding was performed as described previously [308].  Briefly, US28-expressing membrane 
extracts were coated in a 96 well MicroWell™ MaxiSorp™ flat bottom plate (Sigma-Aldrich) overnight at 
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4 °C. Wells were then washed and blocked with 2% (w/v) skimmed milk (Sigma-Aldrich) in PBS. Different 
concentrations of nanobodies were incubated. Nanobodies were detected with mouse-anti-Myc 
antibody (1:1000, clone 9B11, Cell Signaling Technology) and Goat anti-Mouse IgG-HRP conjugate 
(1:1000, #1706516, Bio-Rad). Optical density was measured at 490 nm with a PowerWave plate reader 
(BioTek).  
2.17. Nuclear Factor of Activated T-cells reporter gene assay 
HEK293T cells were transfected with 50 ng pcDEF3-HA-US28 VHL/E, 2.5 μg Nuclear Factor of Activated T-
cells (NFAT)-reporter gene vector ( Stratagene) and 2.5 μg empty pcDEF3 DNA as described previously 
[308]. Six hours post-transfection, cells were lifted using Trypsin-EDTA 0.05% (Gibco) and 50000 cells 
were seeded per well in a Poly-L-lysine (Sigma-Aldrich)-treated white bottom 96-well assay plate. 
Nanobodies were added at a final concentration of 100 nM. After 24 h, medium was removed and 25 μL 
Luciferase reagent (0.83 mM D-Luciferine, 0.83 mM ATP, 0.78 μM Na2HPO4, 18.7 mM MgCl2, 38.9 mM 
Tris-HCl (pH 7.8), 2.6 μM DTT, 0.03% Triton X-100 and 0.39% Glycerol) was incubated for 30 min at 37°C. 
Luminescence (1 s per well) was measured using a Clariostar plate reader (BMG Labtech, Ortenberg, 
Germany).  
2.18. Detection of IE gene expression in nanobody-treated monocytes 
CD14+ monocytes were isolated as described above and seeded into a 96 well or 12-well plates. The next 
day, medium was removed and cells were infected with TB40/E IE2-eYFP. Two hours post infection, 
medium was aspirated and replaced with medium containing nanobodies at a final concentration of 100 
nM. Nanobody-containing medium was refreshed every 2-3 days. IE-expression was detected by means 
of IE2-YFP tag or immunostaining of IE as described above. This was either counted manually or imaged 
by the ArrayScan XTI instrument (Thermo Fischer) and data processed using the Target Activation 
experimental tool. 
2.19. PBMC and T cell co-culture and virus reactivation 
Following PBMC isolation from healthy donor peripheral blood, CD14+ monocytes were isolated, plated 
on 96 well plates, and treated with nanobodies as described above. The remaining PBMC were frozen in 
liquid nitrogen until one day prior to co-culture. At this time, the PBMC were thawed and rested 
overnight. CD4+ and CD8+ T cell fractions were isolated as described in §2.1 above and pooled, and these, 
or the remaining PBMC were added to the monocyte cultures at an effector:target cell ratio of 5:1. After 
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two days, the T cells/depleted PBMC were washed away using PBS + 2 mM EDTA, and the medium on 
the monocytes was replenished with X-vivo 15 + L-glutamine containing IL-4 and GM-CSF at 1,000 U/ml 
in order to stimulate differentiation to immature dendritic cells. After 5 days, this medium was aspirated 
and replaced with X-vivo 15 + L-glutamine supplemented with 50 ng/mL LPS for 2 days to induce 
maturation of dendritic cells.  
2.20. Immunotoxin treatments 
Immunotoxins were sent by Synklino ApS on dry ice, thawed on wet ice, and aliquoted and flash frozen 
in liquid nitrogen until use. Immunotoxin dilutions were made in immunotoxin assay buffer (1 mM acetic 
acid, 0.5% w/v BSA) and if not used immediately, these were stored at -20°C for up to 14 days and could 
be thawed once more before discarding. For analysis of cell viability, the CellTiter 96® AQueous One 
Solution Cell Proliferation Assay (Promega), commonly known as the MTS assay (MTS = 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt), was 
used according to the manufacturer’s instructions. Specifically, cells were treated with immunotoxins, or 
blasticidin (100 μg/mL, Invivogen) in 96 well plates for variable time periods in 100 μL culture volume. To 
assess viability, 20 μL of assay reagent was added to culture and the plate incubated for between 1 and 4 
hours. The reaction was stopped by the addition of 25 μL of 10% SDS, and the absorbance at 490 nm was 
measured using an iMarkTM Microplate Absorbance Reader (BioRad).  
2.21. Statistical analysis 
Statistical analysis, including hypothesis testing (t test, analysis of variance (ANOVA), corrections for 
multiple comparisons, non-parametric tests), regression analysis, and ‘curve-fitting’ was performed using 




3. US28 downregulates interferon-responsive genes in myeloid cells 
3.1.  Analysis of the US28-associated proteome 
3.1.1. Introduction 
The virally encoded G protein coupled receptor US28 is likely essential for the establishment and 
maintenance of HCMV latency in myeloid cells [159,173,189,193]. Furthermore, US28 coupling to G 
proteins is required for HCMV latency; loss of G protein coupling via the signalling mutation R129A 
results in lytic infection of myeloid cells [193]. Similarly, while expression of US28-WT in trans 
complements for US28-deletion viruses, expression of US28-R129A or an empty vector control leads to 
lytic infection with US28-deletion viruses [189].  
While previous work has looked at the global effects of US28 expression in myeloid cells on the 
phosphorylation status of important signalling pathways by phosphoarray [189], or examined 
transcription by microarray [173,193], these methods are inherently biased as the cellular targets are 
pre-selected. Therefore, an unbiased proteomic screen was undertaken in our laboratory by Benjamin 
Krishna in collaboration with James Williamson and Paul Lehner (all University of Cambridge). This screen 
compared the host proteomes THP-1 cells which express an empty vector, US28-WT, or US28-R129A. 
Employing a tandem-mass-tag labelling approach, the screen identified 7458 host proteins present in all 
cell lines. The full results are presented in the appendix and summarised in Figure 3-1, Table 3-1, and 
Table 3-2. 
The power of this screen was that it allowed identification of changes in host proteins enacted by US28 
in a signalling-dependent and -independent manner. Changes in host protein abundance common 
between US28-WT and US28-R129A when compared to empty vector represent signalling independent 
changes, and these included CD44 and CD82 proteins, which were each downregulated by both sets of 
US28-expressing cells.  
While I do not rule out that signalling independent changes in myeloid cells driven by US28 may be 
important for HCMV latency, G-protein dependent signalling is absolutely required for latency, and 
therefore we were particularly interested in the direct comparison of host protein abundances in THP-1 
cells expressing US28-WT and US28-R129A. This comparison revealed 42 host proteins whose expression 
was two-fold or more increased or decreased by US28-WT, and my subsequent analyses focussed on 




Figure 3-1 US28 proteomic analysis reveals US28 signalling-dependent and independent changes in myeloid cell 
environment. A, B, C) Empty vector, US28-WT, and US28-R129A THP-1 cells were subject to total cell proteomic 
analysis using a tandem-mass-tag labelling approach as described in Materials and Methods. Each dot represents 
one human protein and is shown in grey if its abundance changes by a factor of less than 2, in red if between 2- and 
4-fold, and in purple if greater than 4-fold. The exception is components of the HLA-DR complex which are 
represented by pink triangles. A) Shows a comparison of US28-WT and US28-R129A, B) compares US28-WT and 
empty vector, and C) compares US28-R129A and empty vector. In each case, the relative abundance of human 





Table 3-1 Proteins upregulated by US28-WT compared with US28-R129A. The Uniprot accession numbers, HUGO 
Gene IDs, number of Unique Peptides quantified, and log2(fold change abundance) between cell lines is presented 
for the top 40-most upregulated proteins (US28-WT vs US28-R129A) after filtering for q value of <0.01. The 




Gene ID US28-WT/EV US28-R129A/EV US28-R129A/US28-WT 
P13928 6 ANXA8 1.286881148 -0.739372092 -2.023269779 
O94851 1 MICAL2 0.101650076 -1.680382066 -1.780908942 
Q12965 11 MYO1E 0.325386415 -1.20756107 -1.531156057 
Q8WWN9 1 IPCEF1 1.051720116 -0.401634795 -1.454031631 
P15144 27 ANPEP 0.742437445 -0.623709617 -1.365871442 
P20701 17 ITGAL 0.645240513 -0.510457064 -1.15521265 
Q11206 2 ST3GAL4 1.232660757 0.123003954 -1.10780329 
O00151 15 PDLIM1 0.980390956 -0.125006361 -1.104697379 
Q6YHK3 20 CD109 0.645240513 -0.432454552 -1.077041036 
P04083 20 ANXA1 1.752748591 0.768925336 -0.98279071 
Q9NP71 1 MLXIPL 0.388465097 -0.577766999 -0.965784285 
Q96PC3 3 AP1S3 0.092207438 -0.833927324 -0.924125133 
Q9HBU1 2 BARX1 0.207892852 -0.717856771 -0.924125133 
Q9NUU6 13 FAM105A 0.297484916 -0.60823228 -0.905088353 
O00421 1 CCRL2 0.070389328 -0.805912948 -0.875671865 
Q8TF42 14 UBASH3B 1.204140717 0.368489001 -0.836501268 
Q13642 5 FHL1 1.286289758 0.468843943 -0.81857936 
Q9BRF8 11 CPPED1 -0.023269779 -0.805912948 -0.783389931 
P08133 47 ANXA6 -0.087733372 -0.803392956 -0.717856771 
Q8IU85 3 CAMK1D 0.232660757 -0.483984853 -0.715485867 
P11169 5 SLC2A3 0.396159489 -0.320125852 -0.715485867 
Q658P3 6 STEAP3 -0.045431429 -0.734563104 -0.689659879 
P30405 9 PPIF 0.618238656 -0.067938829 -0.687334826 
Q8IX19 4 C19orf59; 
MCEMP1 
0.286881148 -0.386468347 -0.673462652 
Q9BX10 13 GTPBP2 0.353887836 -0.312939312 -0.666576266 
Q7L266 2 ASRGL1 -0.744197163 -1.384583703 -0.639354798 
P09525 23 ANXA4 -0.407363571 -1.043943348 -0.637109357 
P20020 15 ATP2B1 0.34596403 -0.286304185 -0.632628934 
O00458 7 IFRD1 0.318461465 -0.305788392 -0.623709617 
Q04726 5 TLE3 0.138814469 -0.477944251 -0.61705613 
Q96PY5 3 FMNL2 0.195347598 -0.413115187 -0.610433188 
Q13683 4 ITGA7 0.100304906 -0.490050854 -0.590744853 
P50281 7 MMP14 0.291603558 -0.295128036 -0.586405918 
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Q9BPW9 5 DHRS9 0.093560176 -0.490050854 -0.584241333 
Q13480 2 GAB1 0.606915942 0.024319679 -0.582079992 
Q96TA1 9 FAM129B -0.416962376 -0.988504361 -0.57132159 
Q9NQ86 4 TRIM36 0.137503524 -0.434402824 -0.57132159 
Q8IWB7 14 WDFY1 0.03562391 -0.526992432 -0.560642822 
Q9P2M4 1 TBC1D14 0.658097205 0.097610797 -0.560642822 
Q6PI78 1 TMEM65 0.187767747 -0.371459681 -0.55851652 
 
 
Table 3-2 Proteins downregulated by US28-WT compared with US28-R129A. The Uniprot accession numbers, 
HUGO Gene IDs, number of Unique Peptides quantified, and log2(fold change abundance) between cell lines is 
presented for the top 40-most downregulated proteins (US28-WT vs US28-R129A) after filtering for q value of 




Gene ID US28-WT/EV US28-R129A/EV US28-R129A/US28-WT 
Q03135 2 CAV1 -1.50635 1.803227 3.311212 
P22090 5 RPS4Y1 -0.69432 2.329985 3.025206 
P13591 4 NCAM1 -0.26708 2.421156 2.688852 
P41218 9 MNDA -2.68966 -0.35476 2.331992 
Q9Y2J8 7 PADI2 -0.71076 1.395611 2.107688 
Q16719 4 KYNU -0.08314 1.840765 1.92372 
P20292 2 ALOX5AP -1.96578 -0.15521 1.807355 
Q92506 1 HSD17B8 -0.03357 1.750178 1.784504 
Q9Y243 1 AKT3 -1.01742 0.679874 1.697774 
P25815 2 S100P 0.506907 2.121347 1.614945 
O15523 2 DDX3Y -0.13765 1.470407 1.608336 
P32929 6 CTH -0.35476 1.218471 1.573375 
O75155 8 CAND2 -0.22263 1.325386 1.54745 
O15394 8 NCAM2 -1.82623 -0.2969 1.53057 
Q6ZMU5 11 TRIM72 0.58111 2.082362 1.500802 
Q9NRW1 1 RAB6B -0.71786 0.747602 1.465713 
P50225 5 SULT1A1 0.16092 1.446786 1.286881 
Q16666 4 IFI16 -1.45008 -0.20923 1.24245 
Q96T66 4 NMNAT3 -0.92687 0.312665 1.239398 
P29728 17 OAS2 -2.152 -0.93236 1.223423 
Q9Y4D7 2 PLXND1 -1.16488 0.051024 1.217851 
P05091 19 ALDH2 -2.27928 -1.09234 1.187134 
P01911 4 HLA-DRB1 -2.27928 -1.1078 1.172488 
Q9BRX8 4 FAM213A -0.6416 0.526069 1.168642 
P31327 9 CPS1 1.151209 2.30188 1.15056 
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Q96BZ4 7 PLD4 -1.02621 0.092207 1.119688 
Q6P5R6 2 RPL22L1 0.326537 1.422771 1.096262 
P01903 6 HLA-DRA -2.30045 -1.20423 1.094912 
P12277 8 CKB 0.342555 1.415759 1.073135 
Q9UMS6 20 SYNPO2 0.049631 1.111031 1.060739 
Q01628 1 IFITM3 -1.25498 -0.21591 1.039138 
B0I1T2 28 MYO1G -0.57132 0.448901 1.020058 
P04229 3 HLA-DRB1 -2.1016 -1.1016 1 
P52895 3 AKR1C2 0.561693 1.560715 0.999278 
Q30154 3 HLA-DRB5 -2.06492 -1.1047 0.961994 
P10153 1 RNASE2 -0.66658 0.290424 0.9568 
P37268 15 FDFT1 -0.32193 0.598365 0.921436 
P29966 6 MARCKS 0.096262 1.010064 0.913033 
P15104 10 GLUL -0.32013 0.587845 0.908429 
P48163 16 ME1 -1.52699 -0.63039 0.896078 
 
 
3.1.2. GO-term enrichment analysis 
Gene ontology (GO) terms are key phrases annotated to genes and proteins in public databases that 
describe associated biological processes, molecular functions, and cellular components. GO-term 
enrichment analysis is a way to analyse larger datasets such as transcriptomes and proteomes and ask 
whether any particular biological pathways or functions are common features in genes that are 
differentially regulated in one’s dataset. To do this, I used the GO-term enrichment tool available at 
geneontology.org [351–353], analysing biological process terms, and input the top 40 upregulated 
proteins (fold changes), or the top 40 downregulated proteins (fold changes) after applying a filtering 
criterion of q value <0.01. As a comparator, I used both the automatically generated list of human genes, 
and a list of all 7458 proteins identified in the screen.  Statistical significance was associated with a False 
Discovery Rate (FDR)-corrected p value of <0.05. There were no significantly enriched terms for the 
upregulated proteins (not graphed). I found between five and nine GO-terms enriched for the 
downregulated proteins, including several terms relating to antiviral defence such as interferon-gamma 
signalling pathway and MHC Class II assembly (Figure 3-2). This was intriguing as US28 has not previously 
been associated with modulation of interferon responses nor MHC Class II (which is itself interferon-
gamma inducible [354]), though it can bind human chemokines and act as a ‘chemokine sink’ during 




Figure 3-2 GO-term enrichment analysis of genes downregulated by US28-WT. Gene IDs from  were input into the 
GO-term enrichment database search feature of geneontology.org and compared with either all human genes 
(upper panel) or all proteins identified in the proteomic screen (lower panel). Biological process GO-terms enriched 
in each comparison with a FDR-corrected value of <0.05 are graphed. 
3.1.3. Interferome analysis 
Following GO-term analysis, I wanted to use a specialist tool, Interferome, (v2.01, www.interferome.org) 
[355] to analyse the downregulated proteins in my dataset. Interferome uses existing microarray and 
transcriptomic datasets for genes induced or downregulated by treating cells with Type I, Type II, or Type 
III interferon. I input the 40-most significantly downregulated genes, or the 40 genes which showed zero 
change in abundance, or the entire dataset into the tool, filtering for human genes and those which are 
induced at least 2.0-fold. Two-thirds (27/40) of the most downregulated proteins we identified are Type I 
or Type II interferon-inducible (Figure 3-3).  In contrast, of the 40 proteins which showed no changes 
(fold change = 0) in abundance between US28-WT and US28-R129A, 12/40 (30%) were included in the 
Interferome database, and 34% of all proteins in the proteome were included in the Interferome 
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database. Fisher’s Exact contingency analysis supports that downregulated proteins are significantly 
more likely to be interferon-inducible (Figure 3-3). One of the downregulated proteins was annotated as 
Type III interferon-inducible, but it is worth noting that there are far fewer datasets for Type III 
interferon included in the Interferome database. Overall, global analyses of the US28-proteomic dataset 
reveal that US28 likely reduces the basal levels of Type I and Type II interferon-inducible genes in a 





Figure 3-3 US28 downregulates Type I and Type II interferon-inducible proteins. The gene IDs of the top 40-
downregulated proteins identified in the screen (Table 3-2), or those of the 40 proteins which showed zero fold 
change, or the whole list of identified proteins, were entered in the Interferome database search function and 
noted if they were positively inducible by either Type I or Type II interferon. A) The proportions of each of these 
datasets which were positively interferon inducible was calculated and graphed (raw numbers of proteins in white). 
Contingency analysis of these groups (Fisher’s Exact) was performed comparing each group in turn. **: p<0.01; 
****: p<0.0001; ns: not significant. B) Interferome-based annotation of Type I and Type II interferon-inducible 




3.1.4. US28 expression reduces STAT1 phosphorylation 
To follow up the global effect on Type I and Type II interferon-inducible proteins, I decided to assess 
STAT1 abundance and phosphorylation status, since STAT1 mediates both Type I and Type II signalling 
pathways. I predicted that relative phosphorylated STAT1 levels (Tyr701 phosphorylation) would be 
lower in the US28-WT cells compared with US28-R129A and empty vector cells. By Western blot, I found 
that US28-WT decreases the absolute levels of total STAT1 and phosphorylated STAT1 compared with 
both empty vector cells, and US28-R129A cells. Furthermore, and as expected, after correcting for total 
levels of STAT1, I found that the relative levels of phosphorylated STAT1 were decreased in US28-WT 
compared with empty vector and US28-R129A cells (Figure 3-4). Unexpectedly, US28-R129A cells had 
higher levels of STAT1 and phosphorylated STAT1 compared with empty vector cells. This apparent 
induction of STAT1 and STAT1 activation by US28-R129A is unexplained and not predicted by the 
proteomic data. Nevertheless, US28-WT overexpression decreases STAT1 levels and phosphorylation, 
providing an obvious mechanism for the downregulation of Type I and Type II interferon-inducible genes 




Figure 3-4 US28-WT decreases STAT1 and phosphorylated STAT1. A) Western blot of lysates from EV, 
US28-WT, and US28-R129A THP-1 cells for phospho-STAT1 (Tyr701), total STAT1, and beta-actin. B and C) 
Quantification of STAT1 and phospho-STAT1 band intensity from two Western blots from two 
independent samples of transduced THP-1 cells. B) shows bands normalised to actin, and C) shows 




3.2. Validation of selected proteins from the US28-associated proteome 
3.2.1. MNDA and IFI16 are downregulated by US28-WT 
Several interferon-inducible proteins showing decreased expression were of interest as potentially 
important targets for US28 during HCMV latency. These included PYHIN-family proteins MNDA (9 unique 
peptides; 5.0-fold downregulated compared to US28-R129A) and IFI16 (4 unique peptides; 2.4-fold 
downregulated compared to US28-R129A). These two related proteins piqued my interest because, as 
detailed in the introduction, IFI16 is a restriction factor for viral replication, and MNDA is a myeloid-
specific PYHIN protein with a putative role in myeloid cell apoptosis. I began by confirming US28-WT-
mediated downregulation of these proteins in independently-transduced US28-expressing THP-1 cells. I 
used the same lentiviral constructs as were used in the proteomic screen and in Krishna et al [189] to 
transduce THP-1 cells. A map of the construct, which drives US28 expression from the SFFV promoter, is 
given in Figure 3-5.  After generating these fresh US28-expressing cell lines, I checked expression levels of 
US28-WT or US28-R129A by RT-qPCR and Western Blot (Figure 3-5) to confirm near-equivalent protein 
expression.  The multiple species of US28 detected by Western blot is consistent with previously 
published western blot detection of US28 [186,193], and likely in part reflects differential levels of 
glycosylation on the predicted N-glycosylation site in the US28 N-terminal domain (Predicted in UniProt 
entry P69332). While the overall average levels of US28 protein expression was near-equivalent in the 
different US28-expressing cell lines, it is possible that there were differences in the relative levels of the 
individual US28 species. This could have potential consequences for localisation and subsequent function 
of US28, particularly if any differences are due to glycosylation differences. It would be beneficial to 
check this by deglycosylation of proteins within cell lysates, and confocal microscopy of immunostained 





Figure 3-5 Generation of independently-transduced US28-expressing cell lines. A) The lentiviral vector into which 
the sequence encoding US28-WT or US28-R129A had previously been cloned. LTR: long terminal repeat; Ψ: the psi 
lentiviral packaging element; RRE: rev response element; pSSFV: the spleen focus-forming virus promoter; MCS: 
multiple cloning site; WPRE: Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element; pSV40: the SV40 
promoter; PuroR: the puromycin resistance gene; LTR/ΔU3: long terminal repeat deleted for the 3’ unique region. 
B) RT-qPCR analysis of US28 expression in transduced cell lines. +RT reactions included reverse transcriptase. -RT 
reactions did not include reverse transcriptase and control for genomic DNA contamination. C) Cells from B were 
lysed and subject to western blot for US28, and actin as a loading control. D) Quantification of three western blots 
for US28 expression. Intensities of all US28-specific bands shown in (C) were summed to generate these data. 
I then used RT-qPCR confirmed that IFI16 and MNDA are both downregulated in US28-WT-expressing 
cells compared to those expressing the signalling mutant R129A (Figure 3-6). Subsequently, I confirmed 
this US28-WT mediated downregulation of IFI16 and MNDA at the protein level by western blot 
(representative blots and quantification of four independent experiments are shown in Figure 3-7). 
Unexpectedly, and similarly to the observations with STAT1, US28-R129A seemed to induce IFI16 and 
MNDA above empty vector cell lines. This was not predicted by the US28 proteomic data, where the 
relative abundance of US28-R129A:empty vector was 0.865 for IFI16 and 0.765 for MNDA, a slight drop 




Figure 3-6 Steady state levels of MNDA and IFI16 mRNA in US28-expressing cells. Relative levels of IFI16 and 
MNDA mRNA were assessed by RT-qPCR in US28-expressing THP-1 cells. Levels of IFI16, and MNDA, were 
normalised to TBP and then to Empty Vector using the ΔΔCt method. 
Despite the unexpected result for US28-R129A cells, it still stands that US28-WT expressing THP-1 cells 
downregulate IFI16 and MNDA compared with cells expressing a mutant US28 at similar levels but which 
is deficient for latency establishment. This US28-mediated downregulation of IFI16 and MNDA appears 





Figure 3-7 US28-WT downregulates MNDA and IFI16. Lysates from US28-expressing THP-1 cells and controls were 
separated by SDS-PAGE and analysed for MNDA (A) and IFI16 (B) levels by Western blotting. C) Four independent 
Western blot analyses were subject to band intensity analysis using the ‘Analyse Gels’ feature of ImageJ and the 
relative levels of MNDA and IFI16 calculated compared to empty vector cells. US28-R129A had 5.4X and 7.3X higher 
levels of MNDA and IFI16, respectively, compared to US28-WT cells. 
3.2.2. Downregulation of steady-state levels of HLA-DR by US28 
The apparent downregulation of MHC Class II components HLA-DRA, HLA-DRB1-15, HLA-DRB1-1, and 
HLA-DRB5, was also an interesting observation as this has clear and documented implications for CD4+ T 
cell recognition [139]. Interestingly, the proteomic data predicts that both US28-WT and US28-R129A 
expressing THP-1 cells downregulate these MHC Class II components compared with empty vector 
control cells, but that US28-WT more extensively downregulates these proteins. To validate these 
observations, I first examined HLA-DRA RNA expression by RT-qPCR; HLA-DRA was chosen as it aids 
primer selection because it is not as polymorphic as the HLA-DRB genes. These data suggest that, for at 
least HLA-DRA, US28-WT expressing cells have similar levels of transcript to empty vector cells, but US28-
R129A cells have more HLA-DRA transcript (Figure 3-8). Again, this is not predicted by the proteomic 
data, but is in accordance with my observations of STAT1, MNDA, and IFI16.  
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I next decided to look at cell-surface expression of HLA-DR protein by flow cytometry, since that is 
ultimately the place where HLA-DR will likely be functional. Here, the results were in good accordance 
with the proteomic dataset (Figure 3-8) and showed that US28-WT cells have approximately half as much 
cell-surface HLA-DR compared with US28-R129A cells, and these in turn have 85% less HLA-DR than 
empty vector cells. 
I then decided to examine whether the inhibition of cell surface expression of HLA-DR by US28 could be 
overcome by addition of interferon-gamma (IFNγ), which is a known potent inducer of HLA-DR 
expression at the level of transcription. In a single experiment, I found that a 24 hour treatment with 1 
ng/mL of IFNγ increased cell-surface expression of HLA-DR on US28-WT and R129A cells to similar levels, 
potentially suggesting that US28-WT does not prevent the cell from responding to IFNγ despite lower 
levels of STAT1. However, a titration of IFNγ with a number of repeats is required to draw strong 
conclusions.   
Taking these results together, I propose that there are at least two mechanisms by which US28-WT is 
able to target cell-surface HLA-DR. One of these mechanisms is signalling dependent, as evidenced by 
the lower levels of HLA-DRA transcript and cell-surface HLA-DR on US28-WT cells compared with US28-
R129A cells. The second mechanism is G protein signalling-independent, as evidenced by the lower levels 
of cell-surface HLA-DR of US28-R129A cells compared with empty vector cells. This could be mediated via 
ligand-inducible signalling and/or a beta-arrestin dependent pathway which can act on G protein down-




Figure 3-8 US28-WT downregulates cell surface HLA-DR. A) RT-qPCR of HLA-DRA in US28-expressing THP-1 cells. 
Levels of HLA-DRA were normalised to TBP and then to Empty Vector using the ΔΔCt method. B) Flow cytometry 
analysis of cell-surface HLA-DR expression in the steady state (media only) or in the presence of IFNγ. 
 
3.3. Mechanism of US28-mediated downregulation 
An obvious next question is how US28 downregulates IFI16, MNDA, and HLA-DR. Global analysis of the 
proteome and subsequent analysis of STAT1 phosphorylation suggests that attenuation of the interferon 
response pathway, including STAT1, is involved (§3.1). However, c-fos, a component of the activator 
protein-1 complex, is also capable of activating IFI16 and HLA-DR transcription [358–360], and is 
attenuated by US28-WT in myeloid cells [193]. The best way to determine which signalling pathways 
US28 uses/attenuates to downregulate these genes would be to use pharmacological activators of the 
pathways to try to restore host gene expression; however, no such activator exists as far as I am aware. 
As an alternative, I used inhibitors of these pathways: Ruxolitinib is a pan-Janus kinase inhibitor, 
upstream of STAT signalling, and T-5224 blocks c-fos binding to DNA. Both inhibitors had to be solubilised 
in DMSO, which becomes a confounding factor because DMSO itself likely activates the AP-1 pathways 
[361,362] and activates transcription of p204 (often thought of as the IFI16 homologue) in mice [363]. 
Due to the respective solubilities of the inhibitors, the final concentration of DMSO in T-5224- treated 
samples was 0.5%, and the final concentration of DMSO in Ruxolitinib-treated samples was 0.03%. 
Despite this potential confounding factor, I proceeded with these treatments. I validated that Ruxolitinib 
blocked STAT1 phosphorylation (Figure 3-9 A). I then looked at expression of IFI16 and HLA-DR (Figure 
3-9 B, D, E) and found that Ruxolitinib partially reduced IFI16 expression in all three cell lines, but 
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downregulated HLA-DR only in the US28-R129A cell line.  IFI16/HLA-DR expression in empty vector or 
US28-R129A expressing cells could not be ‘normalised’ to levels found in US28-WT by Ruxolitinib. 
Therefore, phosphorylated STAT1 likely plays a role, but cannot be the entire mechanism by which IFI16 
and HLA-DR are attenuated in US28-WT cells. In the case of T-5224, inhibition of c-fos partially reduced 
IFI16 and HLA-DR expression in US28-R129A cells, and almost reduced expression of these genes to 
US28-WT levels in the empty vector cells (Figure 3-9 C,D,E). While the interpretation of these 
observations is not straightforward, I believe these data indicate that c-fos is also playing a role in the 
US28-mediated downregulation of IFI16 and HLA-DR. Quite unexpectedly, T-5224 induced HLA-DR and 
IFI16 expression in US28-WT cells. I think this could be due to a basal level of c-fos being required for the 
expression of a host gene that is need by US28-WT to attenuate the numerous cellular signalling 







Figure 3-9 Effect of Janus kinase and c-fos inhibition on IFI16 and HLA-DR expression. A) Empty vector, US28-WT, 
and US28-R129A THP-1 cells were treated with 10 μM ruxolitinib or DMSO as a control for 48 hours. Lysates from 
these cells were then subject to western blot for phospho-STAT1 (Tyr701), STAT1, and actin as a control. B) As (A) 
but instead membrane was probed for IFI16 and actin. C) Empty vector, US28-WT, and US28-R129A THP-1 cells 
were treated with 5μM T-5224 or DMSO as a control for 48 hours. Lysates from these cells were then subject to 
western blot for IFI16 and actin. D and E) Cells were treated as A) and C) and then subject to cell surface HLA-DR 
analysis by flow cytometry. Similar-coloured DMSO controls indicate corresponding concentrations of DMSO to 
inhibitors. D) Shows the mean fluorescence intensity and E) the median fluorescence intensity. I treated the cells 
with the inhibitors, and a colleague, Eleanor Lim, performed the cell-surface staining for HLA-DR and flow 




3.4.  Downregulation of IFI16, MNDA, and HLA-DR during latency 
3.4.1. Introduction 
IFI16, MNDA, and HLA-DR were all downregulated in THP-1 cells expressing US28-WT compared with 
US28-R129A, the signalling mutant that is deficient for latency establishment. The next logical step was 
to determine whether these three selected proteins were also downregulated during HCMV latency, 
itself.  
To analyse whether HCMV latent infection downregulates IFI16, MNDA, and HLA-DR, I needed to use 
fluorescently labelled viruses because (i) our model never results in more than 20% infected cells, with 
an average closer to 5%, and (ii) expression of viral proteins during latency is not readily detectable by 
immunofluorescence (though I will show later that US28 expression is detectable when a C-terminal tag 
is incorporated into the ORF). I use immunofluorescence or flow cytometry to detect infection 
throughout this section, and analyse genes of interest in comparison with fluorescent marker negative 
bystander cells, which have previously been shown to be uninfected on the basis of viral gene expression 
and differentiation-induced reactivation [349]. 
3.4.2. Initial observations with TB40/E IE2-2A-eGFP SV40mCherry virus 
I analysed CD14+ monocytes infected with TB40/E SV40 mCherry/IE2-2A-GFP. This virus drives 
constitutive mCherry expression in both latently and lytically infected cells via the SV40 promoter, but 
GFP expression is restricted to lytically infected cells as a result of IE2 expression, which is linked to GFP 
by the self-cleaving peptide 2A. Therefore, I was able to distinguish IE2-positive (lytic) from IE2-negative 
cells (one hallmark of latency) amongst infected, mCherry positive cells. At four days post infection 
(d.p.i.), I fixed and immunostained the monocytes for our cellular proteins of interest in mCherry 
positive, IE2-2A-GFP negative cells (Figure 3-10). As a control, I also differentiated monocytes with 
phorbol 12-myristate 12-acetate (PMA), which drives IE2-2A-GFP expression through differentiation-
dependent reactivation [365]. I found that IFI16, MNDA, and HLA-DR were all downregulated in latently 




Figure 3-10 HCMV latent infection is associated with downregulation of IFI16, MNDA, and HLA-DR. Primary CD14+ 
monocytes were isolated from peripheral blood or apheresis cones as described in Materials and Methods. The 
monocytes were latently infected with TB40/E SV40-mCherry IE2-2A-GFP and stained by immunofluorescence for 
IFI16, MNDA, or HLA-DR as indicated at four d.p.i and imaged by widefield fluorescence microscopy. Top left image:  
Uninfected monocytes. Second from the left: Monocytes were treated +PMA (to permit lytic infection). mCherry 
(red) serves as a marker for infection and GFP (green) denotes expression from the IE2-2A-GFP cassette. Remaining 
panels: Monocytes were cultured in the absence of PMA. The absence of green fluorescence results from 
suppressed expression of the IE2-2A-GFP cassette and scored as IE negative.  The magnification is indicated (40X or 
20X). White arrows indicate corresponding cells in the upper and lower panels. 
3.4.3. Time course of downregulation with TB40/E SV40eGFP  
I then sought to look at expression of these proteins at earlier time points. US28 is a virion-associated 
protein [159], and incoming US28 is reported to have rapid effects on host cells [193]. I speculated that 
the downregulation of IFI16, MNDA, and HLA-DR might occur early during the establishment of latency, 
perhaps mediated by incoming functional US28. For these experiments, I used TB40/Egfp which marks 
infected cells with GFP expression via the SV40 promoter and confirmed the establishment of latency in 
this system by coculture of monocytes with fibroblasts either with or without PMA-induced reactivation 
(Figure 3-11 A, B). In this latency system, I found a stark and specific loss of IFI16 in infected monocytes 
from 24 hours post infection (h.p.i.) (Figure 3-11 C), a phenotype maintained at 48 and 72 h.p.i as 
measured by immunofluorescence. I quantified these observations in several fields of view for each of 
these three time points, and performed contingency analyses (Fisher’s Exact), which confirmed specific 
loss of IFI16 in latently infected cells (Figure 3-11 D). Loss of IFI16 was observed in ex vivo infected 
monocytes at these time points in a total of four separate donors with TB40/Egfp virus.  
I found a partial downregulation of MNDA by 72 h.p.i (Figure 3-11 E, F), with a very small downregulation 
at 48 h.p.i and no effect at 24 h.p.i, suggesting that modulation of MNDA is delayed compared with 
fellow PYHIN family member, IFI16. 
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For analysis of HLA-DR, I worked with monocytes infected in suspension and analysed cell surface 
expression by flow cytometry, working together with two PhD students in Mark Wills’s laboratory, 
namely George Sedikides and Eleanor Lim. Together, we observed that HLA-DR, but not corresponding 
MHC Class I HLA-A,B,C, were downregulated at 72 h.p.i specifically in GFP positive, latently infected 
monocytes (Figure 3-11 G, H).Therefore, IFI16, MNDA, and HLA-DR are indeed downregulated at early 
times during the establishment of latency in monocytes, with IFI16 showing downregulation within 24 







Figure 3-11 Time course of US28-target gene downregulation. A) Validation of experimental latency using 
TB40/Egfp virus. CD14+ Monocytes were infected and allowed to establish latency for 4 days (left panel, 10X 
magnification). Citrate wash buffer was used to remove externally bound virions. These latently infected cells were 
cultured -/+PMA for 3 days, and at 7 d.p.i, Hff-1 cells were added to the culture to demonstrate production of 
infectious virions. Transfer of virus to Hff-1 was monitored by fluorescence microscopy up to 13 d.p.i., B) Infected 
Hff-1 foci form (A) were counted and summed across the experiment (three wells of CD14+ monocytes per 
condition, graphed). C) CD14+ monocytes infected with TB40/Egfp stained by immunofluorescence for IFI16 at 24, 
48, and 72 h.p.i. and imaged as before using 60X magnification. D) Quantification of IFI16 positive and negative 
monocytes in the uninfected and infected populations from two donors per time point. Raw numbers of cells are 
indicated in white text. Fisher’s exact test indicates a statistically significant difference between uninfected and 
infected populations for each time point (P<0.0001). E) CD14+ monocytes infected with TB40/Egfp were stained by 
immunofluorescence for MNDA at the indicated times and imaged as before using 60X magnification. F) 
Quantification of the signal intensity from infected monocytes at the indicated time points (n=9,7,10, respectively). 
MNDA signal intensity in each nucleus was normalised to the average of uninfected monocytes from each field of 
view. A t-test with Welch’s correction was used to determine statistical significance. ns, not significant, *P<0.05, 
**P<0.01. G) CD14+ monocytes infected with TB40/Egfp (+/- UV inactivation) were analysed for HLA-ABC and HLA-
DR expression at three d.p.i. by flow cytometry. The gating strategy for identifying infected cells (GFP+) is shown. H) 
Histogram showing HLA-ABC and HLA-DR staining in HCMV-uninfected GFP-negative (grey) monocytes, and latently 
infected GFP positive (green) monocytes. 
 
3.4.4. IFI16 is downregulated in a US28-dependent manner, but only in 
undifferentiated myeloid cells 
Having confirmed that IFI16 is downregulated very early during latent infection of monocytes, I then 
sought to establish whether this effect is dependent on US28. I predicted this would be the case because 
of the results of our US28 proteomic screen and the established functionality of incoming virion-
associated US28 [193]. I infected monocytes with either the US28-WT TB40/EmCherry-US28-3XFLAG 
HCMV (US38-3XF), or the corresponding US28 deletion virus TB40/EmCherry-US28Δ (ΔUS28). These 
viruses establish latent and lytic infections, respectively, in CD34+ progenitor cells, Kasumi-3 cells, and 
THP-1 cells [159,193], and I confirmed these phenotypes are also maintained in primary CD14+ 
monocytes by supernatant transfer to permissive fibroblasts (Figure 3-12 A). I was also able to detect 
US28 protein during the establishment of latency in monocytes by immunostaining for the FLAG epitope 
tag on the C terminus of US28 (Figure 3-12 B). This staining is the first time in our laboratory that we 
have been able to clearly observe intracellular expression of US28 using immunofluorescence during 
latency. The pattern of staining is could be an indication of ER or Golgi localisation, in addition to cell 
surface expression, and is in accordance with expression patterns of US28-3XFLAG via retroviral 
transduction in THP-1 cells (Figure 3-13) and US28 expression during lytic infection [366]. However, 
without using confocal microscopy and organelle markers, it is not possible to be certain of the 
subcellular localisation of US28.     
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To determine if US28 specifically downregulates IFI16 in the context of infection, I compared the 
expression of this cellular protein in monocytes infected with US28-3XF or ΔUS28. Consistent withFigure 
3-11, I found that monocytes infected with the US28-3xF virus showed downregulation of IFI16 at 24 and 
48 h.p.i., while monocytes infected with ΔUS28 displayed robust IFI16 expression at 24 h.p.i. (Figure 3-12 
C, D) and only partial downregulation at 48 h.p.i (Figure 3-12 C, E). These data demonstrate that the early 
downregulation of IFI16 in CD14+ monocytes is dependent on US28.  
It would have been interesting to see whether the downregulation of MNDA and HLA-DR is also 
dependent on US28, but the delayed kinetics/partial phenotype associated with MNDA downregulation, 
and the requirement for large number of cells to perform quantitative assessment of HLA-DR expression 
on latently infected monocytes, precluded these studies.  
Work from the laboratory has previously showed that US28 modulates cellular signalling pathways in 
undifferentiated, but not differentiated THP-1 cells [189]. I was therefore curious as to whether the 
effects on IFI16 expression were dependent on cellular differentiation status. This is significant because 
differentiated THP-1 cells and mature dendritic cells are permissive for HCMV lytic infection. To analyse 
whether these effects are differentiation-dependent, I transduced THP-1 cells with a lentiviral vector that 
co-expresses US28 and the fluorescent protein Emerald (US28-UbEm), or co-expresses eGFP and Emerald 
(empty UbEm), as a control. For each population, the Emerald-positive THP-1 cells were isolated by FACS 
(Figure 3-12 F) and I validated US28 expression by RT-qPCR (Figure 3-12 G). I treated half of these cells 
with PMA in order to induce cellular differentiation. I found that undifferentiated US28-expressing THP-1 
cells downregulated IFI16, but PMA-differentiated cells did not downregulate IFI16 (Figure 3-12 H), 
suggesting latency-associated expression of US28 attenuates IFI16 expression.   
I also analysed the effect of cellular differentiation on IFI16 expression following infection in mature 
dendritic cells derived by treating ex vivo CD14+ monocytes with GM-CSF/IL-4/LPS. Again, I found that 
undifferentiated infected CD14+ monocytes downregulate IFI16 in a US28-dependent manner at 48 h.p.i, 
while infected mature dendritic cells do not downregulate IFI16 with WT or ΔUS28 HCMV (Figure 3-12 I). 
Taken together, these results indicate that US28 rapidly downregulates IFI16 during latent infection of 






Figure 3-12 IFI16 is rapidly downregulated in a US28-dependent manner during latent infection. CD14+ 
monocytes were infected with either US28 WT TB40/EmCherry-US28-3XFLAG HCMV or the ΔUS28 equivalent. A) 
Validation of the latent and lytic phenotypes associated with US28-3xF and ΔUS28 monocyte infections, 
respectively. At 7 d.p.i., supernatant from infected CD14+ cells (upper panel) were transferred to Hff1 cells (middle 
brightfield and lower mCherry panels) and formation of plaques was monitored and imaged at 20X magnification. 
B) Detection of US28-3XFLAG during the establishment of latency in CD14+ monocytes. At 2 d.p.i. US28-3xF or 
ΔUS28-infected CD14+ monocytes were fixed and stained by immunofluorescence for US28-3XFLAG using an anti-
FLAG antibody and imaged at 40X magnification. C) US28-3xF and ΔUS28-infected monocytes were stained by 
immunofluorescence for IFI16 at the indicated times and imaged using 40X magnification. White arrows indicate 
corresponding cells. D and E) IFI16 signal intensity in each nucleus was normalised to the average of the uninfected 
cells in a field of view. The results of three fields of view were then averaged to derive the resulting average signal 
intensities for each subpopulation of monocytes at the indicated time points infected with US28-3xF or ΔUS28 
HCMV. Statistical significance was determined using one-way ANOVA. *** indicates P<0.001, ** indicates P<0.01, 
and * indicates P<0.05. F) The sequence encoding US28 was cloned into the lentiviral plasmid pUbEm (US28-
UbEm), and this or empty UbEm plasmid was used to transduce THP-1 cells, which were subsequently cell-sorted 
for Emerald expression.  G) US28 expression was validated in the cells from (F) by RT-qPCR. US28 RNA was 
normalised to cellular TBP and presented as 2-ΔCt. H) US28 expressing and empty vector THP-1 cells were either 
left untreated or treated with PMA for 48 hours before cell lysates were harvested. These lysates were then subject 
to western blotting for IFI16 and beta-actin as a loading control, with molecular weight markers annotated. I) At 48 
h.p.i, either undifferentiated CD14+ monocytes, or monocytes pre-differentiated for 7 days with GM-CSF/IL-4/LPS, 
were fixed and stained for IFI16 and imaged as before at 40X magnification. White arrows indicate corresponding 
infected cells. 
 
Figure 3-13 US28 immunostaining in transduced THP-1 cells. Retroviral plasmids encoding US28-WT (from TB40/E) 
or R129A, each with a C-terminal 3XFLAG tag, and an eGFP marker, were used to transduce THP-1 cells. They were 




Figure 3-14 Fibroblasts which overexpress US28 do not downregulate IFI16. Hff1 cells were transduced with the 
US28-UbEm lentiviral vector as in Figure 3-12 and then fixed and stained for IFI16 expression. White arrows 
indicate transduced cells. 
Additionally, I used the US28-UbEm to transduce fibroblasts (Hff1) cells, and left these as a mixed 
population. Indirect immunofluorescence of transduced Hff1 cells shows no difference in IFI16 
expression with or without US28 expression (Figure 3-14).  
I also analysed IFI16 expression in fibroblasts (Hff1) and epithelial cells (RPE-1), which both undergo lytic 
infection. Previous work suggests that IFI16 expression is not modulated by lytic infection of fibroblasts 
[79,208,367]. In contrast, when I infected both fibroblasts and epithelial cells with the TB40/E 
SV40mCherry strain of HCMV at a MOI of 0.5, I found that IFI16 was downregulated in the majority of 
infected cells at both 24 and 48 hours post infection (Figure 3-15). This was also true for the 
corresponding ΔUS28 virus, indicating that downregulation of IFI16 is not dependent on US28 in these 
cell lines. Supporting this, I found the same downregulation using the Titan strains of HCMV, both WT 
and ΔUS28 (Figure 3-16), when infecting fibroblasts with an MOI <1. 
Clearly, there is some discrepancy between my data and those previously published. Biollati et al [208] 
found increased expression of IFI16 over a time course of infection of fibroblasts (MOI of 1) by western 
blotting; however, in such analyses using whole cell lysates, increases in IFI16 expression in bystander 
cells would have masked any downregulation in infected cells, which is pertinent because I saw clear 
upregulation of IFI16 in uninfected bystander fibroblasts compared with uninfected wells (Figure 3-15 A). 
Additionally, although Cristea et al [79] did not conclude that infection of fibroblasts resulted in a 
decrease in IFI16 expression, close examination of the immunofluorescence data in that paper does 
appear to show a decrease in IFI16 expression. More recently, Nightingale et al [367] have presented a 
comprehensive proteome of fibroblasts at 24, 48, and 72 h.p.i. using an MOI of 5 to 10 in which they did 
not detect any changes in IFI16 expression. The reason for the discrepancy between that study and my 
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data are unclear but it is possible that it results from differences in MOIs, or that there are strain 
dependent differences (in particular a difference between effects of TB40/E and Titan, used in my 
analysis, and Merlin, used in their study) in IFI16 regulation during lytic infection. 
The downregulation of IFI16 I observe during lytic infection of fibroblasts and epithelial cells, as well as 
during ΔUS28 infection of monocytes, perhaps merits further investigation: which viral gene product is 
responsible, and what functional outcome does this have for viral infection? Since IFI16 can repress 
transcription of the early genes UL44 and UL54 [264], downregulation of IFI16 during lytic infection could 
be pro-viral. However, since my research question was focussed on latent infections, I did not pursue 





Figure 3-15 Lytic infection of fibroblasts and epithelial cells leads to downregulation of IFI16 independently of 
US28. Hff1 (A) and RPE-1 (B) cells were infected with TB40/e mCherry with US28-3XFLAG or ΔUS28 at MOIs of 0.5. 





Figure 3-16 Lytic infection of fibroblasts with the Titan strain of HCMV leads to downregulation of IFI16 
independently of US28. (A) Hff1 cells were infected with the Titan strain of HCMV at MOI 0.5. Cells were fixed and 
stained for IE and IFI16 at 24 h.p.i. White arrows indicate the position of infected cells which do downregulate 
IFI16; yellow arrows indicate the position of infected cells which do not downregulate IFI16. (B) Quantification and 
subsequent Fisher’s Exact test of IFI16 positive and negative cells in the infected and uninfected populations in (A). 
Raw numbers of cells are given in white. 
 
3.4.5. Long-term downregulation of IFI16 and MNDA 
I next assessed whether downregulation of IFI16 and MNDA occurs during long term maintenance of 
latency; long term downregulation of HLA-DR is already known to be important for latent carriage of 
HCMV [139]. I infected monocytes with HCMV that drives mCherry from GATA2 promoter, and maintains 
this marker for far longer during latency than SV40 promoter-driven tags[349];  this virus is denoted as 
virus TB40/E GATA2mCherry.  At 10 and 14 d.p.i., IFI16 remained absent and MNDA remained partially 
downregulated in infected cells (Figure 3-17 A). I also differentiated latently infected monocytes to 
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mature dendritic cells to induce reactivation of latent virus, and stained for IFI16 expression, and found 
that IFI16 was also downregulated in this instance. This is not what happened when I infected mature 
dendritic cells (essentially a lytic infection of a now permissive cell type, Figure 3-12). This might reflect 
differences between reactivation and primary infection, but since both observations are snapshots of 
long and complex processes, it would be wrong to conclude too much without further investigation.  
 I also analysed latently infected primary CD34+ hematopoietic progenitor cells (HPCs), a site of long-term 
in vivo latent carriage, as well as the Kasumi-3 cell line, an experimental model for HCMV latency [117]. 
Consistent with my observations in monocytes, and RNAseq experiments in cord blood derived CD34+ 
cells [108], IFI16 levels were low or absent in almost all infected cells imaged at 4 and 10 d.p.i (Figure 





Figure 3-17 IFI16 and MNDA downregulation during long term latency. (A) Monocytes were latently infected with 
TB40/E GATA2 mCherry HCMV. Cells were fixed and stained for MNDA and IFI16 at the indicated times. For 
reactivated dendritic cells (DC), latently infected monocytes were differentiated with GM-CSF/IL-4 at 2 d.p.i. and 
then matured with LPS 5 days later. Cells were fixed and stained for IFI16 3 days after maturation. (B) Primary 
CD34+ HPCs and Kasumi-3 cells were latently infected with HCMV and fixed and stained for IFI16 at the indicated 
time points. (C) The number of infected and uninfected cells with low and high levels of IFI16 were tallied across a 
minimum of three fields of view per time point. The mean proportion of cells with low IFI16 is then graphed along 




3.4.6. Latently infected THP-1 cells show loss of IFI16 and MNDA mRNA 
I was also interested in whether the latency-associated downregulation of IFI16, MNDA, and HLA-DR was 
occurring at the level of mRNA. The analysis of US28-expressing cells suggests that IFI16 and MNDA 
mRNA levels are downregulated by US28, but that HLA-DR downregulation is more complex. I initially 
tried to perform these analyses on FACS-sorted primary monocytes, but too few cells were infected. 
Consequently, I performed the experiment using THP-1 cells infected with the TB40/E GATA2mCherry 
virus. At 24 h.p.i, I extracted RNA from the mCherry negative and the mCherry positive population, that 
had been cell-sorted by staff at the NIHR cell phenotyping hub (Figure 3-18 A), and analysed US28, IFI16, 
MNDA, and HLA-DRA RNA levels by RT-qPCR. I also included the additional PYHIN genes IFIX and AIM2, 
which were not detected by the US28-proteomic screen (Figure 3-18 B). All four PYHIN transcripts were 
clearly downregulated in the infected mCherry positive population compared with the bystander 
mCherry negative population and this is consistent with immunofluorescence data from latently infected 
monocytes and RNA data from US28-expressing THP-1 cells. HLA-DRA mRNA levels were slightly 
increased in the infected cell population, which is in line with Figure 3-8 A, where US28-WT expressing 
cells have a very similar level of HLA-DRA transcript compared with empty vector control cells. While I 
did not verify that cell-surface HLA-DR is downregulated in the THP-1 model of latency, these data 
suggest that latency-associated targeting of HLA-DR might rely on either transcriptional regulation of the 




Figure 3-18 Latently infected THP-1 cells have lower levels of PYHIN mRNAs but not HLA-DRA. (A) THP-1 cells 
were latently infected with TB40/E GATA2mCherry for 24 hours before fluorescence associated cell sorting. 
Uninfected THP-1 cells were used to define the mCherry negative and mCherry positive populations. (B) RNA was 
isolated from the populations sorted in (A) and analysed by RT-qPCR for the indicated genes. All are displayed as 
relative gene expression with respect to TBP housekeeping control (2ΔCt); HLA-DRA is plotted on a linear scale, the 
others on a log scale; n.d., not detected. 
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3.4.7. The role of incoming pUS28 in IFI16 downregulation 
So far, I have shown that HCMV downregulates IFI16 during latency in a US28 dependent manner. IFI16 
levels remain low during the long term maintenance of latency in CD34+ HPCs and CD14+ monocytes. 
Downregulation of IFI16 is initiated within 24 hours of latent infection of monocytes, and this likely 
results from downregulation of IFI16 mRNA levels.  
Interestingly, incoming, virion associated, US28 protein (pUS28) has recently been shown to be 
functional [193] and able to help support suppression of IE gene expression. Therefore, I hypothesised 
that incoming pUS28 may play a role in the very quickly observed downregulation of IFI16 I had noted.  
To address this, I grew a US28 gene deletion virus in a cell line that expresses US28, with the aim of 
generating infectious virions that contained pUS28 but not the US28 gene. I based my approach on the 
publication that showed incoming pUS28 was functional [193]. I grew the TB40/E mCherry US28Δ virus in 
TERT-immortalised Hff1 cells that had been transduced with a US28-V5 lentiviral vector. These cells were 
a gift from Luis Nobre (University of Cambridge). Once I had purified virions, I solubilised these in a high-
salt buffer (see Materials and Methods) and subjected them to SDS-PAGE followed by Western blotting. I 
used pp65 as a marker of virions, and actin as a marker of cells, and blotted for these first, before 
stripping and reprobing the membrane for US28-V5 (Figure 3-19). The stripping process was unsuccessful 
however, and US28-V5 (mouse detection antibody) signal is partially masked by pp65 and actin (also 
mouse detection antibodies). However, if these images are overlayed, it becomes clear that virions 
contained pUS28 when grown in the US28-V5 cell line. This virion preparation will be referred to as 
US28comp. 
I then infected CD14+ monocytes with TB40/E mCherry US28-3XF (which encodes for US28), TB40/E 
mCherry US28Δ, and the US28comp virus. At 24 h.p.i., I fixed and stained for IFI16 (Figure 3-20), since I 
knew from previous experiments that IFI16 is downregulated by WT but not US28Δ viruses. Furthermore, 
US28 protein is likely degraded within 48 hours [193], so I needed to pick a window which maximised any 
observable effects on IFI16. IFI16 expression was clearly downregulated by TB40/E mCherry US28-3XF, 
but remained present in TB40/E mCherry US28Δ infected cells, as expected. Cells infected with 
US28comp showed an intermediate phenotype.  This suggests that incoming pUS28 may, indeed, 
contribute to IFI16 downregulation, but is likely insufficient for full IFI16 downregulation. This 
investigation merits repeating, and further validation of the virion composition, and changes in viral gene 




Figure 3-19 Incorporation of V5-tagged US28 into virions. Left hand panels: lysates from TERT immortalised Hff1 
cells (Hff TERT), or Hff-TERT cells transduced with US28-V5 expression vector, or the latter cell line infected with 
TB40/EmCherry US28Δ, were subjected to western blot firstly for actin (upper panel), then stripped unsuccessfully 
and reprobed for V5 tag (lower panel). Hff V5 cell lines appear to have signal with the V5 antibody that is lower 
than the actin band, and not present in non-transduced Hff TERT cells. Right hand panels: concentrated virions 
were subjected to western blot firstly for pp65 (upper panel), then stripped unsuccessfully and reprobed for V5 tag 
(lower panel). US28 comp refers to TB40/EmCherry US28Δ grown in Hff V5 cell lines, and this track appears to have 
additional signal with the V5 antibody both above and below the pp65 bands, and which is not present in 




Figure 3-20 Incoming US28 may help to drive IFI16 downregulation. A) CD14+ monocytes were infected with either 
TB40/EmCherry-US28-3XFLAG HCMV (WT), the ΔUS28 equivalent, or US28comp. At 24 h.p.i., cells were fixed and 
stained by immunofluorescence for IFI16 and imaged at 40X magnification. B) Distribution of IFI16 intensities 
derived from a minimum of four fields of view (as per (A)). IFI16 intensities were measured using the Measure 
Particles feature of ImageJ. Each cell was assigned as bystander or CMV+ by mCherry intensity. Then, IFI16 
intensities for each cell was normalised to the mean intensity of bystander cells for each field of view. The 




3.5.  Discussion 
The viral GPCR US28 is expressed during both lytic and latent infection of HCMV. While US28 is 
dispensable for lytic replication in vitro [177,178], it is essential for the establishment and maintenance 
of HCMV latency in early myeloid lineage cells [159,173,189,193]. This is attributable, in part, to the 
ability of US28 to suppress the major immediate early promoter; a US28 function specific for 
undifferentiated myeloid cells [160,173,189,193].  
Prior to the beginning of my project, others in my laboratory had hypothesised that this ability of US28 
to so profoundly regulate viral IE gene expression in undifferentiated myeloid cells was likely via US28-
mediated modulation of host protein abundance and, therefore, they wanted to determine whether 
such US28-driven changes could be important for the establishment or maintenance of HCMV latency. 
Previous work has used targeted arrays to assess US28-mediated effects on myeloid cells [173,189,193] 
but, here, my colleagues performed an unbiased proteomic screen to understand how US28 reprograms 
host cells in order to support latent infection. This screen compared host protein abundance in control 
THP-1 cells or THP-1 cells which express either US28-WT or the US28 signalling mutant, US28-R129A. As 
such, I was then able to assess the signalling-dependent and signalling-independent effects of US28. I 
then chose to focus on signalling-dependent changes because G protein coupling via the residue R129A 
is essential for experimental latency [189,193]. However, I predict that some of the signalling-
independent changes driven by US28 could also be important for HCMV latency, since these changes 
included alterations in several cell-surface molecules such as co-stimulatory molecule CD82, adhesion 
molecule CD44, and in receptor tyrosine kinase FLT3. The latter two cellular factors are implicated in 
myeloid cell differentiation, which is intimately linked with HCMV latency and reactivation [107,160,368–
370].  As such, modulating these cell-surface molecules could help to control interactions with immune 
effectors and cellular differentiation-linked reactivation. 
By analysing changes in host protein abundance between US28-WT and US28-R129A expressing THP-1 
cells, I found a number of significant changes in the host proteome which likely result specifically from 
US28 signalling. Interestingly, I found US28-WT downregulated a large number of interferon-inducible 
proteins, including canonical interferon-stimulated genes (ISGs) like OAS2 and IFITM3, as well as MNDA, 
IFI16, and several HLA-DR components. I found that levels of both total STAT1 and phosphorylated STAT1 
were reduced in US28-WT expressing cells, providing a potential mechanism for this effect, but analysis 
conducted using a c-fos inhibitor indicated that c-fos likely also plays a role. Modulation of interferon 
signalling has not previously been reported for US28, but in the context of the latently infected 
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monocyte, a general block in downstream interferon signalling may be important for maintaining the 
polarisation of the monocyte [371,372], or perhaps to avoid the anti-viral activities of ISGs.  I believe 
these questions merit further interrogation. 
I chose to focus on the two PYHIN proteins and the set of HLA-DR components which are downregulated 
by US28. I confirmed downregulation of IFI16, MNDA, and HLA-DR in THP-1 cells which overexpress US28 
and recapitulated these effects in experimental latency in primary CD14+ monocytes. HLA-DR was 
previously reported to be downregulated during experimental latency in granulocyte-macrophage 
progenitor cells, which prevents CD4+ T cell recognition and activation [125,139,373]. Whilst this down-
regulation of MHC Class II involved the expression of the latency-associated gene UL111A [139], my data 
argue that viral US28 could also contribute to this phenotype. I will discuss the functional effects of 
MNDA and IFI16 downregulation in later chapters.  
My results clearly characterised a rapid downregulation of IFI16 during the establishment of latency in 
monocytes, which occurred within the first 24 h of infection and was also maintained during long term 
latency in monocytes and CD34+ HPCs. This effect was clearly US28-dependent as ΔUS28 virus failed to 
display immediate IFI16 down-regulation. However, we did observe a partial downregulation of IFI16 in 
ΔUS28-infected monocytes at later time points of infection. I think it likely that this involves an 
unidentified lytic-phase viral gene product, which may be required for overcoming the known IFI16-
mediated restriction of HCMV lytic infection [208,215,264,286] and occurs as a result of ΔUS28 virus 
initiating a lytic infection in undifferentiated monocytes.  
My observation that the US28-dependent downregulation of IFI16 occurred rapidly (within 24h of 
infection) may, in part, be attributable to incoming US28, which has been shown by others to be  
functional [193]. IFI16 protein has a short half-life of approximately 150 minutes in fibroblasts [374] and 
therefore, incoming US28 protein may rapidly target IFI16 transcription in latently infected monocytes, 
as it does in both US28-expressing THP-1 cells and latently infected THP-1 cells, resulting in loss of IFI16 
within 24 hours of infection; this is then maintained by subsequent latency-associated de novo US28 
expression. By generating virions that contained pUS28 but not US28 coding sequence, I generated 
evidence that pUS28 contributes, but is not sufficient, for IFI16 downregulation at 24 h.p.i.; since US28 
mRNA is detectable within 24 hours of latent infection (Figure 3-18), it is feasible that de novo synthesis 
of pUS28 ‘finishes the job’ of downregulating IFI16. 
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4. IFI16 can activate IE gene expression during latency and needs to be 
targeted for latency-associated IE suppression 
4.1. Introduction 
In Chapter 3, I demonstrated that HCMV latency induces IFI16 downregulation in a US28 dependent 
manner. An obvious question is how this might be beneficial to the virus during latency. In §1.6.4, I 
outlined the evidence for IFI16 being a sensor of double stranded DNA, other mechanisms of viral 
restriction, and modulation of human and viral gene expression. While I will discuss DNA sensing in 
Chapter 6, here I focus on applying known IFI16-mediated modulation of HCMV gene expression during 
lytic infection to what might be happening during HCMV latency. 
In fibroblasts, IFI16 can activate MIEP activity while restricting the transcription of UL54, and perhaps 
UL44; this is possibly dependent on the tegument protein pp65/UL83 [79,208,264].  Since IE gene 
expression must be suppressed in order to establish latency, I hypothesised that downregulation of IFI16 
would be important for repressing the MIEP. 
Here, I demonstrate the merit in that hypothesis by overexpressing IFI16, and showing that this drives IE 
gene expression in myeloid cells via NF-κB activation. 
4.2. Overexpression of IFI16 
I cloned the sequence encoding IFI16 (isoform IFI16-B, NM_001206567.1, nucleotides 291–2482) into the 
lentiviral expression vector pHRsin SV40 Blast, which drives transgene expression from the SV40 
promoter. I generated control empty vector and IFI16 overexpressing THP-1 cell lines via lentiviral 
transduction twice to generate two independent sets of cell lines, and verified overexpression of IFI16 by 
western blot and by immunofluorescence (Figure 4-1). The IF staining also demonstrated that I had a 




Figure 4-1 Overexpression of IFI16 in THP-1 cells. (A) Western blots of IFI16 expression from two independent 
transductions of THP-1 cells with IFI16 overexpression vectors, empty vectors (EV), or MNDA overexpression vector 
(M, described in Chapter 5). Actin is used as a loading control. (B) Immunofluorescence staining of IFI16 expression 
of cell lines generated in A, left hand panel, M not included.  
4.3. IFI16 overexpression drives IE gene expression 
I then infected control empty vector and IFI16 overexpressing THP-1 cells with HCMV strain TB40/E IE2-
eYFP [348]. This results in expression of IE2 (also known as IE86, UL122) as an IE2 yellow fluorescent 
protein fusion. Typically, undifferentiated THP-1 cells infected with HCMV express only low amounts of IE 
[119,141]. I found that IFI16 overexpression significantly increased IE2 expression in THP-1 cells over a 
number of paired experiments (Figure 4-2). These experiments were analysed as pairs, to account for a 
number of factors. Firstly, passage of THP-1 cells over time decreases overall infectability of the cell lines: 
experiments were all performed on passage-matched cells, but over several months and different 
batches of cells which had been stored in liquid nitrogen. I also made two independently transduced sets 
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of cell lines. The matching also controls for differences between batches of IE2-eYFP virus such as 
particle-to-plaque forming unit (p.f.u.) ratio. 
 
Figure 4-2 IFI16 overexpression drives IE gene expression. Empty vector or IFI16-overexpressing cells were 
infected with TB40/E IE2-eYFP virus, and IE2-eYFP positive nuclei were imaged (A) and counted by fluorescence 
microscopy (B). Results from five paired experiments are shown, which were analysed by paired two-tailed 
Student’s t-test. 
 
4.4. IFI16 activates the MIEP independently of other viral factors 
To understand whether IFI16 mediated induction of IE gene expression was an effect on the MIEP, and 
whether other virion components were required for this activity, I used an MIEP-eGFP reporter cell line 
[118]. These are THP-1 cells in which an integrated 1151 bp region of the MIEP drives the expression of 
eGFP [118]. In these undifferentiated THP-1 cells, the MIEP is epigenetically repressed unless stimulated 
(for example by differentiation) [118]. I treated these MIEP-eGFP THP-1 cells with control lentiviruses or 
lentiviruses which drive the overexpression of IFI16, ensuring equivalent lentivirus infection of reporter 
cells by correcting for p24 concentration. The p24 ELISA was performed by Isobel Jarvis, University of 
Cambridge, and gave the following values: empty vector lentivirus, 411 ng/mL; IFI16 lentivirus, 67.0 
ng/mL.  Transduced cultures were maintained for two weeks, after which I validated IFI16 expression by 
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immunofluorescence and then analysed eGFP expression by flow cytometry (Figure 4-3 A, B). I found 
that the IFI16-overexpressing cells had increased eGFP expression compared with controls, suggesting 
that IFI16 overexpressed in isolation and in the absence of additional HCMV components, drives MIEP 
activity. Furthermore, culturing THP-1 MIEP-eGFP reporter cells with supernatants from the empty 
vector or IFI16-overexpressing cell lines in Figure 4-1 resulted in no significant MIEP activity, suggesting 
that the effect is mediated intracellularly, and not by a secreted factor (Figure 4-3 B). 
 
Figure 4-3 IFI16 drives MIEP activity. (A) EV and IFI16 lentivirus concentration was determined by p24 ELISA and 15 
ng p24 equivalents of each lentivirus was used to transduce MIEP-eGFP THP-1 cells. Cells were maintained for two 
weeks in culture, and IFI16 overexpression was validated by immunofluorescence. B) Left hand comparison: cells 
described in (A) were assessed for eGFP fluorescence by flow cytometry. Right hand comparison: non-transduced 
MIEP-eGFP expressing cells were incubated with supernatants from cells described in Figure 4-1 for two days. eGFP 
expression was quantified by flow cytometry.  A statistical comparison of the median fluorescence intensity was 
performed using two-tailed Mann-Whitney test; ns, not significant and * P<0.05. 
 
4.5. IFI16 drives IE gene expression via NF-κB at the MIEP 
IFI16 activates NF-κB signalling in a number of contexts [224,250], and our previous work indicates that 
US28-mediated attenuation of NF-κB signalling is important for the establishment of latency [189]. 
Therefore, I hypothesised that IFI16 activates the MIEP via NF-κB. By using the NF-κB pathway inhibitor, 
BAY11-7082, we were able to ameliorate the effect of IFI16 overexpression on IE , suggesting that NF-κB 
plays an important role in this pathway (Figure 4-4 A, C). I also infected IFI16-overeexpressing cells with a 
recombinant HCMV that lacks NF-κB sites within the MIEP [146] to check whether activation of the MIEP 
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by IFI16 requires the well-established NF-κB binding sites present within the  MIEP. In this analysis, IFI16 
overexpression failed to induce IE gene expression in the NF-κB site deletion virus, unlike IFI16 cells 
infected with the revertant strain (Figure 4-4 B,C).  Taken together, these data are consistent with the 
view that IFI16 activates IE gene expression in early myeloid lineage cells through NF-κB binding to the 
MIEP.  
 To begin to unpick how NF-κB is activated by IFI16, I analysed nuclear NF-κB localisation in IFI16 
overexpressing cells (Figure 4-5), since localisation of NF-κB is a principle way by which its activity is 
regulated [375]. Undifferentiated THP-1 cells have only a small cytoplasmic volume, making 
quantification challenging, but I appeared to see greater nuclear NF-κB in cells which overexpress IFI16. 
This is consistent with previously published observations in epithelial cells [250]. In that study, Caposio et 
al [250] demonstrated that IFI16 activates NF-κB via the attenuation of IκBα expression. IκBα, known 
formally as NFKBIA, inhibits NF-κB by binding and preventing  NF-κB translocation to the nucleus [375]. 
Caposio et al [250] suggest that IFI16 overexpression sequesters Sp1 transcription factors, thus 
preventing binding of Sp1 to the IκBα promoter. To see if this was occurring in my system, I analysed 
NFKBIA/ IκBα gene expression by RT-qPCR in empty vector and IFI16 overexpressing cell lines, as well as 
in US28 expressing THP-1 cells described in Chapter 3. I found that, contrary to what one might have 
predicted from the Caposio et al [250] study, IFI16 overexpression increased IκBα RNA expression. 
Furthermore, US28-WT expressing cell lines, which have reduced nuclear NF-κB, also have reduced IκBα 
RNA levels. This suggests that the Sp1 mechanism is not at play in my system. Indeed, IκBα is induced by 
NF-κB as part of a negative feedback loop [376], and so my results are consistent with IFI16 increasing 
NF-κB activity, and US28-WT decreasing NF-κB activity. IFI16 can also contribute to NF-κB activity by 
etoposide-induced DNA damage sensing pathway, via ATM and STING [224]; whether a DNA/DNA 





Figure 4-4 IFI16 activates IE gene expression via NF-κB. (A) Empty vector or IFI16-overexpressing cells were 
infected with TB40/E IE2-eYFP virus in the presence of the IKKα inhibitor BAY11-7082 which inhibits the NF-κB 
pathway, or DMSO as a control.  IE2-eYFP positive nuclei were imaged and counted by fluorescence microscopy at 
48 hours post infection. (B) Empty vector or IFI16-overexpressing cells were infected with a revertant WT-like 
TB40/E at MOI 3, TB40/E with NF-κB binding sites deleted from the MIEP (ΔNF-κB) at MOI 3 or MOI 15. At 48 h.p.i., 
cells were fixed and stained for IE and the number of IE positive nuclei were counted. Graph shows the results of 
three experiments and statistical analysis by 2-way ANOVA using Sidak’s multiple comparison test. ** P<0.01, ns, P 
> 0.05. C) Empty vector or IFI16-overexpressing cells were infected as per A) and B) at MOI 3, but cells were instead 
analysed for IE72 expression by RT-qPCR. PCR products were then run on a 2% (upper panel, IE72) or 1.2% (lower 
panel, GAPDH) agarose gel. UI refers to uninfected cells, DMSO is the solvent control, BAY refers to BAY11-7082, 
Rev refers to the revertant TB40/E and ΔNF-κB to the NF-κB binding site mutant virus.  The positive control (+ve 




Figure 4-5 IFI16 overexpression increases nuclear NF-κB. (A) Empty vector or IFI16-overexpressing cells were fixed 
and stained for NF-κB, with Hoechst as a nuclear stain, at 40X magnification to assess levels of nuclear NF-κB. (B) 
IκBα, gene name NFKBIA, RNA level was assessed by RT-qPCR in the indicated cell lines, and normalised to GAPDH 




Here I found that preventing IFI16 expression has a clear benefit to the establishment of HCMV latency. 
This contrasts with previous analyses of latency in other viral systems, where IFI16 expression is 
necessary to repress lytic viral transcription [271,285]. In my model, IFI16 overexpression activated MIEP 
activity in the absence of additional viral proteins, and, furthermore, IFI16 overexpression increased IE 
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positive nuclei in latently infected THP-1 cells. IFI16 activates the MIEP during lytic infection [79,264], 
though in these cases an additional viral gene product, UL83, is thought to be required. My results 
suggest that UL83 is not required for IFI16-mediated activation of the MIEP in undifferentiated myeloid 
cells, and suggest that IFI16 activates NF-κB to achieve this, as use of either an NF-κB pathway inhibitor 
or deletion of NF-κB binding sites from the MIEP prevented IFI16-mediated IE expression. I believe this 
provides one mechanism by which US28 blocks NF-κB activity early during latency, a phenomenon 




5. MNDA is a potential restriction factor for HCMV latency 
5.1.  Introduction 
In Chapter 3 I demonstrated that HCMV latency induces partial MNDA downregulation, and that, in 
THP-1 cells, US28 expression alone is sufficient for MNDA downregulation. Very little is known about the 
function of MNDA, and thus it was not obvious why MNDA might be a target for downregulation during 
HCMV latency.  In the Introduction, I outlined what is known about MNDA: it is a PYHIN protein, it can 
bind DNA [292]; it may enhance YY1 binding to DNA [298]; it has a potential role in myeloid cell death 
[303,304]; it displays the properties of a master transcriptional regulator of the myeloid lineage [293–
297]. Here, I overexpress MNDA in THP-1 cells and find that these cells show lower levels of latent 
infection based on a reduction in the numbers of cells expressing fluorescent reporters in recombinant 
HCMV strains routinely used to detect latently infected myeloid cells. Some of the follow up studies, 
including the use of independently generated sets of MNDA-overexpressing cell lines, were performed 
by an undergraduate Part II student, Esme Fowkes, under my supervision and will be attributed to her 
where applicable. These analyses show that this effect is unlikely to be explained by a failure of virus to 
enter cells. The data suggest that MNDA could be a restriction factor for HCMV latency, but further 
analysis is required, including the mechanism of restriction.  
5.2. Overexpression of MNDA 
I cloned the sequence encoding MNDA (NM_002432) into the lentiviral expression vector pHRsin SV40 
Blast, which drives transgene expression from the SV40 promoter. I generated control empty vector and 
MNDA overexpressing THP-1 cell lines via lentiviral transduction on multiple occasions, to generate three 
independent sets of cell lines during the course of this project. I, or Esme Fowkes in the case of the 
second and third transduction, verified overexpression of MNDA by western blot and by 
immunofluorescence (Figure 5-1). The IF staining also demonstrated that I had a heterogenous 





Figure 5-1 Overexpression of MNDA.  (A) Western blot of MNDA expression from the first transduction of THP-1 
cells with MNDA overexpression vectors, empty vectors (EV), or IFI16 overexpression vector (described in Chapter 
4). Actin is used as a loading control. (B) Immunofluorescence staining of IFI16 expression of cell lines generated in 
A, IFI16 not included. C) Western blot of MNDA expression from the three independent transductions (1, 2, 3). D) 
As (B), but for the second set of transduced cell lines (2). C and D were experiments performed by Esme Fowkes 
under my supervision. 
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5.3. MNDA-overexpressing cells fail to drive fluorescent reporter 
expression following latent infection 
To begin to understand why MNDA is targeted during HCMV latency, I infected empty vector or MNDA-
overexpressing cells with TB40/E viruses that, in our models of HCMV latent infection, express 
fluorescent proteins. These contain SV40 GFP or GATA2 mCherry expression cassettes, and I introduced 
these in Chapter 3. I found, using the cell obtained in the first transduction, a clear and significant 
reduction in the numbers of cells which become infected, and measured by GFP or mCherry fluorescence 
by microscopy (Figure 5-2 A, B).  I was then able, in conjunction with Esme Fowkes, to reproduce the 
observations with the GATA2mCherry virus in the independently-transduced cell lines (Figure 5-2 C, D). 
Because the reduction in apparent levels of HCMV latent infection occurred using two different reporter 
proteins, expressed from different promoters, I believe it unlikely that this is a simple effect of MNDA 
non-specifically affecting reporter gene expression outside the context of a viral genome. However, it 
would be prudent to rule that out by performing reporter assays on transfected plasmids, for example 





Figure 5-2 MNDA-mediated restriction of virus-associated fluorescent reporter expression. A) Empty vector (EV) 
or MNDA-overexpressing cells from transduction 1 were infected with TB40/E SV40 GFP. At 3 d.p.i., cells were 
counterstained for Hoechst and imaged. B) Quantification of GFP positive cells from (A) and those from a similar 
experiment except using TB40/E GATA2mCherry virus. C) EV and MNDA cells from tranductions 2 and 3 (T2, T3) 
were infected with TB40/E GATA2mCherry virus. The next day, cells were imaged. D) Quantification of mCherry 
positive cells from (C). C and D were experiments performed by Esme Fowkes. Statistical analysis by two-way 
ANOVA and Sidak’s multiple comparison test, **, P<0.01; ****, P<0.0001. 
5.4. MNDA-overexpressing cells do take up viral genome following latent 
infection 
The observations outlined in Figure 5-2 suggested that MNDA may act as a restriction factor for HCMV 
latency. There are many potential mechanisms by which this could be occurring, which I will discuss in 
§5.5. One mechanism I was able to begin to explore was whether MNDA overexpression leads to a 
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failure to take up and maintain viral genome. In a straightforward analysis, DNA from infected cells from 
the latter two independent transductions was harvested at 24 h.p.i. and analysed for relative HCMV DNA 
content (Figure 5-3).  These data were accrued from the same experiments as shown in Figure 5-2 C/D, 
where, for transductions 2 and 3, there was a 10-to-20-fold difference between the proportions of 
mCherry positive cells. When analysing relative HCMV content, there was a decrease in HCMV DNA in 
both MNDA-overexpressing cell lines, compared with control empty vector cells.  However, empty vector 
cells had only 1-to-2-fold increases in HCMV DNA, which seems unlikely to be sufficient to explain the 10-
to-20-fold difference seen in fluorescence reporter. To further understand the differences in DNA levels, 
I would perform an extension of this analysis and analyse the relative HCMV DNA content at 3 h.p.i., 24 
h.p.i., 48 h.p.i, 72 h.p.i, and 6 d.p.i., to distinguish between an entry phenomena and genome 
maintenance phenomena, both of which would clearly impact latent carriage and latency-associated 
gene expression.  
 
Figure 5-3 Relative HCMV DNA levels in infected control and MNDA-overexpressing cells. EV and MNDA cells from 
transductions 2 and 3 were infected with TB40/E GATA2mCherry virus. The next day, after imaging, cells were 
washed in a low pH citrate buffer to remove any cell-surface bound but uninternalized HCMV particles. Total DNA 
was then harvested and subject to qPCR for HCMV DNA using the UL44 promoter region as the HCMV target and 
GAPDH promoter region as host genomic DNA control. Results are expressed as 2^ΔCt(GAPDH promoter-UL44 





Very little is known about the function of the myeloid specific PYHIN protein MNDA, but it is partially 
downregulated during HCMV latency. In this Chapter, I began to address why it may be targeted during 
latency by overexpressing MNDA in THP-1 cells. I found that MNDA-overexpressing cells show lower 
levels of latent infection based on a reduction in the numbers of cells expressing fluorescent reporters in 
recombinant HCMV strains routinely used to detect latently infected myeloid cells, suggesting a form of 
antiviral restriction mediated by MNDA. Though viral genome levels were decreased in MNDA-
overexpressing cells, I reasoned that this was insufficient to explain the difference in fluorescent reporter 
expression. While the analysis of genome uptake and carriage requires additional analysis, I am 
interested in analysing potential additional mechanisms of antiviral restriction. 
The most important of these would be to analyse expression (both RNA, and protein if possible) of viral 
latency-associated transcripts such as US28, UL138, LUNA, and beta2.7. LUNA is particularly of interest 
because its promoter activity is driven by GATA2 sites during latency [142], which would provide a good 
comparison for mCherry expression in the GATA2mCherry virus. As described previously, IFI16 
transcriptionally represses many different viral genes/promoters (for example HCMV UL54, HIV lytic 
transcription [264,271]). It is therefore feasible that the related protein MNDA could be performing a 
similar role.  
If I were to find that MNDA enacts antiviral restriction by repression of HCMV latent transcription, there 
would be many potential lines of further investigation. I would wish to see if MNDA restricts 
transcription of all foreign DNA, for example by transfection of GFP expression plasmids. I would also 
look at other viruses, including herpesviruses such as HSV-1, other DNA viruses, retroviruses, and 
possibly RNA viruses. I would also investigate whether MNDA restricts transcription during HCMV lytic 
infection, by differentiating the cells prior to infection. It might be informative to transduce cells that do 
not typically express MNDA, for example fibroblasts, to see if MNDA is able to act as a restriction factor 
in these cell types. 
Overall, my data appear to show a potentially very interesting and, as yet, undescribed function of 
MNDA as an antiviral restriction factor. However, there are multiple confounding issues which need to 
be addressed (such as whether this effect is a result of MNDA action specifically on SV40/GATA2 
promoters) and, of course, detailed additional studies will eventually need to be carried out to identify 
the mechanism of any such restriction. 
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6. US28-mediated interference with DNA sensing 
6.1. Introduction 
I have already shown that US28 downregulates interferon-inducible genes when expressed in isolation, 
including IFI16, and that one US28-mediated effect on IFI16 appears to result in inhibition of IFI16-
mediated activation of the viral MIEP. However, IFI16 is also involved in the double stranded DNA 
sensing pathway (see §1.6.4). An attractive hypothesis would, therefore, be that the expression of US28 
also interferes with the ability of myeloid cells to sense double stranded DNA and induce a Type I 
interferon response. Furthermore, as US28 is expressed during latent infection, US28 could be required 
to evade sensing of the viral genome or viral transcription intermediates during the establishment or 
maintenance of HCMV latency.  
Here, I explore whether US28 is capable of interfering with DNA sensing in myeloid cells, and the 
potential contributions of IFI16 and MNDA to such a phenomenon. Some experiments described were 
performed by Esme Fowkes, an undergraduate Part II student under my supervision, and these will be 
clearly detailed. 
6.2. Undifferentiated THP-1 cells make far smaller responses to DNA 
stimuli compared with PMA-differentiated THP-1 cells 
I wanted to take a reductionist approach and analyse the effect of US28 expression on responses to 
transfected DNA, a well-established insult for the induction of the interferon response, in 
undifferentiated THP-1 cells overexpressing US28. However, the vast majority of publications that 
examine interferon or pro-inflammatory responses in THP-1 cells differentiate their cells with PMA prior 
to analysis [206,224,256,377]. This was not an option for my studies, because, as previously reported 
[189], and shown again in Chapter 3, US28 alters cellular signalling and transcription in a differentiation 
dependent manner; in particular, US28 does not downregulate IFI16 in differentiated myeloid cells.  
Consequently, I compared the response of undifferentiated and PMA-differentiated THP-1 cells to 
transfected DNA. I decided to use pUC19 plasmid that had been digested with the restriction enzyme 
BglI in order to create ‘DNA ends’ which are established to be good substrates for DNA sensing in some 
settings [378,379] (Figure 6-1 A). I first analysed IL-1β production by ELISA, as IL-1β is reported to be 
generated by IFI16-induced sensing in some settings [380,381]. As shown in Figure 6-1 B, PMA-
differentiated THP-1 cells make detectable IL-1β responses to LPS (a positive control), mock transfection, 
and transfection of digested pUC19. The response to mock transfection likely results from a cell-type 
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dependent pro-inflammatory response to the liposome-based transfection reagent [382], and the 
magnitude of the response to transfected DNA is increased with respect to mock. However, 
undifferentiated THP-1 cells did not produce quantifiable levels of IL-1β under either mock or DNA 
transfection conditions. 
 
Figure 6-1 PMA pre-treatment of THP-1 cells leads to greater responses to transfected DNA. A) The 2698 bp 
plasmid pUC19 was digested with the restriction enzyme EcoRI to generate a single-cut, linear fragment, or with 
BglI to generate a 1118 bp and a 1580 bp fragment. Uncut plasmid, and molecular markers (M), were also 
separated on a 1 % agarose gel. Plasmid digestion and separation was performed by Esme Fowkes under my 
supervision. B) THP-1 cells were differentiated with PMA or left undifferentiated (-PMA) for 48 hours prior to 
stimulation with indicated reagents. Two independent undifferentiated samples were assessed. Mock transfection 
contained Fugene6, the liposome-based transfection reagent. 2 μg/mL of BglI-digested pUC19 was used for DNA 
transfections and 100 ng/mL LPS was used for LPS stimulation. After 24 hours, the cell culture supernatants were 
assayed for IL-1β by ELISA. LoQ indicates the lower limit of quantification for the ELISA. Single biological replicates 
were analysed by ELISA in duplicate. C) As B, except RNA from the stimulated cells was analysed for interferon beta 
(IFNB) expression. The graph shows single biological replicates analysed in triplicate by RT-qPCR. D) As B, except 
RNA from the stimulated cells was analysed for CXCL10 expression. The graph shows a single biological replicate 
analysed in triplicate by RT-qPCR for the +PMA condition, and two biological replicates for the -PMA condition. 
However, only one sample from the -PMA/mock condition had detectable levels of CXCL10 by RT-qPCR; this is 
indicated by ‘#’. 
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I also analysed IFNβ and CXCL10 RNA levels in a similar experiment. IFNβ is a Type I interferon and has 
been shown many times to be produced in response to transfected DNA and viral infections, and this 
involves IFI16 [256]. CXCL10 is often used as a ‘surrogate’ for Type I interferon because its expression can 
be activated by NF-κB and IRF3, just like Type I interferons [383]. These analyses showed similar results 
to those for IL-1β; PMA-differentiated cells made measurable, substantial responses to transfected DNA 
(Figure 6-1 C,D), but undifferentiated THP-1 cells made much smaller responses.  This meant that 
detecting differences in responses between undifferentiated THP-1 cells overexpressing genes of interest 
would be difficult. 
6.3. US28-WT expression in myeloid cells may interfere with DNA sensing 
Despite identifying potential difficulties assessing interferon responses in undifferentiated THP-1 cells, I 
pursued this line of investigation in undifferentiated THP-1 cells which express US28-WT or US28-R129A, 
or empty vector control THP-1 cells (described in Chapter 3). I transfected US28-WT and US28-R129A 
cells with uncut pUC19, or the dsDNA analogue poly dA:dT, and analysed IFNβ mRNA levels the following 
day (Figure 6-2 A). I found a clear trend suggesting that US28-WT cells have attenuated responses to 
both plasmid and poly dA:dT, which is consistent with these cells expressing lower levels of the DNA 
sensor IFI16; however, the magnitude of the response is generally very low even in US28-R129A cells. I 
also found an attenuation of CXCL10 gene expression after transfecting BglI-digested pUC19 into US28-
WT THP-1 cells compared with US28-R129A or empty vector cell lines (Figure 6-2 B), though it was 
difficult to be sure that US28-R129A cells responded to the stimulus over and above the CXCL10 levels 
found in mock transfected cells. I also found what appeared to be a weakened response to the same 
DNA stimulus when analysing IL-1β production, but a lack of replicates and the existence of only a weak 
trend make these results inconclusive. Finally, I also tried to analyse both IFNα and IFNβ protein 
production by ELISA following stimulus with digested or undigested plasmid, but the ELISA failed to 
detect any IFNα or IFNβ protein in the cell culture supernatants (data not shown). Overall, these 
experiments do not lead me to draw strong conclusions about whether US28 expression interferes with 
DNA sensing, but I believe the trend shown in Figure 6-2 A hints at such an effect and merits further 
repetition and optimisation of the transfection conditions. For example, it may be that these genetically 
modified THP-1 cells were of too high a passage number to make responses, and early passage 




Figure 6-2 US28-WT expressing THP-1 cells make attenuated cytokine responses to transfected DNA. A) US28-WT 
or US28-R129A –expressing THP-1 cells (2x105) were mock transfected, or transfected with 1 μg of uncut pUC19, or 
1 μg of the dsDNA analogue poly dA:dT. After overnight incubation, RNA was extracted and analysed for levels of 
IFNB mRNA, using GAPDH as a housekeeping gene. Results represent the average of two biological replicates 
analysed in technical triplicate and are displayed as 2-ΔΔCt with respect to mock transfected cells. B) Empty vector, 
US28-WT or US28-R129A –expressing THP-1 cells (2x105) were mock transfected, or transfected with 2 μg of 
digested pUC19. After 24 hours, RNA was extracted and analysed for levels of CXCL10 mRNA, using GAPDH as a 
housekeeping gene. Results represent the average of two biological replicates analysed in technical triplicate and 
are displayed as 2ΔCt with respect to GAPDH. Where one or both of those biological replicates did not contain 
detectable CXCL10 mRNA, the bar is marked with a # or ##, respectively. C) As B, except cell culture supernatants 
were subject to ELISA for IL-1β.  Results represent the average of one (empty vector) or two (US28-WT) biological 
replicates analysed in technical duplicate. LoQ indicates the lower limit of quantification for the ELISA. 
One prediction from these data, and data presented in Chapter 3, might be that latently infected primary 
CD14+ monocytes make lower interferon responses following infection in comparison with monocytes 
infected with ΔUS28 HCMV. To that end, I compared the secretion of IFNα, IFNβ, and IL-1β (Figure 6-3) 
following infection by ELISA. In the first analysis, I found that IFNβ is produced by monocytes and is 
measurable by ELISA (Figure 6-3 A). Addition of poly dA:dT to the media (no transfection reagents) was 
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sufficient to drive IFNβ secretion. Infection with Titan WT also appeared to induce IFNβ secretion, over 
and above uninfected and UV-inactivated virus-treated monocytes. A higher level of IFNβ was detected in 
monocytes infected with Titan ΔUS28, which is consistent with the hypothesis. However, analysis of the 
viral inoculum itself showed that all three viral conditions (UV-inactivated, Titan WT, Titan ΔUS28) 
contained high levels of IFNβ. Though the inoculum is removed after 2 hours of infection, and the cells 
washed with PBS, it is not possible to rule out the contribution of contaminating IFNβ in the viral inocula. 
Furthermore, the particle:p.f.u. ratio is not known for each virus isolate, and it is feasible that a higher 
induction of IFNβ in Titan ΔUS28-infected monocytes could be due to an increase in the proportion of non-
infectious particles in the inoculum.  
The same potential confounders are present when interpreting the analysis of IFNα and IL-1β in the 
supernatants of monocytes infected with TB40/EmCherry US28-3XFLAG (‘WT’) or TB40/EmCherry ΔUS28 
(Figure 6-3 B,C). Indeed, one donor had higher IFNα secretion after 24 hours infection with WT virus than 
with ΔUS28 HCMV. Two further independent donors had similar IFNα secretion after 48 hours infection 
with both viruses. Monocytes from the third donor were differentiated to dendritic cells and the infections 
repeated; here no induction of IFNα was detected. This might be because dendritic cells secrete different 
profiles/subtypes of Type I interferons to monocytes [384,385]. Because the infection and washing 
protocol was identical for differentiated and undifferentiated monocytes, it does suggest that the 
induction of IFNα was likely due to detection of virus particles or other danger associated molecular 
patterns (DAMPs), and it was not due to contaminating IFNα in the viral inoculum, though I can not entirely 
rule this out. The particle:p.f.u. ratio was also not known for these TB40/E viruses. The results of an analysis 
of IL-1β production were consistent with the hypothesis that latent infection is in some way anti-
inflammatory, but given the confounders described in this section it is not possible to draw strong 
conclusions from this experiment.  
To truly understand whether there is a difference in interferon/inflammatory responses between latent 
infection with WT HCMV, and infection in the absence of US28, I would need to work with highly purified 
infectious virions, with near-to-identical particle:p.f.u. ratio, and no contaminating cytokines or DAMP. I 





Figure 6-3 Infected monocyte interferon and IL-1beta responses. A) CD14+ monocytes were left uninfected (UI), 
treated with UV-inactivated Titan WT, infected with Titan WT or Titan ΔUS28, or treated with 1 μg/mL poly dA:dT. 
For UV or live virus treatments, these viruses were aspirated after two hours and the cells washed three times with 
PBS. After 24 hours, before the supernatants were harvested and assayed for IFNβ by ELISA (teal bars, 24 hours post 
infecton (i)/treatment (t)).  To measure incoming IFNβ, viral inocula were placed into empty wells and harvested after 
2 hours before assay for IFNβ by ELISA (grey bars, Inoculum). LoQ, lower limit of quantitation. B) Undifferentiated 
CD14+ monocytes were left uninfected (UI) or infected with TB40/E mCherry US28-3xFLAG (WT), or TB40/EmCherry 
ΔUS28. Alternatively, CD14+ monocytes were differentiated to mature dendritic cells (DC) with GM-CSF/IL-4/LPS as 
described in Materials and Methods prior to infection. At the indicated time post infection, supernatants were 
harvested and assayed for IFNα by ELISA. LoQ, lower limit of quantitation. C) As B, but supernatants from 
undifferentiated monocytes were harvested after 48 hours of infection and assayed for IL-1β by ELISA. LoQ, lower 
limit of quantitation. 
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6.4. IFI16 and MNDA super-expression drive Type I interferon responses to 
DNA in undifferentiated THP-1 cells 
While I could not draw strong conclusions about whether US28 interferes with DNA sensing, I was still 
interested in whether IFI16 and MNDA were part of the DNA sensing machinery in undifferentiated 
myeloid cells. I took THP-1 cells overexpressing IFI16 and MNDA, or empty vector controls (described in 
Chapter 4 and Chapter 5, IFI16 transduction 2 and MNDA transduction 1) and transfected these with 
BglI-digested pUC19, as described in §6.2. I then analysed IFNβ and CXCL10 by RT-qPCR, and IL-1β by 
ELISA (Figure 6-4). As described in §6.2, empty vector control THP-1 cells made little-to-no response to 
the transfected DNA. However, in a single experiment, overexpression of IFI16 and MNDA substantially 
increased the IFNβ and CXCL10 response to transfected DNA, though, interestingly, not IL-1β responses. 
From this, I conclude that IFI16 contributes to interferon responses to transfected DNA in 
undifferentiated myeloid cells, as it does in differentiated myeloid cells, and other cell types such as 
keratinocytes [201,206,224,256]. Excitingly, MNDA also contributed to interferon responses to 
transfected DNA, which has not been previously published. MNDA overexpressing cells had higher levels 
of IFNβ and CXCL10 in both mock and DNA transfected conditions, and I can rule out that MNDA 
overexpression simply increased IFI16 expression by the western blot presented in Figure 4-1 in Chapter 
4. The same effect on IL-1β did not occur, indicating that an inflammasome type response is unlikely to 
be a function of IFI16 and MNDA in undifferentiated myeloid cells. If these results can be repeated, it 





Figure 6-4 IFI16 and MNDA overexpression drives interferon but not IL-1beta responses to transfected DNA. A) 
Empty vector (EV), IF16-overexpressing, and MNDA overexpressing THP-1 cells (2x105) were mock transfected or 
transfected with 2 μg of digested pUC19. After 24 hours, RNA was extracted and analysed for levels of IFNβ mRNA, 
using GAPDH as a housekeeping gene. Results represent the mean of one biological replicate analysed in technical 
triplicate, displayed as 2ΔCt with respect to GAPDH B) As A), except RNA was analysed for levels of CXCL10 mRNA, 
using GAPDH as a housekeeping gene. Results represent the average of two biological replicates analysed in 
technical triplicate and are displayed as 2ΔCt with respect to GAPDH. Where one of those biological replicates did 
not contain detectable CXCL10 mRNA, the bar is marked with a ‘#’. C) As B, except cell culture supernatants were 
subject to ELISA for IL-1β.  Results represent the average of two biological replicates analysed in technical duplicate. 
LoQ indicates the lower limit of quantification for the ELISA. Results for PMA differentiated THP-1 cells (from Figure 
6-1) are plotted on this graph to indicate that the ELISA was able to detect IL-1β in cell culture supernatants. 
 
6.5. Discussion 
In this Chapter, I have investigated whether US28 may be preventing DNA/other nucleic acid sensing in 
the context of latent infection of undifferentiated myeloid cells, and whether this is linked to the US28-
mediated downregulation of IFI16 and/or MNDA.  I analysed the ability of US28 to interdict in DNA 
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sensing in a reductionist system (THP-1 cells transfected with DNA or DNA analogues), and in the context 
of latently infected monocytes.  
I was greatly hindered in this investigation by a general failure of undifferentiated THP-1 cells to make 
robust and substantial interferon/inflammatory cytokine responses to transfected DNA, and the 
presence of confounding factors during virus infections. Furthermore, I did not assess whether interferon 
treatment has any impact on the efficiency of latency establishment and downstream reactivation. This 
analysis would be greatly needed to correctly interpret any US28-mediated effects seen. These 
important experiments could not be performed due to time limitations. 
While differentiated THP-1 cells were competent for generating interferon responses to transfected 
DNA, I could not use differentiated THP-1 cells for my analyses because US28 expression has a very 
different phenotype in differentiated myeloid cells [189], and does not downregulate IFI16 in this 
context (Chapter 3). I found some indications and trends that suggested that US28 may interdict in DNA 
sensing when expressed in isolation in myeloid cells; it is possible that further extensive optimisation of 
the system would lead to the kind of reproducible data necessary to draw robust conclusions. My overall 
view of the data generated during infections of monocytes is that it is impossible to interpret without 
knowing the particle:p.f.u. ratio and having highly purified virion preparations.  
Perhaps the most interesting pieces of data generated here were results suggesting that MNDA could be 
acting as a DNA sensor, like the other three PYHIN proteins. MNDA overexpression clearly resulted in 
increased interferon responses to transfected DNA. A more detailed, mechanistic understanding of the 
role of MNDA in such a response is now required. To gain such an understanding, I would generate 
MNDA knock-out THP-1 cells, or iPSCs, by CRISPR-Cas9, to determine whether MNDA is necessary for 
interferon responses, or just enhances these responses. I would transduce cells that do not normally 
express MNDA (e.g. fibroblasts, 293T, keratinocytes) with MNDA-overexpression constructs to determine 
if MNDA can also contribute to DNA sensing there. I would determine whether MNDA binds DNA as part 
of the mechanism by ChIP, and/or whether it interacts with canonical components of DNA sensing 
pathways (e.g. STING, cGAS). I would also determine if MNDA functions independently of STING, cGAS, 
etc, by repeating the analysis presented in Figure 6-4 in STING/cGAS knockout cells. Finally, I would like 
to determine whether MNDA interactions with DNA sensing pathways are independent of, or linked to, 
the restriction on HCMV latency as presented in Chapter 5. 
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7. Selective shock and kill using anti-US28 nanobodies 
7.1.  Introduction 
Single-domain camelid antibodies, termed nanobodies (Nb) are promising molecules for experimental, 
diagnostic, and therapeutic tools [307,309,310]. Collaborators at the Vrije Universtiteit, The Netherlands, 
have developed several US28-targeting nanobodies than can interfere with aspects of US28 ligand 
binding and signalling [182,308,318]. I worked closely with Timo de Groof, a PhD student from Martine 
Smit’s group at Vrije Universiteit, to analyse the effect of two US28-targetting nanobodies on latently 
infected cells. The first, VUN100, has previously been characterised [308], and inhibits US28 ligand 
binding. The second is a bivalent form of VUN100, termed VUN100b. Our collaboration aimed to address 
whether either of these nanobodies could interfere with US28 functions that are important for the 
maintenance of latency. In particular, if either nanobody were to block MIEP suppression, we would 
predict IE gene expression during HCMV latency – a phenomenon we have previously shown to make 
latently infected monocytes vulnerable to T cell killing [145].  
Here, I will present the characterisation of VUN100b, the effect of VUN100 and VUN100b on latently 
infected monocytes, and the subsequent impact on T cell killing and reactivation. Timo de Groof 
performed the binding studies, immunostaining, and analysis of the effect on US28 signalling in cell lines. 
I performed the majority of the studies on latently infected monocytes, with Timo de Groof performing 
some of these during a month-long visit to our laboratory. Eleanor Lim, a PhD student in Mark Wills’s 
laboratory here at the Department of Medicine, performed T cell isolations and assisted with assays 
involving T cell killing. 
7.2. US28 nanobodies induce immediate early gene expression 
7.2.1. Bivalent nanobody VUN100b binds US28 and inhibits US28-mediated 
signalling 
The existing US28-specific nanobody VUN100 is an antagonist of US28 – it inhibits ligand binding to US28 
and ligand-dependent US28 activity [308]. By generating a bivalent format of VUN100, termed VUN100b, 
it was hoped that a higher affinity molecule displaying inverse agonist properties would be generated; in 
several cases, bivalent nanobodies that target chemokine receptors are already known to be inverse 
agonists [309,311]. In the case of a US28 inverse agonist, the molecule would block US28 signalling 
independently of ligand presence. VUN100b is composed of: N-VUN100-30GS-VUN100-C, where N and C 
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are the N and C termini, VUN100 is the monovalent Nb in the N-C orientation in both arms, and 30GS is a 
30 amino acid glycine-serine linker. 
Characterisation of VUN100b binding by ELISA found that it had a 5-to-10 fold higher affinity for US28 
than VUN100, as defined by the concentration that gave 50% binding (Figure 7-1 A). While VUN100 can 
bind US28, and has previously been shown to inhibit ligand binding [308], we found that VUN100 was 
not able to impact constitutive US28 signalling in a reporter assay; however, VUN100b could block the 
ability of US28 to activate a Nuclear Factor of Activated T-cells (NFAT)-luciferase reporter by 50% (Figure 
7-1 B). This indicated that VUN100b had additional activity against US28 compared with VUN100, 
consistent with the bivalent format being an inverse agonist. To test the specificity of VUN100 and 
VUN100b binding to US28, THP-1 cells expressing US28-WT (see Chapter 3) were incubated with these 
nanobodies, or an irrelevant nanobody, and immunostained for US28 expression and the Myc epitope 
tag used for nanobody production and purification. This showed that only US28 expressing cells were co-
stained with nanobody (Figure 7-1 C). Finally, an analysis of the effect of these nanobodies (at saturating 
concentrations) on US28 signalling in myeloid cells showed that US28 expression attenuates ERK1/2 
phosphorylation in THP-1 cells, a phenomenon that is important for MIEP suppression and the 
establishment of latency [189]. In contrast, neither irrelevant Nb nor VUN100 treatment could block 
ERK1/2 dephosphorylation in the presence of US28, but that VUN100b treatment increased ERK1/2 
phosphorylation (Figure 7-1 D), demonstrating that VUN100b can block US28 signalling in 






Figure 7-1 Characterisation of VUN100b and comparison with VUN100. A) VUN100 and VUN100b binding to 
membrane extracts from US28-expressing HEK293T cells was analysed by ELISA.  B) HEK293T cells expressing US28 
and containing a Nuclear Factor of Activated T-cells (NFAT)-luciferase reporter were untreated (untr) or treated 
with an irrelevant nanobody (Irr Nb), VUN100 or VUN100b for 24 h prior to luminescence measurement. C) 
Immunofluorescence microscopy of nanobody binding to US28-expressing THP-1 cells. US28 was detected using a 
polyclonal rabbit-anti-US28 antibody (US28, red). Bound nanobody was detected using the Myc-tag present on the 
nanobodies and an anti-Myc antibody (Nb, green). D) lysates of THP-1 empty vector transduced cells (Mock) or 
US28-expressing THP-1 cells were probed for phospho-ERK1/2 levels by western blot. Cells were untreated (untr) or 
treated with an irrelevant nanobody (Irr Nb), VUN100 or VUN100b at 100 nM for 48 h prior to harvest of the lysate. 
Levels of phosphorylated ERK1/2 relative to total ERK1/2 protein levels were determined and normalized to actin 
protein levels. Subsequently, relative phosphorylated protein levels were normalized to untreated THP-1 mock cell 
lysates. Representative figure is shown while data is plotted as mean ± S.D. and is obtained from three or four 
independent experiments. Statistical analyses were performed using unpaired two-tailed t-test. *, p < 0.05; ***, p < 
0.001. These analyses were performed by Timo de Groof and panels C and D use US28-expressing THP-1 cells, 
described in Chapter 3, which I provided. 
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7.2.2. VUN100b induces IE gene expression in latently infected monocytes 
Given that US28 signalling is essential for latency in monocytes, and that VUN100b inhibits US28 
signalling in monocytic THP-1 cells, I reasoned that VUN100b would likely inhibit some US28 activity 
during latency in CD14+ monocytes, leading to derepression of the MIEP and activation of IE gene 
expression.  The monovalent VUN100 inhibits ligand binding activity, which, based on previously 
published data, we predicted would have a lesser effect on US28-mediated suppression of the MIEP 
[189,193]. 
I used the IE2-eYFP reporter virus to monitor IE2 gene expression during experimental latency. As 
described in Chapter 4, IE2 expression is generally repressed in latently infected monocytic cells but can 
be reactivated using differentiation or other stimuli (such as IFI16 overexpression). I was able to monitor 
IE2 gene expression in living cells, but I was also able to fix and stain for total IE at 2 or 6 d.p.i.. This latter 
protocol then enabled automated analysis of the number of IE positive cells and was useful when there 
were very large numbers of IE positive cells in each well. This type of analysis was performed for five 
independent donors, and showed that both VUN100 and VUN100b increased IE gene expression in 
latently infected monocytes (Figure 7-2, Figure 7-3). VUN100b consistently caused a 2-to-10-fold 
increase in IE gene expression, but VUN100 significantly increased IE gene expression in some, but not 




Figure 7-2 VUN100 and VUN100b increase IE gene expression in latently infected monocytes. Primary CD14+ 
monocytes were latently infected with TB40/E IE2-eYFP for 2 hours prior to incubation with the indicated 
nanobodies, left untreated, or treated with PMA to induce differentiation. Nanobodies were replenished every 2 or 
3 days A) At 2 d.p.i., latently infected monocytes from Donor 2 were fixed and stained for total IE protein. B) 
Proportions of IE positive cells in A were analysed by Cellomics ArrayScan plate reader. Statistical analysis 
performed by one-way ANOVA followed by Tukey’s multiple comparison test. **, P<0.01.  C) At 6 d.p.i., latently 
infected monocytes from Donor 4 were imaged. Merged Brightfield and YFP channel images are shown. D) IE2-eYFP 




Figure 7-3 VUN100b consistently upregulates IE gene expression in latently infected monocytes. Primary CD14+ 
monocytes were latently infected with TB40/E IE2-eYFP for 2 hours prior to incubation with the indicated 
nanobodies, or left untreated, or treated with PMA to induce differentiation. Nanobodies were replenished every 2 
or 3 days. At 6 d.p.i., latently infected monocytes were imaged and IE2-eYFP positive cells from were counted. The 
mean number of IE positive nuclei in each well is shown, statistical analysis performed by one-way ANOVA followed 
by Tukey’s multiple comparison test. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001; ns, P>0.05. 
I wished to confirm the specificity of VUN100b for US28 during latency by performing a similar analysis 
on cells latently infected with either WT, or ΔUS28 HCMV. I was unable to perform a direct comparison 
of matched strains, but I did perform a small-scale comparison of monocytes from Donor 3 infected with 
TB40/E IE2-eYFP with those infected with Titan ΔUS28. As predicted, while VUN100b increased the 
number of IE expressing monocytes latently infected with IE2-eYFP, VUN100b failed to have any effect 
on IE expression in monocytes infected with Titan ΔUS28 (Figure 7-4). This is important because it 
indicates that VUN100b does not drive a general increase in permissiveness for lytic infection in 




Figure 7-4 VUN100b is only capable of activating IE gene expression in monocytes in the presence of US28. 
Primary CD14+ monocytes (donor 3) were latently infected with TB40/E IE2-eYFP or Titan ΔUS28 for 2 hours prior to 
incubation with the indicated nanobodies. Nanobodies were replenished every 2 or 3 days. At 6 d.p.i., infected 
monocytes were fixed and stained for total IE, and imaged using the ArrayScan XTI instrument. 
7.2.3. VUN100b does not drive full virus reactivation 
Published data have shown that treatment of latently infected monocytes with the US28 inhibitor 
VUF2274 leads to full viral reactivation [189]. In our previous shock and kill strategies, reactivation of 
expression of lytic HCMV antigens in latently infected monocytes led to T cell recognition and killing 
[145]. However, in any such strategy, full virus reactivation would be unfavourable because of the 
potential for an acute infection and the likelihood  of expression of viral immune evasion genes known to 
be expressed at early and late times of lytic infection [20,386]. Therefore, I wished to ensure that 
VUN100 and VUN100b do not drive full virus reactivation. I analysed viral gene expression by RT-qPCR 
and production of infectious virus via coculture with indicator fibroblasts in the absence or presence of 
nanobodies.  As shown in Figure 7-5 A, substantial production of infectious virus occurred when latently 
infected monocytes are differentiated with PMA to induce full virus reactivation. These levels were not 
produced when latently infected monocytes were treated with VUN100 or VUN100b, despite the similar 
levels of IE2 expressed in latently infected monocytes from that same donor treated with VUN100b or 
PMA (Figure 7-2 D).  These results are supported by the analysis of expression of a panel of viral genes 
(Figure 7-5 B). While IE1/IE72 gene expression was increased by VUN100b, the expression of UL32, a 
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true-late gene encoding tegument protein pp150, was undetected in latently infected monocytes treated 
with nanobodies. In contrast, monocytes differentiated with PMA or infected with HCMV ΔUS28, which 
causes lytic infection, do express UL32. 
The expression of the early gene and viral DNA polymerase complex component UL44 was increased by 
VUN100b, but not to the same extent as PMA differentiation or ΔUS28 infection. The same pattern was 
present with the immune evasion gene US11. US11 participates in virally-induced MHC Class I 
downregulation during lytic infection [386–390]. Since we were interested in US28-specific nanobodies 
as reagents for shock and kill interventions, we wished to avoid major induction of T-cell immune evasins 
like US11. Pleasingly, these results indicated that there was only a small upregulation of US11 after 




Figure 7-5 VUN100 and VUN100b treatment does not lead to full lytic replication in monocytes. Primary CD14+ 
monocytes were latently infected with TB40/E IE2-eYFP for 2 hours prior to incubation with the indicated 
nanobodies, or left untreated, or treated with PMA to induce differentiation and virus reactivation. Nanobodies 
were replenished every 2 or 3 days. Alternatively, primary CD14+ monocytes were infected with Titan ΔUS28.  A) 
Monocytes from donor 4 were cocultured with indicator fibroblasts. After 7 days, IE2 positive plaques were 
counted. B) At 6 d.p.i., total RNA from monocytes from donor 3 were isolated and subjected to RT-qPCR for the 
indicated viral transcripts. Expression was normalised to GAPDH and is presented as 2ΔCt. Where transcript was not 
detected, ‘n.d.’ replaces a bar. statistical analysis performed by one-way ANOVA followed by Tukey’s multiple 
comparison test. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001; ns, P>0.05. 
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7.3. US28-specific nanobody treatment of latent monocytes directs their T 
cell killing 
Following my promising results using nanobodies to activate IE gene expression in latently infected cells, 
I assessed whether this ability of nanobodies to activate IE expression in latently infected monocytes also 
allowed their T-cell recognition and killing and also whether this led to a reduction in differentiation-
induced reactivation of HCMV from them.  I isolated PBMC from a seropositive individual and separated 
the CD14+ monocytes from these PBMC. I then latently infected monocytes with the IE2-eYFP reporter 
virus and treated with either irrelevant nanobody or VUN100b. The IE2-eYFP reporter would allow 
tracking of IE2-positive monocytes during latency and reactivation in living cells. One major caveat to the 
use of this virus is that it is a BAC-derived strain of HCMV and is deleted in the US2-US6 region, which 
encode several proteins that downregulate MHC Class I and II molecules or otherwise interfere with 
antigen presentation [386,391]. However, as described above, this virus does encode US11, which is 
sufficient to downregulate some MHC Class I molecules [388–390]. 
After 6 days’ treatment of latently infected monocytes with nanobodies, PBMC were separated into a 
CD4+/CD8+ population (T cells) and the remaining, CD4+/CD8+ depleted, PBMC (Figure 7-6, Figure 7-7). I 
included CD4+ T cells because there are HCMV-specific CD4+ CTLs in healthy donors [392,393]. IE positive 
cells were counted, and then the latently infected monocytes were cocultured with T cells or depleted 
PBMC at an effector:target ratio of 5:1 in the presence of nanobody (Figure 7-7 A). The count just prior 
to coculture indicated that VUN100b increase IE gene expression and this difference was consistent in 
the replicate wells (Figure 7-7 B, C).  
 IE positive cells were then counted at 18 and 40 hours after addition of PBMC/T cells. In all cases, there 
was a drop in the number of monocytes expressing IE protein which, formally, might have been due to 
increasing suppression of the MIEP as latency was being established. However, VUN100b/depleted 
PBMC treated wells continued to have higher numbers of IE positive cells than irrelevant nanobody 
treated controls, while VUN100b/T cell treated wells had low levels of IE positive cells, suggesting that IE 
positive cells were being killed in the presence of VUN100b and T cells (Figure 7-7 B, D). 
At 48 hours post addition, the PBMC/T cells were also removed and the monocytes differentiated to 
immature DCs using GM-CSF/IL-4 in the absence of nanobodies. This differentiation to immature DCs is 
known not to reactivate IE gene expression [152] and, consistent with this, all four conditions (irrelevant 
antibody +/- T cells, VUN 100b +/- T cells) generated very low levels of IE positive cells. After 5 days’ 
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incubation with GM-CSF/IL-4, differentiating cells were matured with LPS stimulation, which induces full 
virus reactivation [152]. Two days later, reactivating IE positive cells were counted (Figure 7-7 B, E). In 
the presence of depleted PBMC, both VUN100b and irrelevant nanobody-treated cells saw IE 
reactivation. Irrelevant nanobody-treated cells also saw IE reactivation if they had been cocultured with 
T cells, though admittedly at slightly lower levels than PBMC-depleted cells; this might be because the T 
cells in this condition kill any monocytes that spontaneously express IE. However, VUN100b/T cell 
treated cells showed almost no reactivation, demonstrating that VUN100b directs T cell killing of 
experimentally latent monocytes which is reflected in a lack of subsequent levels of reactivation. 
 
Figure 7-6 T cell separations from PBMC. CD4+ and CD8+ cells were separated from the previously monocyte-
depleted PBMC (Pre-separation) by MACS. Purity of the CD4/CD8 depleted PBMC and CD4+ and CD8+ fractions was 




Figure 7-7 VUN100b directs T cell killing of latently infected monocytes. A) Schematic of the experimental design. I 
isolated monocytes, latently infected these cells, and treated with nanobody/cytokines, and performed all 
counting. Eleanor Lim isolated T cells, added these to monocytes, and washed the cells away at the appropriate 
time. B) Time course of IE positive cells following co-culture with autologous T cells or depleted PBMC in the 
presence of irrelevant or VUN100b nanobodies. C) IE2 positive cells in latently infected monocytes at 6 d.p.i.in the 
presence of indicated nanobodies. These data represent the wells that subsequently had either T cells or depleted 
PBMC added. D) IE2 positive cells 2 days post co-culture with the indicated nanobodies and cells. E) IE2 positive 




The HCMV latent reservoir is a significant barrier to eradication of the virus from hosts [20,320]. 
Reactivation of latently infected cells can lead to disease or mortality in immunosuppressed transplant 
patients and immunocompromised individuals, but despite this, no current antiviral agents target this 
latent viral reservoir [14,28,394]. Our laboratory continues to examine the shock and kill strategy for 
targeting latent viral reservoirs using molecules that target epigenetic modifiers, like HDACi [145], to 
induce transient activation of IE gene expression, an antigen recognised by up to 5% of a seropositive 
individual’s CD8+ T cells [395].  However, a virus-specific strategy may be preferable in terms of avoiding 
off-target effects within patients.   
US28 is essential for HCMV latency in monocytes [189], and likely in CD34+ HPCs [159,173,193], at least 
in part because US28 suppresses the MIEP in undifferentiated myeloid cells. Therefore, targeting the 
function of US28 during latency disrupts latency establishment, as shown using the small molecule 
inhibitor VUF2272 [189]. However, this leads to full virus reactivation, which could harm patients, and 
will also lead to the expression of virally-encoded immune evasion genes.  In this chapter, I collaborated 
with a group from Vrije Universiteit to examine the effects of a US28-targeting nanobody that partially 
inhibits US28 signalling.  
The previously described US28-targeting nanobody VUN100 was used to develop a new bivalent format 
VUN100b [308]. The new nanobody had a higher affinity for US28 than VUN100 and was able to inhibit 
US28 signalling in myeloid cells, while both VUN100 and VUN100b specifically bound US28 expressed in 
isolation in THP-1 cells. How the bivalent nanobody has the additional signalling blockade function is 
unknown, but is consistent with other bivalent nanobodies that target cell surface GPCRs [317,318,396].   
When used at saturating concentrations, both VUN100 and VUN100b could induce IE gene expression in 
latently infected monocytes. It would be interesting to analyse the dose dependency of this effect from a 
mechanistic perspective, as well as with a view to treatment. VUN100 blocks ligand binding, and the 
ligand binding activity of US28 has been shown to be required for the establishment in some, but not all, 
experimental latency systems [189,193,195]. Our results suggest that some mode of ligand binding by 
US28 is important for efficient latency establishment. However, the magnitude of the dependency 
appeared to show donor-to-donor variability, raising questions about the role of US28 ligand binding 
during HCMV latency in vivo.  
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VUN100b, a partial inverse agonist of US28, consistently upregulated IE gene expression without 
substantial induction of expression of viral immune evasins, nor full virus reactivation. This is a major 
advantage for a shock and kill strategy, which requires detection by T cells [320].  Furthermore, these 
findings suggest that there is a threshold of inhibition of US28 signalling to induce full virus reactivation. 
This potential ‘sweet spot’ of IE reactivation induced by VUN100b could then lead to recognition and 
killing by T cells from seropositive individuals and makes VUN100b a candidate for shock and kill therapy 
of living donors and transplant recipients prior to immunosuppression and transplant. However, 
additional experiments will need to be performed in ex vivo myeloid cells and PBMC to check the 
efficiency of this strategy. The T cell experiment presented in Figure 7-7 should be repeated with a 
different virus strain that has an intact US2-11 region and is therefore fully competent for viral 
interference for antigen presentation. The experiment can then be extended to analyse production of 
infectious virus after reactivation. The analysis then needs to be repeated on naturally latent myeloid 
cells from a seropositive donor, that is, not experimentally infected, to see that naturally latent virus may 
be partially reactivated and recognised following VUN100b treatment. These experiments are in 
progress.  
Finally, I believe that the nanobody could also be coupled to toxins, effector molecules, and affinity tags 
to facilitate manipulation of latency infected cells in clinical and experimental settings. The potential of a 
US28-binding molecule coupled to a toxin is described in Chapter 8. The effector molecule could be 
something that enhances T cell recognition, such as the anti-CD3 single-chain variable fragment 
conjugated to an anti-EGFR nanobody for use in cancer immunotherapy [397]. The most exciting 
potential use for those studying HCMV latency is a nanobody-affinity tag conjugate that would allow the 
enrichment of experimentally and naturally latent cells from populations that contain low numbers of 
bona fide latently infected cells; typically, this is less than 10% in experimental latency and less than 
0.01% of monocytes or HPCs from seropositive individuals [398]. We have now generated a VUN100-





8. Improved US28-specific immunotoxins kill latently infected 
monocytes  
8.1.  Introduction 
The US28-specific immunotoxin F49A-FTP kills lytically and latently infected cells in culture following 48 
or 72 hours of incubation [172,334]. In conjunction with Synklino ApS, I wanted to test newer candidate 
US28-specific immunotoxins for (i) antiviral activity at low concentrations and (ii) efficacy following 
shorter incubation times. These modifications to improve F49A-FTP would be beneficial to any strategy 
for killing latently infected cells in solid organs using ex vivo normothermic perfusion (EVNP). While the 
exact modifications/mutations in F49A-FTP made by Synklino ApS is proprietary information, 
modifications were generated in the N-terminal region, containing the modified CX3CL1, and in the linker 
region between CX3CL1 and the endotoxin domains. SYN001 is the ‘original’ F49A-FTP compound; 
SYN002 has a modified linker; SYN004 has a modified N-terminal region; SYN005 has both the modified 
linker and the modified N-terminal region.  
Here, I show that SYN002 and SYN005 can kill US28-expressing THP-1 cells and latently infected 
monocytes with greater efficacy than SYN001 and are also efficacious after only a short incubation with 
cells. 
8.2. US28-specific immunotoxins kill US28-expressing THP-1 cells 
I began by comparing the ability of the original F49A-FTP and the three new immunotoxins to kill THP-1 
cells that overexpress US28 or control THP-1 cells (described in Chapter 3). I chose to analyse killing using 
the MTS assay (see Materials and Methods). Strictly speaking, this colorimetric assay measures cell 
viability, as the tetrazolium compound in the assay reagent is converted to a formazan compound by 
metabolically active cells that are producing NADH or NADPH. The absorbance of the formazan product 
in the cell culture medium is directly proportional to the number of living cells. In the initial experiment, I 
treated cells with a range of concentrations of each immunotoxin, and assayed cell viability after 48 
hours (Figure 8-1). This initial experiment indicated that, up to 10-8 M, none of the four immunotoxins 
killed THP-1 cells that do not express US28, but all four could kill US28-expressing THP-1 cells. 





Figure 8-1 US28-specific immunotoxins kill US28-expressing THP-1 cells but not control THP-1 cells. Empty vector 
control or US28-expressing THP-1 cells (described in Chapter 3) were treated with the indicated immunotoxins for 
48 hours before assaying for cell viability by MTS assay. Cell viability is presented as percentage of the assay value 
obtained for cells treated with the immunotoxin-solubilisation buffer only. Curve fitting was performed using 
GraphPad Prism 8, comparing the fits of a’ four-parameter log(concentration) vs response curve’ with a ‘horizontal 
line’; the curve which fitted better according to least squares regression analysis was then plotted. 
I then repeated this analysis but, in addition to incubating US28-expressing THP-1 cells with 
immunotoxins for 48 hours, I also removed immunotoxin at 3, 6, and 24 hours post treatment. I then 
assayed cell viability at 48 hours post initial incubation with immunotoxin. I also chose to use a slightly 
different range of concentrations to give more data points on the killing curves for more accurate 
modelling, and determination of 50% cellular cytotoxicity values (CC50). In this analysis, I found that short 
incubations of as little as 3 hours with the immunotoxins could still kill US28-expressing cells (Figure 8-2, 
Table 8-1). Increasing incubation times increases the efficacy of killing marginally (for example, CC50 for 
SYN005 was 0.115 nM at 3 hours, 0.063 nM at 6 hours, and 0.029 at 24 hours), but that 48 hours gave no 
additional benefit to 24 hours. This is consistent with the mechanism of action of this immunotoxin; once 
sufficient immunotoxin is internalised (perhaps only 1000 individual molecules), translation is arrested 
and apoptosis is irreversibly induced [337].  
Furthermore, this analysis confirmed the individual immunotoxins did not perform equally well.  Quite 
clearly, SYN002 and SYN005 can kill more US28-expressing THP-1 cells at lower concentrations than 
SYN001, the original immunotoxin; with a 24-hour incubation, the difference between CC50 values for 
SYN005 and SYN001 was approximately 10-fold.  In contrast, SYN004 appears less potent than SYN001. 
SYN005 was also between 2- and 5-fold more potent than SYN002 at 3 of the 4 incubation times tested; 
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on this basis, I decided to take forward SYN002 and SYN005 for further testing in latently infected 
monocytes. 
 
Figure 8-2 US28-specific immunotoxins kill US28-expressing cells after short incubation times. US28-expressing 
THP-1 cells were treated with the indicated immunotoxins for the indicated incubation times. 48 hours after initial 
incubation with immunotoxin, cell viability was assessed by MTS assay. Cell viability is presented as percentage of 
the assay value obtained for cells treated with the immunotoxin-solubilisation buffer only. Curve fitting was 
performed using GraphPad Prism 8, specifically the non-linear regression analysis using a’ four-parameter 




Table 8-1 CC50 and respective 95% confidence intervals (CI) for immunotoxins at given incubations times. All 
values in nM. Values were interpolated using GraphPad Prism 8, specifically the non-linear regression analysis using 




SYN001 SYN002 SYN004 SYN005 
3 hours CC50 0.619 0.211 2.09 0.115 
95% CI  0.476, 0.802 0.158, 0.281 1.25, 3.54 0.073, 0.186 
6 hours CC50 0.485 0.177 0.577 0.063 
95% CI  0.371, 0.635 0.139, 0.225 0.383, 0.854 0.043, 0.090 
24 hours CC50 0.237 0.106 0.684 0.029 
95% CI  0.167, 0.330 0.081, 0.139 0.514, 0.924 0.017, 0.046 
48 hours CC50 0.384 0.185 0.928 0.149 
95% CI  0.322, 0.455 0.127, 0.271 0.780, 1.11 0.126, 0.175 
 
8.3. US28-specific immunotoxins kill latently infected monocytes 
Before assessing efficacy of SYN002 and SYN005 on latently infected primary CD14+ monocytes, I needed 
to formally confirm that neither immunotoxin was toxic to uninfected monocytes, as is predicted by 
Figure 8-1. Once again, I used the MTS assay to determine cell viability after both a 4 hour and a 48 hour 
incubation with SYN002 and SYN005, with blasticidin as a positive control for cell killing. Four hours was 
chosen as a realistic incubation time for any potential normothermic perfusion of kidneys with the 
immunotoxins. I found no evidence of cytotoxicity up to 10-7M with either immunotoxin (Figure 8-3) and 




Figure 8-3 US28-specific immunotoxins do not kill uninfected primary monocytes at relevant concentrations 
Primary CD14+ monocytes were incubated with the indicated immunotoxins for 4 or 48 hours, or blasticidin at 10 X 
lethal concentration as a positive control. 48 hours after initial incubation, cell viability was determined by MTS 
assay. Cell viability is presented as percentage of the assay value obtained for cells treated with the immunotoxin-
solubilisation buffer only. Curve fitting was performed using GraphPad Prism 8, comparing the fits of a’ four-
parameter log(concentration) vs response curve’ with a ‘horizontal line’; the curve which fitted better according to 
least squares regression analysis was then plotted. 
 
I initially chose 1 nM as the concentration to test to kill latently infected cells as it represents a 
concentration able to kill 80-95% of US28-expressing THP-1 cells.  I latently infected primary CD14+ 
monocytes with TB40/E mCherry US28-3XF, or ΔUS28 as a control for the specificity of immunotoxin for 
US28. At 5 days post infection, I treated infected cells with immunotoxins SYN002 and SYN005, as well as 
SYN001 at 1 nM and SYN001 at 10 nM for comparison. After 4 hours, I changed the media on half the 
wells. At the end of 48 hours, I counted all infected cells as marked by mCherry fluorescence. As shown 
in Figure 8-4, all four immunotoxin treatments killed a proportion (50-70%) of latently infected cells, but 
not those infected with ΔUS28-HCMV. This reconfirms the specificity of the immunotoxins for US28. The 
absolute differences between treatments were small, but there was a trend to suggest that SYN002 and 
SYN005, with a 4 hour incubation and at a concentration of 1 nM, were better able to kill latently 





Figure 8-4 SYN002 and SYN005 kill latently infected monocytes. Primary CD14+ monocytes were latently infected 
with the indicated viruses. At 5 d.p.i., cells were treated with the indicated immunotoxins. Four hours later, the 
media was changed to immunotoxin-free media (+) or left unchanged (-). Then, 48 hours after initial immunotoxin 
incubation, mCherry positive cells were counted. Note that a media change experiment with SYN001 at 10 nM was 
not performed. Statistical analysis was performed using 2-way ANOVA followed by Dunnett’s multiple comparison 
test between immunotoxin treatment and buffer only. *, P<0.05; **, P<0.01; ***, P<0.001; ns, not significant. 
 
The analysis represented in Figure 8-4 did not allow me to categorically determine whether SYN002 or 
SYN005 was more potent. I therefore compared the antiviral performance of these two immunotoxins 
against latently infected monocytes and productively infected fibroblasts across a further range of 
concentrations. As shown in Figure 8-5, there was still little difference between the performances of 
SYN002 and SYN005 against latent cells (Figure 8-5 A) or lytically infected cells (Figure 8-5 B-D) regardless 
of MOI, or whether IE2 protein or the late protein pp28 was analysed. Furthermore, SYN005 was toxic to 
fibroblasts at high concentrations if it was not removed from culture medium. In these analyses, SYN002 
and SYN005 had almost identical potencies; perhaps this is not surprising given that they both contain 
the same modifications in the linker region and only differ in the N-terminal region.  
The final analysis I performed addressed whether the killing of latently infected cells with SYN002 and 
SYN005 resulted in subsequent loss of reactivation of the latently infected cells in the population 
following their differentiation. To do this, I latently infected monocytes with TB40/E GATA2mCherry, 
which maintains red fluorescence for longer than mCherry driven by the SV40 promoter [349]. I used a 4 
or 48 hour treatment with immunotoxin, and counted remaining mCherry+ cells at 48 hours post 
treatment (Figure 8-6 A). I then differentiated the cells to immature dendritic cells using GM-CSF/IL-4 for 
6 days. At the end of this time (8 days post treatment), I counted red cells again (Figure 8-6 B), before 
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maturing the dendritic cells with LPS, which induces full virus reactivation [152]. Four days post LPS 
treatment, I fixed cells and dual-stained for mCherry and IE, and then counted double-positive cells 
(Figure 8-6 D). I also transferred supernatants from these cells to fibroblasts, to assess release of 
infectious virions (Figure 8-6 E). These analyses confirmed results from the previous donors, and 
additionally showed that the immunotoxin treatments lead to a loss of reactivation that matched the 
levels of lost latently infected cells. The 8-day time point (after differentiation of latently infected 
monocytes to immature dendritic cells) additionally suggested that SYN005 is more potent with a 48 
hour immunotoxin treatment, but not with a 4 hour treatment. A summary of the results from 3 donors 
is shown in Figure 8-6 C, demonstrating approximately 50% average loss of latently infected cells treated 





Figure 8-5 SYN002 and SYN005 have similar antiviral activities against lytic and latent infections. A) CD14+ 
monocytes were latently infected with TB40/EmCherry US28-3XFLAG. At At 6 d.p.i., cells were treated with the 
indicated immunotoxins (n= 3 or n=6) for 4 hours before media removal. Then, 48 hours after treatment, mCherry+ 
cells were counted. Individual counts for each well are graphed. Buffer only controls are shared. Statistical analysis 
by 2-way ANOVA using Sidak’s multiple comparison test; ns, not significant/P>0.05. B) Hff1 cells were infected with 
TB40/E IE2-eYFP at MOI of 1. At 24 h.p.i., cells were treated with the indicated immunotoxins in triplicate, and then 
24 hours later the immunotoxin was removed. After a further 24 hours, IE2 positive cells in three fields of view 
were averaged for each well. Data points show mean of three wells ± SD. C, D) Hff1 cells were infected with TB40/E 
IE2-eYFP at MOI of 0.01. At 24 h.p.i., cells were treated with the indicated immunotoxins in triplicate. Four days 
after this, cells were fixed and counterstained for pp28. The total number of pp28 (C) or IE2 (D) positive cells in 
each well was counted. # indicates that Hff1 cells (infected and uninfected) were killed by SYN005 at 10-8 M. Data 






Figure 8-6 SYN002 and SYN005 kill latently infected monocytes and reduce reactivation. A, B) Primary CD14+ 
monocytes were latently infected with TB40/E GATA2mCherry. At 5 d.p.i., cells were treated with the indicated 
immunotoxins. At 4 or 48 hours post treatment, immunotoxin was removed.  Then, 48 hours after initial 
immunotoxin incubation, mCherry+ cells were counted (A) before differentiating cells with GM-CSF/IL-4 for 6 days; 
at this point (8 days post treatment), mCherry+ cells were counted again (B). C) Summary of killing experiments 
from three donors, normalised to buffer only killing counts 48 hours after immunotoxin incubation. D, E) 
Differentiating cells from B were stimulated with LPS to induce maturation of dendritic cells and full virus 
reactivation.  After 4 days of stimulation, supernatants were transferred to Hff1 cells and the mature DCs were 
fixed and stained for IE and mCherry; double positive cells were counted (D). Supernatants were incubated with 
Hff1 cells for 21 days and then mCherry+ plaques were counted. Statistical analysis was performed using 2-way 
ANOVA followed by Tukey’s multiple comparison test. **, P<0.01; ***, P<0.001; ****, P<0.0001; ns, not significant. 
 
8.4. Discussion 
A proportion of pUS28 is expressed on the outer membrane of infected cells during both lytic replication 
and latency [172,174] (Chapter 3, §3.4.4). This makes US28 a druggable target, and exploiting the 
chemokine-binding properties of US28 is one approach to remove latent viral reservoirs and lytically 
infected cells from patients or grafts. A previous US28-targetting immunotoxin, F49A-FTP, could kill 
lytically infected cells in vitro and in vivo, and experimentally and naturally latent myeloid cells following 
72 hour incubations [172,334].  
Here, I tested the ability of three derivations of F49A-FTP to kill US28-expressing cells over a shorter time 
frame and at lower concentrations, with the aim of finding candidate immunotoxins suitable for 
treatment of solid organ grafts using EVNP. SYN004 did not show any improvement over the original 
immunotoxin, but SYN002 and SYN005 were more potent, and functioned after short (< 6 hour) 
incubations with US28-expressing THP-1 cells. These results were supported by the specific killing of 
latently infected monocytes at 1 nM, and concomitant loss in reactivation following their differentiation: 
I found an approximate 50% drop in survival of latently infected cells and reactivation.  
However, in the published analysis of F49A-FTP-mediated killing of latently infected monocytes and 
CD34+ progenitor cells, a 72 hour incubation killed 50-70% of latent cells and reduced reactivation by 80-
100% [172].  There are several differences between my experiments and the previous published analysis: 
the concentration of immunotoxin, the incubation length, and the virus strains used. Figure 8-4 suggests 
that SYN002 and SYN005 at 1 nM are equally effective as SYN001 at 10 nM in my experimental set up, so 
this concentration difference is unlikely to explain why I did not see an 80-100% drop in reactivation with 
SYN002 and SYN005. Figure 8-6 suggests that increasing the FTP incubation time (from 4 hours to 48 
hours) did not increase killing substantially, making it less likely, but still possible, that a 72 hour 
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incubation has added benefit to latent cell killing. The previously published analysis also used both 
TB40/E SV40 GFP and Titan strains of HCMV; I have used TB40/E SV40 mCherry and TB40/E 
GATA2mCherry. I cannot rule out that there were differences in US28 expression or anti-apoptotic 
activity with the virus sets, which could explain the discrepancies between the datasets. It would be 
informative to immunostain for US28 expression in my analysis, to assess whether cells that are not 
killed by immunotoxin have typical levels of cell-surface US28, and to sequence viruses that replicate 
following reactivation to check for resistance mutations.  
To understand the difference between my results and those previously published, I believe it would be 
informative to compare killing of latently infected monocytes by SYN001, SYN002, and SYN005 at 1 nM, 
10 nM, and an intermediate concentration such as 5 nM using a short incubation time (4 hours) and the 
long incubation time (72 hours). It is also necessary to extend the experiments presented here and 
analyse killing naturally latent monocytes from seropositive individuals. This would hopefully also help to 
determine whether SYN002 or SYN005 is more potent, which I was unable to do in my experiments.  
Overall, there is promise for an improved immunotoxin to be used for targeting of latent reservoirs in 
solid organ grafts prior to transplantation via EVNP. A schematic of the EVNP system for kidneys is shown 
in Figure 8-7. In a collaboration with the Department of Surgery, here at the University of Cambridge, we 
plan to access paired kidneys from seropositive cadavers. These will be perfused with heated buffer to 
improve renal function but, at the same time, an immunotoxin will be added to the perfusate and 
delivered to the kidney. As we are also able to collect leukocytes that are flushed from the kidney, we 
will then reactivate these leukocytes ex vivo to analyse whether immunotoxin can kill naturally infected 
cells within the kidney to reduce viral loads and prevent subsequent reactivation. This, we hope, could 
lead to a novel strategy to reduce the incidence of CMV reactivation and disease from seropositive grafts 




Figure 8-7 Ex vivo normothermic perfusion configuration, adapted from [399]. The donor organ is cannulated at 
the renal artery and vein, and ureter (for urine collection). Prior to oxygenation and heating, a venous reservoir 
containing buffers to improve organ viability can be supplemented with the US28-targeting immunotoxin (SYNx). 
This enters the kidney through the renal artery and exits through the renal vein where a leukocyte filter can collect 





9. General Discussion 
I have presented results in this thesis that advance our understanding of the HCMV protein US28, and 
the potential for targeting US28 in a therapeutic intervention. I have also established roles for two host 
factors, namely IFI16 and MNDA, in HCMV latent infections.   
I analysed the results of a proteomic screen which compared THP-1 cells that express US28-WT, US28-
R129A, or empty vector control. This allowed both the analysis of signalling-dependent and signalling-
independent changes to host factors induced by US28. Because G protein-mediated signalling is critical 
to HCMV latency [189,193], I focussed my attention on the signalling-dependent changes. A large 
number of ISGs were downregulated by US28-WT. I validated that three of these proteins, namely IFI16, 
MNDA, and HLA-DR, were indeed downregulated by US28-WT expressed in isolation, and also 
downregulated during HCMV latency in primary monocytes; IFI16 was also downregulated in CD34+ 
HPCs. I believe this is indicative of the quality of the proteomic screen in detecting US28-mediated 
changes during HCMV latency and the results of the screen will hopefully be useful to other HCMV 
investigators, as well as my own laboratory. I did not investigate other ‘hits’ in the proteomic screen 
except for caveolin-1, but I was unable to develop robust methods for detecting caveolin gene 
expression by RT-qPCR or protein analysis during the course of the project. Future investigations into the 
screen may provide additional insights into the biology of HCMV latency; for example, caveolin-1, which 
is downregulated by US28-WT, could affect cellular trafficking, a phenomenon shown by other to be 
extensively manipulated by HCMV latency [400,401]. Other potentially interesting ‘hits’ were discussed 
in Chapter 3. 
I have considered, though not extensively investigated, the potential implications of a general 
downregulation of interferon-inducible genes during HCMV latency. Previous analysis in bulk populations 
of monocytes latently infected with HCMV has suggested that ISGs, are actually induced following latent 
infection [402]. I believe this can be linked back to the fact that in a population of infected monocytes, 
some are bona fide infected and carry viral genomes, and some are uninfected bystander monocytes, 
but all have still seen virus particles and any cytokines in the viral inoculum. The secretome of latently 
infected monocytes also has effects on bystander cells [127]. In my experimental system, bystander 
monocytes comprise the vast majority of monocytes in the population, and thus bulk analysis of latently 
infected monocyte populations is compromised by the presence of bystander cells. It was for this reason 
that I analysed latency-associated effects on specific genes by immunofluorescence or cell-sorting using 
fluorescence reporter viruses. I therefore propose that there is a downregulation in ISG expression in 
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bona fide latently infected monocytes, which could be important for the maintenance of the polarisation 
of the monocyte [371,372], since latently infected cells are proposed to have an immunosuppressive 
monocyte phenotype [173], or to avoid anti-viral activities of ISGs. Interestingly, a single-cell 
transcriptomic analysis of latently infected CD34+ HPCs also saw downregulation of ISGs including MNDA 
and IFI16 [108], and my own work also showed a decrease in IFI16 in latently infected CD34+ cells, 
suggesting that this phenomenon is conserved in different sites of HCMV latency. 
The downregulation of ISGs and, in particular, IFI16, begs the question of whether the production of 
interferon itself is avoided. In Chapter 6, I presented some evidence that US28 may be attenuating the 
response to DNA stimuli, and that both IFI16 and MNDA overexpression enhance Type I interferon 
responses to transfected DNA. I also found some weak evidence that in bulk populations of latently 
infected monocytes, Type I interferon is produced. What I was unable to determine is whether bona fide 
latently infected cells produce interferon, whether this is modulated by US28, and, indeed, whether this 
has a positive or negative effect on HCMV latency. To investigate these questions, I would perform 
intracellular cytokine staining for IFNα/IFNβ in cells latently infected with fluorescent reporter viruses, 
with or without US28. I would also treat latently infected monocytes with Type I interferon and measure 
the maintenance of viral genome, maintenance of latent phenotype by lack of IE expression and 
infectious virus production, and levels of reactivation following differentiation. It would also be 
informative to know whether any substrates for pathogen sensing are produced during latent infection. 
One way to perform this would to follow procedures described by Alandijany et al. [262]. In their study 
of the early events of HSV-1 infection, they labelled viral genomes within viral inocula with 5-Ethynyl-2'-
deoxyuridine (EdU). After infection, viral genome can be visualised using ‘click chemistry’, and any 
sensing machinery components associated with viral genomes can be identified by immunofluorescence 
staining. For IFI16 and MNDA in particular, an immunoprecipitation (IP) with viral genome would also be 
informative, however, I have doubts about the specificities of the antibodies available for these genes, 
and good antibody is crucial for such IP experiments. Epitope tagging IFI16 and MNDA may be 
appropriate, but it is difficult to genetically modify ex vivo hematopoietic lineage cells. Members of my 
laboratory have recently established an inducible pluripotent stem cell model for HCMV latency [121], 
which may make this sort of experiment feasible in the future. 
My analysis of IFI16 overexpression in THP-1 cells confirmed that IFI16 is part of the DNA sensing 
machinery, as has been proposed by many other studies (see Introduction). However, it also revealed 
that a separate activity of IFI16 is at play during HCMV latency; the ability of IFI16 to modulate viral gene 
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expression. While the majority of viral genes (herpesvirus family, HBV, HIV-1) are transcriptionally 
repressed in some manner by IFI16 [257,264,268,271,274], the HCMV MIEP is activated by IFI16 in 
fibroblasts [79,264]. During this project, I confirmed that IFI16 could activate the MIEP in 
undifferentiated THP-1 cells, and that this occurred independently of other viral gene products. I also 
identified that the activation of the MIEP was mediated by NF-κB binding at the MIEP, but not how IFI16 
activates NF-κB. I provided evidence that it was not via Sp1 sequestration from IκBα promoters, a 
mechanism previously proposed to occur in endothelial cells [250]. It would be interesting to determine 
whether MIEP activation and DNA sensing by IFI16 are linked by NF-κB activation, since a recent study 
found a mechanism by which IFI16, in concert with ATM, can activate STING and non-canonical NF-κB 
signalling in response to nuclear DNA damage [224]. 
In response to transfected DNA, cells in which I had overexpressed MNDA had the same phenotype as 
cells overexpressing IFI16 with respect to increased interferon production, suggesting that MNDA is also 
a component of DNA sensing machinery. To date, no report has been published which demonstrates this 
function of MNDA, though one lab has reported similar results at a conference (A. Bowie, personal 
communication). This phenomenon deserves greater investigation; what is the mechanism of sensing? 
Does MNDA interact directly with DNA to enact this response? What kind of nucleic acid substrates can 
invoke an MNDA-mediated Type I interferon response? Knocking down or knocking out MNDA would 
also help to determine the role of MNDA, but I would need a robust system to test interferon induction, 
since I had great difficulty getting robust interferon responses in undifferentiated THP-1 cells (until, of 
course, I overexpressed MNDA or IFI16 within them). I also identified MNDA as a potential restriction 
factor for HCMV latency. I discussed the additional experiments required for characterisation of this 
function of MNDA in Chapter 5, but it is interesting that, whilst MNDA and IFI16 overexpression both 
lead to increased interferon responses, MNDA leads to a failure to express viral reporter cassettes. In 
contrast, IFI16 increases IE gene expression. Understanding the differences between MNDA and IFI16 
function will be important in addressing the role of PYHIN proteins in HCMV latency, and during other 
viral infections. 
For many of my observations, I could rely upon evidence from infection of primary cells, which is a highly 
relevant model for studying HCMV latency. For many other observations, I relied up protein 
overexpression in the model cell line THP-1. I discussed the limitations of THP-1 cells as a model for 
HCMV latency in the introduction (§1.3.2), but protein overexpression also has its limitations as a way in 
which to investigate protein function. For example, overexpression of the membrane protein US28 in 
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isolation in THP-1 cells could lead to abnormal processing and localisation of pUS28 which could lead to 
abnormal protein function, and not reflect what occurs when expressed during latency.  Some 
mammalian expression systems give tuneable protein expression which could give more physiologically 
relevant results (e.g. [403]). However, I was able to validate several of the results seen with 
overexpression with US28 in the context of HCMV latent infection. For the analyses of MNDA and IFI16 
function, it would be helpful to adopt a complementary approach, such as gene knock-out by CRISPR-
Cas9 [404]  or knock-down by shRNA [405], to validate the phenotypes seen with overexpression, 
During the course of this project, I was also able to investigate two reagents that really illustrate that 
US28 is an ‘Achilles Heel’ for HCMV latency and persistence. A summary of the evidence (see 
Introduction) suggests that US28 is likely essential for HCMV persistence in vivo [159,173,189,193,195]. 
At least some proportion of US28 protein is expressed on the cell surface during latent and lytic 
infections [172,174] (Chapter 3), and can be targeted by nanobodies and immunotoxins to induce T cell-
mediated killing, and direct cytotoxicity, respectively. In using the nanobodies, I was also able to confirm 
that US28-signalling is important for latency in monocytes, and provide evidence that ligand binding by 
US28 also has a role in the maintenance of HCMV latency in monocytes. These molecules, or derivatives 
thereof, could have therapeutic potential for reducing latent viral loads in transplant donors, grafts, or 
recipients, which, it is hoped, would reduce adverse CMV disease in transplant patients. Since US28 is 
essential for HCMV latency, important for cell-cell spread in endothelial cells [178], and likely 
immunomodulatory [175], resistance mutations to nanobodies and immunotoxins may decrease viral 
fitness. As US28 represents an entirely separate viral target to ganciclovir, I believe combination therapy 
involving GCV and a US28-targetting molecule is worth pursuing as a strategy for reducing the burden of 
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